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Leishmaniosis is an important vector-borne zoonosis caused by Leishmania infantum. The 
disease is widespread across several continents and endemic in the Mediterranean region. The 
domestic dog is the main vertebrate reservoir for the parasite and control of canine 
leishmaniosis (CanL) is deemed to be essential for the control of human cases of the disease. 
Due to the heterogeneous distribution of infection in endemic areas, epidemiological 
surveillance should be carried out focally, including both screening of canine populations and 
vector detection, the two determinant factors for parasite survival and expansion. 
CanL control measures are usually directed at the canine reservoir through the detection and 
treatment of infected individuals, as well as disease prevention through insecticide treatments 
and/or canine immunoprophylaxis. Vaccination against CanL is relatively recent and evidence 
of its impact in infection control at the community level is still insufficient. This is also the case 
for CaniLeish® vaccine, the first CanL vaccine to be licensed in Europe, in 2011. Pre-licensing 
studies were performed exclusively in homogeneous populations of beagle dogs,  
experimentally infected or introduced in endemic areas, and very little is known regarding this 
vaccine’s performance in native and heterogeneous dog populations from L. infantum endemic 
areas. 
The study presented in this thesis is divided into two parts. The first consists of a CanL 
epidemiological study in Girona province, a previously uncharacterized region of north-eastern 
Spain. The results obtained confirmed the endemicity of CanL in Girona province, 
characterized by a high prevalence of L. infantum infection in dogs (19.5%), together with the 
detection of a significant proportion of asymptomatic infected individuals (93.2%). The 
increase of dogs’ age and lower altitude of the kennel location were identified as risk factors. 
The two antigens tested to assess dog exposure to Phlebotomus perniciosus (SGH and rSP03B 
salivary antigens) proved to be suitable, with specific antibodies showing a marked decrease 
during the non-transmission season, which allowed detection of recent host exposure to 
vectors. In addition, detected levels of antibodies against both SGH and rSP03B were 
associated with seropositivity to L. infantum. 
The second part of this thesis describes a one year field trial of CaniLeish® vaccine, performed 
in a native heterogeneous canine population from Girona province. These dogs were kept in 
their natural housing conditions throughout the study and were naturally exposed to an L. 
vi 
 
infantum transmission season. Results showed that CaniLeish® vaccine induces the production 
of non-specific antibodies interfering with the serological diagnosis of L. infantum infection in 
dogs and that this interference could have a greater impact between one and four months 
post-vaccination. Vaccine trial results did not confirm CaniLeish® reported efficacy in 
preventing active L. infantum infection or clinical disease in dogs during the first year post-
vaccination. These results were supported by an apparently short-lived vaccine-induced 
cellular mediated immunity, assessed in this study through the quantification of gamma-
interferon (IFN-γ) produced by trial dogs at one and nine months post-vaccination. 
The results presented in this thesis support the need for maintaining and extending 
epidemiological surveillance in CanL endemic areas, in order to better characterize current 
CanL distribution and to anticipate possible L. infantum expansion trends.  Additionally, further 
CaniLeish® evaluation studies are needed, together with active vaccine surveillance, to 





















LIST OF ACRONYMS 
 
ALT Alanine aminotransferase  
ALP Alkaline phosphatase 
BCG Bacillus Calmette-Guérin 
BUN Blood urea nitrogen 
CanL CanL – Canine leishmaniosis 
CBC Complete blood count 
CLWG Canine Leishmaniasis Working Group 
CMI Cellular mediated immunity 
DNA Deoxyribonucleic acid 
ELISA Enzyme linked immunosorbent assay 
FML Fucose-mannose ligand 
GGT Gamma-glutamyl transferase 
HL Human leishmaniosis 
ICT Immunochromatographic test 
IFAT Immunofluorescence antibody test 
Ig Immunoglobulin(s) 
IFN-γ Gamma interferon 
IL-2 Interleukin-2 
iNOS Inducible nitric oxide synthase 
kDNA Kinetoplast DNA 
LiESP Purified excreted-secreted proteins of L. infantum 
LST Leishmanin skin test 
MDP Muramyl-dipeptide 
MHC Major histocompatibility complex 
MHC II Major histocompatibility complex class II 
NO Nitric oxide 
OD Optical density 
PBMC Peripheral blood mononuclear cells 
PCR PCR – Polymerase chain reaction 
PSA Parasite surface antigen 
qPCR Quantitative real time polymerase chain reaction 
QuilA Saponin adjuvant isolated from Quillaja saponaria 
viii 
 
rSP03B 43-kDa yellow-related recombinant protein 
SGH Salivary gland homogenate 
SLA Soluble Leishmania antigens 
SNOAPAD Standardized Nomenclature of Animal Parasitic Diseases 
TLRs Toll-like receptors 
TNF-α Tumour necrosis factor-α 
UPC Urinary protein-to-creatinine (ratio) 













LIST OF FIGURES 
 
Figure 1. Geographical distribution of the human leishmaniases……………………………………… 3 
Figure 2. Distribution of HL in Spain…………………………………………………………………………………. 4 
Figure 3. Taxonomic classification of the genus Leishmania……………………………………………… 5 
Figure 4. Location of the province of Girona…………………………………………………………………….. 43 
Figure 5. Flow chart of pre-vaccination screening and criteria followed for selection of 
individuals for the vaccine field trial………………………………………………………………..... 
 
49 
Figure 6. Map of Girona province. Field trial locations are marked in black circles; the 
number of study dogs per location (n) is presented…………………………………………. 
 
50 
Figure 7. Map of altitudinal distribution in Girona province. Sampling locations are 
marked as black dots…………………………………………………………………………………………. 
 
52 
Figure 8. Vaccine field trial chronogram…………………………………………………………………………… 59 
Figure 9. Dynamics of anti-P. perniciosus salivary proteins IgG response in dogs from an 
endemic area during a sand fly activity season………………………………………………….. 
 
84 
Figure 10. Correlation between IgG recognizing SGH and rSP03B protein in dogs naturally 
exposed to P. perniciosus………………………………………………………………………………….. 
 
85 
Figure 11. Dynamics of dogs’ IgG recognizing SGH (a) and rSP03B protein (b) in the 
different sampling locations during a sand fly activity season…………………………… 
 
88 
Figure 12. Median and interquartile range ELISA units observed in control and vaccine 
groups at each sampling point…………………………………………………………………………… 
 
97 










































LIST OF TABLES 
 
Table 1: Alternative host species and possible reservoirs of L. infantum in Europe…… 9 
Table 2. Leishmania species reported in the domestic dog (Canis familiaris)……………………. 12 
Table 3. Clinical signs and lesions reported in CanL distributed by organic system…….  14 
Table 4. Main laboratory findings associated with CanL…………………………………………….. 16 
Table 5. Girona counties. Geographical position (2015) and demography (2017)……… 45 
Table 6. Metereological data from Girona counties (2016)…………………………………………  46 
Table 7. True seroprevalence for canine Leishmania infantum infection observed in each 





Table 8. Results of the questionnaire asked to dog owners regarding their knowledge of 
canine leishmaniosis and the methods used to prevent the infection (n=33)………. 
 
71 
Table 9. Number of dogs analysed and Leishmania infantum seropositivity observed for 
each category of the explanatory variables, followed by the results of the 




Table 10. Median values of normalized OD readings for SGH and rSP03B obtained per 
sampling month in all locations……………………………………………………………………………. 
 
83 
Table 11. Median values of normalized OD readings for SGH and rSP03B obtained per 
sampling location at all time points……………………………………………………………………… 
 
87 
Table 12. Estimates of the multilevel linear regression model of the relationship between 
log transformed normalized SGH OD values and sampling time, location and dog 




Table 13. Estimates of the multilevel linear regression model of the relationship between 
log transformed normalized rSP03B OD values and sampling time, location and 
























































































1.1. THE LEISHMANIASES 
 
The term “leishmaniases” is used to describe a wide spectrum of clinical presentations caused 
by vector-transmitted protozoan parasites of the genus Leishmania Ross, 1903 (Kinetoplastida, 
Trypanosomatidae) (Gradoni, 2018). 
In humans, Leishmania infections have diverse clinical presentations: visceral leishmaniosis 
(VL), post-kala-azar dermal leishmaniosis (PKDL), cutaneous leishmaniosis (CL), diffuse 
cutaneous leishmaniosis (DCL), mucocutaneous leishmaniosis (MCL) and mucosal leishmaniosis 
(ML), CL being the most common (Akhoundi et al., 2017). 
Leishmania parasites have a worldwide distribution and leishmaniases are present on all 
continents except Antarctica (Bañuls et al., 2007) (Figure 1). According to the WHO Global 
Health Observatory, 94 countries and territories were considered to be endemic for 
leishmaniases in 2016 (WHO, 2018a). An estimated 700.000 to 1 million new human cases and 
20.000 to 30.000 deaths occur annually due to infections by Leishmania (WHO, 2018b). 
 
 







In Spain, the notification of human leishmaniosis (HL) was mandatory at national level from 
1992 to 1995. Following this, a new decentralized surveillance system based on the political 
structure of the autonomous regions was implemented. HL was classified as a regional 
endemic disease and no longer of mandatory notification in non-endemic Autonomous 
Communities (Real Decreto 2210/1995). Since 2015, it is again of mandatory notification at 
national level (Orden SSI/445/2015). 
HL is hypoendemic in the country, with 0.41 cases registered per 100,000 inhabitants (Alvar et 
al., 2012) (Figure 2). The disease is considered to be under-declared and the sub notification of 
cases to the National Surveillance System is estimated to be approximately 50% (Suarez 
Rodríguez et al., 2012). The Spanish Centralized Hospital Discharge Database recorded 3442 
new cases of leishmaniosis amongst the 8010 HL hospitalization records between 1997 and 
2011 (Herrador et al., 2015). In addition, there has been an epidemic outbreak in the 
Community of Madrid that began in July 2009 (Boletín Epidemiológico Comunidad Madrid, 
2011; CCAES, 2012; Molina et al., 2012b).  
 
 






1.2. THE PARASITE 
 
From the 54 Leishmania species described so far, 31 are known to be parasites of mammals 
(Akhoundi et al., 2017, 2016) and at least 21 species are pathogenic for humans (Akhoundi et 
al., 2016; WHO, 2010). 
Isoenzyme analysis is considered the gold standard method for typing Leishmania species 
(Rioux et al., 1990). More recently, DNA and protein based methods have been developed for 
the identification of these parasites with multilocus microsatellite typing and sequencing most 
commonly used (Akhoundi et al., 2017; Lachaud et al., 2017; Maurício, 2018; Talmi-Frank et 
al., 2010; van der Auwera and Dujardin, 2015). 
An updated taxonomic classification of the genus Leishmania is presented in Figure 3. 
 
 
Figure 3. Taxonomic classification of the genus Leishmania (adapted from Akhoundi et al., 
2017). Information is missing for the Paraleishmania section and Sauroleishmania subgenus.  
Asterisk (*) and plus (+) signs denote synonymous species. Underlined: No final classification. 
Bold: Human pathogenic species. Leishmania names in quotation marks are unofficial names 
without formal descriptions. Old and New world species are highlighted in blue and red 






The species included in the subgenus Leishmania multiply in the vectors’ midgut and foregut 
and are present in Eurasia, Africa and the Americas whilst members of the Viannia subgenus 
multiply in the vector’s hindgut and are restricted to the American continent (Lainson and 
Shaw, 1987). The parasites most commonly responsible for VL belong to the Leishmania 
subgenus, while both groups contain parasites causing CL. In recent years, new species have 
been described in unexpected hosts and locations, including some being isolated from humans 
(Cotton, 2017). 
Leishmania infantum is the species with the widest geographical distribution. It is present in 47 
countries throughout Europe, Africa, Asia and Central and South America (WHO, 2010), and is 
the only autochthonous species in Spain (Alvar et al., 2012). Isoenzyme analysis shows that 
there is a high diversity within L. infantum species, with 39 identified zymodemes (Pratlong et 
al., 2013; Pratlong, pers.com.), although the most prevalent is MON-1 (Gallego et al., 2001). In 
Spain, 32 zymodemes have been isolated from patients with leishmaniases, most of them HIV-
positive patients (Chicharro et al., 2003; Gallego et al., 2001; Martín-Sánchez et al., 2004; 




Transmission of Leishmania parasites is mainly vectorial, through the bite of Phlebotomine 
sand flies (Diptera, Psychodidae) (Gállego, 2004; Killick-Kendrick, 1999; Maroli et al., 2013). 
Sand fly vectors in Eurasia and Africa belong mainly to the Phlebotomus genus, while 
Lutzomyia spp. are responsible for transmission in the American continent (Akhoundi et al., 
2016; Maroli et al., 2013). In the New World, the vectorial role of Psychodopygus and 
Nyssomyia genus is also considered (Maia and Depaquit, 2016). From the 800 known species, 
98 are suspected or proven vectors of Leishmania parasites (Maroli et al., 2013).  
Other phlebotominae (Sergentomyia genus) and arthropoda (ticks, biting midges and others) 
have also been taken into account as possible vectors of Leishmania (Dantas-Torres, 2011; 
Maia and Depaquit, 2016; Slama et al., 2014; Solano-Gallego et al., 2012). Nevertheless, due to 
the sole molecular detection of the parasites in the majority of cases, the confirmation of 
these species fulfilling all the criteria to be considered vectors of Leishmania parasites 




In the Mediterranean region, eight Phlebotomus species have been incriminated as vectors of 
L. infantum according to conventional criteria (Killick-Kendrick, 1999; WHO, 2010): P. ariasi, P. 
balcanicus, P. kandelakii, P. langeroni, P. neglectus, P. perfiliewi, P. perniciosus and P. tobbi 
(reviewed in Alten et al., 2016). All belong to the subgenus Larroussius, except P. balcanicus, 
which is a member of the Adlerius subgenus. 
The vector species historically present in Spain are P. ariasi and P. perniciosus, from which the 
parasite has been isolated in Andalusia, Aragon, Catalonia and Madrid regions (Alcover et al., 
2012; González et al., 2017; E. Guilvard et al., 1996; Lucientes-Curdi et al., 1988; Martín-
Sánchez et al., 2006, 1994; Morillas-Márquez et al., 1991; Rioux et al., 1986; Sanchez et al., 
1995). In addition, L. infantum DNA has been detected in P. perniciosus in Extremadura (Bravo-
Barriga et al., 2016). Furthermore, a stable population of P. langeroni infected with L. infantum 
was recently detected by PCR in the south of the country (Sáez et al., 2018), showing that 
additional overlooked vector species may exist. 
Vectorial transmission is influenced by the presence and density of sand flies which, in turn, is 
highly influenced by abiotic factors, showing a positive correlation with environmental 
temperature and a negative association with relative humidity (Dantas-Torres et al., 2014; 
Gálvez et al., 2010a; Tarallo et al., 2010). However, in a study carried out in Spain separately 
analysing two vector species, P. ariasi and P. perniciosus, opposite correlations were observed 
for each of the species (Ballart et al., 2014), highlighting the importance of performing 
individual species analyses. P. ariasi favoured humid or sub-humid areas, whilst P. perniciosus 
was more abundant in semi-arid zones (Aransay et al., 2004; Ballart et al., 2014; Gállego et al., 
1990). 
The sand fly activity period in Spain is variable and can extend from the end of March to the 
middle of December in the south of the country (Morillas-Márquez et al., 1983), although in 
central and northern regions the sand fly activity season is considered to be from June to 
October (González et al., 2017). This also corresponds to the period of higher potential risk for 
L. infantum transmission in the Mediterranean region (Alten et al., 2016). P. perniciosus shows 
a diphasic seasonal trend with two recognized abundance peaks in July and September, while 
P. ariasi presents a monophasic abundance cycle, peaking in August (Alten et al., 2016; Gálvez 






1.2.2. Epidemiological cycles 
 
Depending on the species, Leishmania parasites can present an anthroponotic or a zoonotic 
life cycle (Ashford, 2000; Bañuls et al., 2007; Gállego, 2004). Most Leishmania species known 
to cause disease in humans are considered to present a zoonotic epidemiological cycle 
(Gramiccia and Gradoni, 2005) or to have recent zoonotic origins (Ashford, 2000). In fact, the 
possibility or demonstration of animal reservoirs for anthroponotic species has been reported 
(Dereure et al., 1991; Kassahun et al., 2015; Singh et al., 2013). 
A great number of animals have been found infected with Leishmania species and are 
considered parasite hosts, but only a minority is suspected of having a possible role in parasite 
maintenance and transmission in a particular scenario (i.e. parasite reservoirs). Leishmania 
reservoirs show regional and temporal variation, and only a local study including ecological 
and parasitological analysis could determine whether a species may serve as a reservoir in a 
given environment (Roque and Jansen, 2014). In the Americas, Leishmania hosts belong to the 
orders Didelphimorphia, Cingulata, Pilosa, Rodentia, Primata, Carnivora, and Chiroptera, whilst 
in the Old World implicated animal orders are Carnivora, Hyracoidea, Rodentia and 
Lagomorpha (Gramiccia and Gradoni, 2005; Roque and Jansen, 2014). 
In the Mediterranean region, the cycle is zoonotic and domestic, with the dog acting as the 
principal reservoir of L. infantum. Other animal species, proven or suspected reservoirs of L. 
infantum in Europe have been revised by Millán et al. (2014) and Pennisi (2015) and are listed 
on Table 1. For the large majority, there is no evidence that these can act as reservoirs (Portús 
et al., 2002; Quinnell and Courtenay, 2009), but cats, black rats, foxes, hares and rabbits are 
considered to be able to maintain a wild or domestic epidemiological cycle (Jiménez et al., 
2014; Maroli et al., 2007; Marín-Iniesta et al., 1982; Martín-Sánchez et al., 2007; Molina et al., 









Table 1. Alternative host species and possible reservoirs of L. infantum in Europe. 
Species 
Proven infectiousness to 
sand flies*/Isolation of 
parasites** References 
Badger (Meles meles)  del Río et al., 2014 
Beech marten (Martes foina)  Muñoz-Madrid et al., 2013 
Black rat (Rattus rattus) */** Helhazar et al., 2013; 
Morillas-Márquez et al., 
1985; Muñoz-Madrid et al., 
2013; Navea-Pérez et al., 
2015; Pozio et al., 1985; 
Zanet et al., 2014  
Brown rat (Rattus norvegicus)  Helhazar et al., 2013 
Domestic cat (Felis catus 
domesticus) 
*/** Ayllon et al., 2008; Hervás et 
al., 1999; Maia et al., 2010; 
Maroli et al., 2007; Martín-
Sánchez et al., 2007; Millán 
et al., 2011; I. Moreno et al., 
2014; Solano-Gallego et al., 
2007 
Domestic goat (Capra hircus)  Fisa et al., 1999; Portús et 
al., 2002 
Domestic ferret (Mustela 
putorius furo) 
 Brianti et al., 2005 
Domestic horse (Equus 
caballus) 
** Fernández-Bellon et al., 
2006; Gama et al., 2014; 
Portús et al., 2002; Rolão et 
al., 2005; Solano-Gallego et 
al., 2003 




 Sobrino et al., 2008 
European brown hare (Lepus 
europaeus) 
 Rocchigiani et al., 2018; Ruiz-
Fons et al., 2013; Tsokana et 
al., 2016 
European mink (Mustela 
lutreola) 
 del Río et al., 2014 
European rabbits (Oryctolagus 
cuniculus) 
*/** Díaz-Sáez et al., 2014; 
Jiménez et al., 2014; I. 
Moreno et al., 2014; Ortega 
et al., 2017; Risueño et al., 
2018 
Genet (Genetta genetta)  del Río et al., 2014; Millán et 




Risueño et al., 2018; Sobrino 
et al., 2008 
Golden jackal (Canis aureus)  Hervás et al., 1996 
Grey wolf (Canis lupus)  Muñoz-Madrid et al., 2013 
Oleaga et al., 2015; Risueño 




 Muñoz-Madrid et al., 2013 
House mouse (Mus musculus)  Helhazar et al., 2013; Navea-
Pérez et al., 2015 
Iberian hare (Lepus 
granatensis) 
*/** Molina et al., 2012b; I. 
Moreno et al., 2014; Ortega 
et al., 2017; Ruiz-Fons et al., 
2013 
Iberian lynx (Lynx pardinus)  Sobrino et al., 2008 
Algerian mouse (Mus spretus)  Millán, 2018 
Otter (Lutra lutra)  Oleaga et al., 2018 
Pine marten (Martes martes)  del Río et al., 2014; Millán et 
al., 2011; Oleaga et al., 2018 
Pole cat (Mustela putorius)  del Río et al., 2014 
Red fox (Vulpes vulpes) ** Abranches et al., 1984; 
Criado-Fornelio et al., 2000; 
del Río et al., 2014; Fisa et 
al., 1999; Marín-Iniesta et al., 
1982; Muñoz-Madrid et al., 
2013; Oleaga et al., 2018; 
Piantedosi et al., 2016; 
Portús et al., 2002; Risueño 
et al., 2018; Sobrino et al., 
2008; Verin et al., 2010 
Stone marten (Martes foina)  del Río et al., 2014; Oleaga et 




 Millán, 2018 
Wild cat (Felis silvestris)  del Río et al., 2014; Oleaga et 
al., 2018; Risueño et al., 
2018 
Wood mouse (Apodemus 
sylvaticus) 
 Navea-Pérez et al., 2015; 
Risueño et al., 2018 
Detection of L. infantum by serological and/or molecular diagnostic techniques. 
*Infectiousness to sand flies has been proven by xenodiagnoses 





1.3. CANINE LEISHMANIOSIS  
 
Canine leishmaniosis (CanL) is an important veterinary disease, present in at least 50 countries 
(Alvar et al., 2004). Kaszak et al. (2015) have estimated that CanL affects more than 2.5 million 
dogs in more than 70 countries, although other authors assert that these figures occur in the 
Mediterranean basin alone (Moreno and Alvar, 2002). In this region, it has been estimated that 
50 to 80% of the canine population is infected and that the prevalence of the disease ranges 
between 2% and 5% (Saridomichelakis, 2009). 
The term CanL is usually used to refer to the infection by L. infantum, although dogs can also 
be infected by other Leishmania species, which are listed in Table 2. Being the main known 
reservoir of L. infantum (Dantas-Torres, 2007; Gállego, 2004; Otranto et al., 2017; Ready, 
2010), dogs assume a crucial role in the maintenance of the parasite’s life cycle. Likewise, 
surveillance and control of infected canids in endemic regions is essential for the management 
of CanL, as well as for the reduction of HL (Gavgani et al., 2002). 
In dogs, the zymodeme MON-1 of L. infantum is the most prevalent, although 17 out of 39 
zymodemes have been characterized in dogs’ strains (Aït-oudhia et al., 2011; Gallego et al., 














Table 2. Leishmania species reported in the domestic dog (Canis familiaris) 
Leishmania spp. Geographical distribution References 
L. aethiopica Sudan Dereure et al., 2003 
L. amazonensis Brazil Tolezano et al., 2007 
L. arabica Saudi Arabia Peters et al., 1986 
L. braziliensis South America Aguilar et al., 1987; Marquez 
et al., 2017; Mayrink et al., 
1979; Pirmez et al., 1988; 
Reithinger and Davies, 1999; 
Vélez et al., 2012 
L. colombiensis Venezuela Delgado et al., 1993; 
Reithinger and Davies, 1999 
L. donovani East Africa; Sudan Dereure et al., 2003; 
Mutinga et al., 1980; Sukkar 
et al., 1981 
L. guyanensis Colombia, Ecuador Reithinger and Davies, 1999; 
Santaella et al., 2011 
L. infantum Africa, America, Asia, Europe Gállego, 20041 
L. major Egypt, Saudi Arabia Elbihari et al., 1987; Pratlong 
et al., 2009 
L. mexicana Ecuador, USA Hashiguchi et al., 1991; 
Mayrink et al., 1979; 
Reithinger and Davies, 1999 
L. panamensis Colombia, Costa Rica, Ecuador, 
Panama 
Dereure et al., 1994; Vélez et 
al., 2012; Reithinger and 
Davies, 1999 
L. peruviana Peru Llanos-Cuentas et al., 1999; 
Reithinger and Davies, 1999 
L. pifanoi Ecuador Dantas-Torres, 2009; 
Reithinger and Davies, 1999 
L. tropica India, Iran, Morocco, Syria Dereure et al., 1991; 
Lemrani et al., 2002; 
Pratlong et al., 2009 
Adapted from Alvar et al., 2004; Dantas-Torres, 2009; Dantas-Torres et al,. 2012; Gállego, 
2004; Reithinger and Davies, 1999; Solano-Gallego et al., 2009 







The northward expansion of CanL in Europe, along with the possible spread of human cases, is 
well documented (Ballart et al., 2013b; Gramiccia and Gradoni, 2005; Maroli et al., 2013; 
Medlock et al., 2014). Surveys performed at border areas between CanL endemic and non-
endemic regions prove that the infection is present in locations where it had not been 
documented before (Ballart et al., 2013a; Capelli et al., 2004; Cassini et al., 2013; Dumitrache 
et al., 2016; Vaselek et al., 2017). Also, mathematical models and predictive risk maps forecast 
an expansion of Leishmania vectors due to climate change and anthropogenic impact on the 
landscape (Espejo et al., 2015; Fischer et al., 2010; Koch et al., 2017). 
New cases of CanL have been registered in non-endemic areas where no vectorial transmission 
exists, mainly as a result of dog movement to endemic countries (Dandrieux et al., 2018; Maia 
and Cardoso, 2015). In some cases, however, autochthonous canine infection has been 
proven, most certainly through direct contact (Boggiatto et al., 2011; Gibson-Corley et al., 
2008; Karkamo et al., 2014; Naucke and Lorentz, 2012; Svobodova et al., 2017; Tánczos et al., 
2012). Therefore, CanL in Europe is no longer only a problem of Mediterranean countries 
(Dujardin et al., 2008; Pennisi, 2015; Ready, 2010). Although leishmaniosis is included in the 
OIE list of notifiable diseases (OIE, 2018), this is not clearly reflected in the European or 
country-level legislation (BOE, 2014; Official Journal of the European Union, 2012), meaning 
that a common European strategy for leishmaniosis surveillance and control does not exist. 
The work described in this thesis is set in a European Mediterranean country and refers 
exclusively to canine infection by L. infantum; therefore, the term CanL will, for the reminder 
of this dissertation, used to refer strictly to infection of dogs by this Leishmania species.  
The terminology used to describe the disease caused by Leishmania parasites changes 
according to authors’ personal preference. The term “leishmaniasis” is frequently used to refer 
to the human disease, while “leishmaniosis” is more commonly applied to the veterinary 
condition (Miró and López-Vélez, 2018). In this dissertation, the guidelines of the Standardized 
Nomenclature of Animal Parasitic Diseases (SNOAPAD) will be followed, and the term 
“leishmaniosis” will be applied both for the veterinary and the human diseases (Kassai, 2006; 
Kassai et al., 1988). “Leishmaniosis” is also the term used by the World Organization for Animal 







1.3.1. Clinical presentation 
 
The course of L. infantum infection in the canine host is highly influenced by the host’s 
immune response (more details in section 1.3.5), which introduces a high individual variability 
into the clinical outcome (Hosein et al., 2017). Likewise, factors such as parasitic burden, 
virulence of Leishmania strain, previous infections or coinfections can also affect the polarity 
of clinical manifestations (Saridomichelakis, 2009; Solano-Gallego et al., 2009). Consequently, 
dogs with CanL can present a broad range of clinical signs and clinicopathological 
abnormalities, which are usually nonspecific (Paltrinieri et al., 2016; Solano-Gallego et al., 
2011). The incubation period since infection and until the appearance of clinical disease in 
dogs can last from three months to seven years (Alvar et al., 2004; Miró et al., 2008; Oliva et 
al., 2006; Solano-Gallego et al., 2001a). CanL is a multisystemic disease that can potentially 
affect any organ or tissue, as well as present a diffuse or localized progression. The most 
common clinical signs observed in “classical” CanL are progressive weight loss, generalized 
lymphadenomegaly, onycogryphosis and non-pruritic exfoliative dermatitis (Solano-Gallego et 
al., 2011, 2009). Non regenerative anaemia, mild thrombocytopenia, leukogram changes and 
indicators of renal dysfunction and/or inflammatory immune response are the most frequently 
detected clinicopathological alterations (Foglia Manzillo et al., 2013; Paltrinieri et al., 2016). 
Clinical signs and laboratory abnormalities observed in CanL are presented in Tables 3 and 4. 
 
Table 3. Clinical signs and lesions reported in CanL distributed by organic system 
Clinical signs and lesions References* 
General  
o Poor body condition 
o Exercise intolerance 
o Lethargy 
o Loss of appetite 
o Pale mucous membranes 
o Fever 
 
Reticuloendothelial Santana et al., 2008 
o Generalized lymphadenopathy 
o Splenomegaly 
Cutaneous Ferrer et al., 1988; 
Lombardo et al., 2014 





o Erosive-ulcerative dermatitis 
o Nodular dermatitis 
o Papular dermatitis 
o Pustular dermatitis 
o Mucosal ulceration 
o Nasal hyperkeratosis 
o Footpad hyperkeratosis 
Ophthalmic Naranjo et al., 2005;  




o Anterior uveitis 
Musculoskeletal  
o Muscular atrophy 
o Atrophic masticatory myositis 
o Skeletal myositis 
Renal  
o Polyuria and polydipsia 
Cardiac Martínez-Hernández et 
al., 2017 
o Myocardial lesions 
Coagulation/vascular  
o Epistaxis  
Articular Agut et al., 2003;  
Santos et al., 2006 
o Arthritis 
o Lameness 
Digestive Adamama-Moraitou et 
al., 2007;  
Pinto et al., 2011  
o Vomiting 
o Diarrhoea 
Neurological Giannuzzi et al., 2017; 
Márquez et al., 2013; 
Zobba et al., 2017 
The most common clinical signs are marked in bold. 
*References presented in the table correspond to specific studies; general references for 
clinical signs and lesions were:  Ciaramella et al., 1997; Foglia Manzillo et al., 2013; Koutinas 
and Koutinas, 2014; Noli and Saridomichelakis, 2014; Paltrinieri et al., 2016, 2010; 












Table 4. Main laboratory findings associated with CanL 
Laboratory findings References 
Hemogram Koutinas and Koutinas, 
2014;  
Maia and Campino, 2018; 




Paltrinieri et al., 2016, 
2010;  
Saridomichelakis, 2009; 
Solano-Gallego et al., 
2011, 2009 
o Mild to moderate non-regenerative anaemia 
o Thrombocytopenia 
o Leukocytosis or leukopenia 
 
Biochemical parameters 
o Renal azotaemia (↑BUN and creatinine) 
o Hepatic dysfunction (↑ALT, ALP and GGT) 
o Hyperglobulinemia 
o Hypoalbuminemia 
o Decreased albumin/globulin ratio 
 
Serum protein electrophoresis 








o Increased UPC ratio 
o Decreased urine specific gravity 
The most common laboratory findings are marked in bold. 
 
 
Clinical staging systems for CanL have been proposed by two working groups, the Canine 
Leishmaniasis Working Group (CLWG) and LeishVet (Roura et al., 2013; Solano-Gallego et al., 
2009). These have the purpose of providing clinically useful information for therapeutic 
decisions and for prognostic purposes. However, independent peer validation of these 
suggested systems is still lacking (Noli and Saridomichelakis, 2014). 
An important feature of canine L. infantum infection is the high prevalence of asymptomatic 
dogs, particularly in CanL endemic areas (Alvar et al., 2004; Ballart et al., 2013a; Baneth et al., 
2008; Fisa et al., 1999; Solano-Gallego et al., 2001a). Again, this is a result of the individual’s 
immune response, which in some cases is capable of controlling the parasite (Solano-Gallego 




direct or indirect techniques) in the absence of symptoms or clinicopathological abnormalities 
(Molina et al., 1994; Paltrinieri et al., 2016). Apart from immunological resistance, the 
asymptomatic state can also denote an early stage of infection, in which case a later 
development of clinical signs is expected (Fisa et al., 2001; Miró et al., 2012). Although parasite 
clearance has been mentioned in dogs (Fisa et al., 1999), there is no reliable evidence of it 
(Cavaliero et al., 1999; Manna et al., 2008b; Solano-Gallego et al., 2016a), meaning that 
asymptomatic infected individuals are at risk of developing clinical disease throughout their 
lives (Alvar et al., 2004; Baneth et al., 2008). Furthermore, asymptomatic dogs assume a 
particularly important role from an epidemiological perspective, as they represent overlooked 
reservoirs of L. infantum in endemic areas. Previous studies have already demonstrated that 
these dogs are infectious to sand flies (Borja et al., 2016; de Mendonça et al., 2017b; Laurenti 
et al., 2013; Molina et al., 1994; Quinnell and Courtenay, 2009) and capable of maintaining the 




As mentioned, an important concept in L. infantum infection, especially in endemic areas, is 
that parasite detection on the vertebrate host does not equate to active disease (Moreno and 
Alvar, 2002). A vast number of dogs are capable of controlling the infection either in a latent 
form or a transitory state, leading to eventual parasite clearance (Fisa et al., 1999; Miró et al., 
2012). This adds complexity to CanL diagnosis which, in some cases, will require the use of 
multiple diagnostic tests (Morales-Yuste et al., 2012; Otranto et al., 2009). 
Furthermore, the techniques used for CanL diagnosis must be adapted to each situation. Dogs 
presented to veterinary practitioners are commonly symptomatic individuals, and the 
challenge here may be to exclude differential diagnosis and to confirm that the clinical signs 
observed are produced by L. infantum infection, regardless of parasite detection (Paltrinieri et 
al., 2016; Solano-Gallego et al., 2011). Specific laboratory tests aimed at etiologic diagnosis 
include direct methods (cytology, histopathology, parasite culture, molecular tests, and, less 
frequently, xenodiagnosis) and indirect techniques (serology and cellular immune response 
evaluation) (Gomes et al., 2008; Maia and Campino, 2008; Maroli et al., 2010; Noli and 
Saridomichelakis, 2014; Rodríguez-Cortés et al., 2010; Solano-Gallego et al., 2009; Travi et al., 




prevalence surveys, will be addressed later, under the “Epidemiologic studies” chapter (section 
1.3.4). 
Due to the variety of possible outcomes after L. infantum infection (Noli and Saridomichelakis, 
2014), the differentiation between exposure and disease through the available diagnostic 
methods can be particularly difficult. In any case, clinical examination should be the first step 
of CanL diagnosis (Solano-Gallego et al., 2009). In endemic areas, and due to the serious 
consequences of a delayed diagnosis, it is recommended that the disease be investigated in 





Several methods have been proposed for CanL prevention and control, both at the individual 
and at the population levels. These strategies are mainly focused at: 1) reducing the number of 
infected and infectious animals by early detection and treatment of infected dogs, and 2) 
avoiding new CanL infections by applying insecticides to both infectious and naïve dogs and/or 
through immunomodulation and vaccination (Alvar et al., 2004; Maroli et al., 2010; Miró et al., 
2017b; Otranto and Dantas-Torres, 2013; Quinnell and Courtenay, 2009; Reguera et al., 2016; 
Ribeiro et al., 2018; Travi et al., 2018). 
First line treatment regimens are based on the association of a leishmanicidal drug 
(pentavalent antimony meglumine antimoniate or miltefosine) and a leishmaniostatic 
(allopurinol) (Solano-Gallego et al., 2009). More recently, immunomodulators aimed at 
reducing parasite burden and boosting the host’s immune response [domperidone (Gómez-
Ochoa et al., 2009) or P-MAPA, a protein aggregate of magnesium-ammonium 
phospholinoleate-palmitoleate anhydride (Melo et al., 2014; Santiago et al., 2013)] have also 
been added to the classical therapeutic protocols. 
Treatment of dogs with CanL has the aim of improving diseased dogs’ quality of life and 
extending their life expectancy, while it also has an impact on the parasite load, thus reducing 
dogs’ infectiousness to sand flies (Otranto and Dantas-Torres, 2013). Post-treatment decrease 
in infectiousness has been shown by xenodiagnosis studies for a few chemotherapeutic 




infection risk at the population level. However, no CanL treatment has proved to achieve 
consistent parasite clearance and clinical improvement is only transitory (Manna et al., 2008b; 
Torres et al., 2011), with affected dogs usually needing recurring treatment cycles (Solano-
Gallego et al., 2009). For this reason, and because the assessment of an individual’s 
infectiousness for diagnostic purposes is not feasible, permanent use of topical insecticides is 
recommended in animals known to be infected (Noli and Saridomichelakis, 2014). 
Culling of infected dogs has been the approach used in some countries as a method for 
leishmaniosis control. In Brazil, where cases of HL have been recently expanding to urban 
areas, treatment of affected dogs is not allowed and CanL detection campaigns, followed by 
culling of seropositive dogs, is the control method recommended by the Ministry of Health 
(Ministério da Saúde Brasileiro, 2014). However, besides being an unethical procedure, there is 
no real evidence supporting its efficacy in reducing the number of CanL or HL cases (Costa, 
2011; Costa et al., 2013; Courtenay et al., 2002; Dye, 1996; Reithinger et al., 2004). 
Furthermore, indiscriminate dog culling may have a detrimental effect if, by removing 
seropositive resistant animals responsible for increasing herd immunity, it induces an increase 
in disease transmission (Fox et al., 1971). It is currently known that only a small proportion of 
dogs are responsible for most transmission (Courtenay et al., 2002) and that infectiousness 
correlates with parasite load, especially on ear skin biopsies (Courtenay et al., 2014), while 
serological tests seem to be unable to discriminate the most infectious dogs (de Mendonça et 
al., 2017b). Therefore, the development of a diagnostic test able to differentiate between 
infected (which may not be responsible for transmission) and infectious dogs is essential to 
efficiently direct control efforts in areas of high transmission (Courtenay et al., 2014; de 
Mendonça et al., 2017b; Duthie et al., 2018). 
The application of topical insecticides with proven efficacy against sand flies is still considered 
the most effective method for preventing L. infantum infection in dogs (Brianti et al., 2014; 
Courtenay et al., 2009; Foglia Manzillo et al., 2006a; Goyena et al., 2016; Killick-Kendrick et al., 
1997; Maroli et al., 2001; Guadalupe Miró et al., 2007; Molina et al., 2012a; Otranto et al., 
2013). However, due to the need of repeated applications (spot-on preparations and sprays) or 
product replacement (dog collars), owner compliance is critical to achieve a satisfactory 
coverage and efficacy (Maia et al., 2018; Reithinger et al., 2004). The effect of systemic 
insecticides administered to dogs in the reduction of CanL and HL is under research (Gomez et 
al., 2018; Gomez and Picado, 2017) and it can prove to be an effective method to aid infection 
control in endemic countries. Insecticides can also be used in the environment, through indoor 




al., 2010), and novel vector control methods, such as attractive toxic sugar baits, are under 
development (Qualls et al., 2015). 
Preventive treatments aimed at stimulating the dog’s immune system can be unspecific 
(immunomodulators) or specific (vaccines). Domperidona, described before as a 
complementary therapy for CanL, is also used as a preventive treatment in L. infantum 
endemic regions (Sabaté et al., 2014). There are currently three licensed vaccines for CanL: 
Leish-Tec® (Hertape) in Brazil and CaniLeish® (Virbac) and LetiFend® (LETI) in Europe (Reguera 
et al., 2016). A fourth vaccine was commercialized in Brazil for 11 years, having been 
withdrawn in 2014 by the Brazilian Ministry of Agriculture due to lack of evidence for its 
effectiveness (MAPA, 2014). The vaccines available for CanL will be assessed later, under the 
section “Commercially approved vaccines against CanL” (section 1.3.6). 
Control of L. infantum infection directed at the domestic dog can prove insufficient in some 
settings, where other animal species could be implicated in the maintenance and transmission 
of zoonotic leishmaniosis (Antoniou et al., 2013; del Río et al., 2014; Millán et al., 2014; Navea-
Pérez et al., 2015; Zanet et al., 2014) (see Table 1). However, in the majority of species other 
than dogs, a reservoir status for the parasite has not been proven (Courtenay et al., 2009; 
Portús et al., 2002). Particularly noteworthy is the recent case of Fuenlabrada (Madrid region, 
Spain), where Iberian hares (Lepus granatensis) and European rabbits (Oryctolagus cuniculus) 
were identified as the animal reservoirs for L. infantum parasites (Jiménez et al., 2014; Molina 
et al., 2012b) in the largest HL community outbreak in Europe (Arce et al., 2013). 
Alternative routes have been confirmed for L. infantum transmission between dogs: 
transplacental (Boggiatto et al., 2011; da Silva et al., 2009; Vida et al., 2016), venereal (Silva et 
al., 2009) and blood transfusion (Owens et al., 2001). These routes assume importance mostly 
in non-endemic countries (Karkamo et al., 2014; Naucke and Lorentz, 2012), since transmission 
by sand fly bites in endemic areas is much more effective than any other route 
(Saridomichelakis, 2009). Based on these findings, breeding dogs from endemic areas should 
be tested and any infected animal should be excluded from reproduction. Likewise, any blood 







1.3.4. Epidemiological studies 
 
According to the CLWG, an “exposed” dog is clinically healthy and presents low-titer anti-
Leishmania antibodies in the absence of parasite isolation (either by cytological, histological, 
parasitological or molecular methods). The presence of specific anti-Leishmania antibody titers 
together with parasite detection characterizes an “infected” dog (Paltrinieri et al., 2010). 
However, in CanL endemic areas, molecular parasite detection in peripheral blood or skin 
during the infection transmission season should be carefully interpreted and may not be 
sufficient to classify a dog as infected (Solano-Gallego et al., 2011). Infected dogs can be 
asymptomatic, which can be indicative of a “resistant” state or early infection, as mentioned 
previously. In these cases, resistance can be more accurately ascertained through the 
detection of an effective anti-Leishmania cellular-mediated immune response (Solano-Gallego 
et al., 2000). Infected symptomatic dogs are considered “diseased”, which means they present 
CanL (Paltrinieri et al., 2010). These definitions are essential to better understand the 
information yielded by different epidemiological studies. 
The distribution of L. infantum in canine populations from endemic regions is highly 
heterogeneous (Maia et al., 2018; Pennisi, 2015). Reported infection prevalence can vary 
substantially within a country, as described in a study which compiled published data from 
France, Italy, Portugal and Spain (Franco et al., 2011). In this study, observed point CanL 
prevalences within these endemic countries varied from 0 to more than 80%. In Spain, 
reported canine L. infantum infection seroprevalence varies from 1.6% in the northwest (Miró 
and Molina, 2006) to 34.6% in the south (Morillas-Márquez et al., 1996), with a range of 
intermediate values reported across the territory (Acedo Sánchez et al., 1996; Alcover et al., 
2013; Amela et al., 1995; Amusategui et al., 2004; Arnedo Pena et al., 1994; Ballart et al., 
2013a; Botet and Portús, 1993; Cabezón et al., 2010; Couto et al., 2010; Encinas Grandes et al., 
1988; Fisa et al., 1999; Gálvez et al., 2010b; Goyena et al., 2016; Lepe et al., 2000; Martín-
Sánchez et al., 2009; G. Miró et al., 2007; Miró et al., 2017a, 2012; Morales-Yuste et al., 2011; 
Morillas-Márquez et al., 1996; Nieto et al., 1992; Segovia and Martin-Luengo, 1985; Solano-
Gallego et al., 2001a). 
Reasons for this heterogeneous distribution can be related to factors affecting parasite or 
vector prevalence, as well as host-related factors. Additionally, study design and the diagnostic 




Diagnostic methods most frequently used in epidemiological studies are serological and 
molecular (Ballart et al., 2013a; Cabezón et al., 2010; Fisa et al., 1999; Maia et al., 2016; Miró 
et al., 2012; Solano-Gallego et al., 2001a), but parasite detection by direct exam or culture, as 
well as tests for specific cellular immunity assessment are also used (Fernández-Bellon et al., 
2008; Iniesta et al., 2002; Solano-Gallego et al., 2000). Epidemiological surveys usually include 
large numbers of animals to be sampled under field conditions, whereby diagnostic tests used 
for this purpose should be easy to perform and interpret, low-cost, and either applicable in 
field settings or by making use of samples that can be easily transported.  
Serological methods are one of the most commonly employed approaches for detection of L. 
infantum infection (Solano-Gallego et al., 2014). Serology detects canine humoral response to 
L. infantum, which can occur as early as one month after an infective phlebotomine bite 
(Moreno and Alvar, 2002), although it has been reported to go up to 22 months in some cases 
(Oliva et al., 2006). Therefore, serological tests are indicators of host-parasite contact, but not 
of parasite presence (Solano-Gallego et al., 2009). These methods are considered to be good 
predictors of the onset of clinical signs, and good indicators of active infection, as diseased 
dogs tend to present significantly higher levels of anti-Leishmania antibodies (Oliva et al., 
2006). Enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence (IFAT), 
two of the most frequently used serological quantitative methods, are the screening tests 
recommended by the World Organization for Animal Health for prevalence and surveillance 
studies (OIE, 2014). Research on anti-L. infantum immunoglobulin (Ig) isotypes and IgG 
subclasses has attempted to correlate serological profiles with protective cellular mediated 
immunity (CMI) and infection outcome (reviewed in Maia and Campino, 2018). Results across 
studies tend to provide evidence of an increase in all Leishmania-specific Ig subtypes in 
symptomatic dogs, when compared to asymptomatic individuals (Iniesta et al., 2005; Reis et 
al., 2006; Rodríguez-Cortés et al., 2007a). Similar trends are reported for IgG subclasses 
(Iniesta et al., 2005; Laia Solano-Gallego et al., 2001b), although some authors have found a 
clear correlation between IgG2 levels and disease progression (Cardoso et al., 2007; Iniesta et 
al., 2007). Lack of consistency across IgG subclasses studies could be a result of the low 
specificity of the polyclonal antisera commercially available and used in most laboratories 
(Day, 2007). When monoclonal antibodies to IgG were used, no substantial difference between 
subclasses was detected (Quinnell et al., 2003a; Strauss-Ayali et al., 2007). Serological 
qualitative methods or rapid immunochromatographic tests (ICT), which are easy to perform 
and provide immediate results, are also used in veterinary daily practice and in epidemiological 




accurately assess the level of infection and for follow-up purposes (Noli and Saridomichelakis, 
2014). 
Molecular diagnostic techniques are used to detect parasite DNA in different organs or tissues. 
Likewise, a positive result in a conventional polymerase chain reaction (PCR) test confirms the 
presence of Leishmania, but has no predictive value on the infection outcome (Otranto et al., 
2009). Alternatively, quantitative PCR (qPCR) methods can be used to assess parasite loads in 
different organs and to provide useful information for follow-up on positive animals (Francino 
et al., 2006). Molecular techniques are highly specific, but their sensitivity depends on the 
sample used (Solano-Gallego et al., 2016a) and on the target DNA sequence (Akhoundi et al., 
2017; Paltrinieri et al., 2016). Bone marrow, lymph node and skin usually harbour high parasite 
loads and provide higher sensitivity for PCR techniques (Noli and Saridomichelakis, 2014; 
Solano-Gallego et al., 2011). The use of non-invasive samples, such as conjunctival swabs (Di 
Muccio et al., 2012; Strauss‐Ayali et al., 2004), cerumen (Belinchón-Lorenzo et al., 2016) and 
hair (Belinchón-Lorenzo et al., 2013; Corpas-López et al., 2016), has proved to yield good 
results and could be considered as a useful diagnostic alternative for large-scale field studies. 
Peripheral blood is usually regarded as a less sensitive sample (Solano-Gallego et al., 2011), but 
studies show that the detection of Leishmania DNA in blood is far more common than has 
been previously recognized (Francino et al., 2006; Rodríguez-Cortés et al., 2007b). The 
application of qPCR to blood specimens significantly increases the detection sensitivity 
(Francino et al., 2006) and this method is considered adequate to complement serological 
results in large-scale epidemiological field studies (Maia et al., 2009; Solano-Gallego et al., 
2016a).  
Parasite detection by direct microscopic examination or parasite culture is highly specific, but 
these techniques present low sensitivity. Although still frequently used in veterinary practice 
(Bourdeau et al., 2014) and recommended by several authors as the first line diagnostic test 
(Gharbi et al., 2015; Paltrinieri et al., 2010; Saridomichelakis, 2009), direct visualization of 
amastigotes on lymph node smears or skin lesions imprints depends greatly on parasite load, 
on the examiner’s experience and may be unfeasible in field settings. Parasite culture is 
laborious, time-consuming and can take several weeks to provide definitive results (Maia and 
Campino, 2008); for these reasons, it is generally used for research purposes only (Miró et al., 
2008). 
The detection of Leishmania-specific CMI has also been used in epidemiological studies. In field 




technique identifies exposed and usually resistant animals (Solano-Gallego et al., 2000), as 
dogs with active CanL (and the expected immunosuppression) frequently test negative to LST 
(Solano-Gallego et al., 2005). Likewise, LST can be used to assess exposure and resistance to 
the parasite at the community level, but cannot be used to identify infected or diseased 
individuals (Iniesta et al., 2002). LST is easy to perform and inexpensive, which makes it 
adequate for testing a large number of animals in field conditions. However, a follow-up is 
needed after 72h and a possible iatrogenic induction of false positives can occur after repeated 
inoculations (Fernández-Bellon et al., 2005). Additionally, leishmanin antigen for veterinary use 
has not been internationally standardised and is not available commercially worldwide (OIE, 
2014), which may hamper its application. Some of the most common laboratory-based CMI 
techniques include the lymphoproliferation assay (LPA) and the quantification of specific 
Leishmania-induced cytokines produced by canine lymphocytes. Although these techniques 
also evaluate CMI, they seem to measure distinct parameters of the cellular-mediated 
response, as their results only partially overlap with each other and when compared to LST 
(Fernández-Bellon et al., 2005; Iniesta et al., 2002). Unlike LST, and being in vitro assays, there 
is no risk of iatrogenic-induced false-positive results with repeated testing. However, these are 
complex and time-consuming techniques that require access to laboratory facilities and several 
days of sample processing. The recent development of easier-to-perform techniques that 
make use of whole blood instead of isolated peripheral blood mononuclear cells (PBMC) may 
allow its use in field settings (Zribi et al., 2017). 
Detection of host-vector contact can provide useful information to complement studies of 
vector population dynamics and host-vector interactions, to assess the risk of Leishmania 
infection (Carvalho et al., 2015; Rohoušová et al., 2005; Vlkova et al., 2011) and to measure 
the effectiveness of vector-control programmes (Clements et al., 2010; Gidwani et al., 2011). 
Exposure of vertebrate hosts to sand flies can be assessed by the detection of antibodies 
against sand fly saliva in the hosts’ blood, a method that has proven to be highly specific 
(Vlkova et al., 2011) and was successfully used as a marker of exposure to L. infantum vectors 
(Kostalova et al., 2015; Martín-Martín et al., 2014). The recent development of a rapid ICT 
which detects host contact with P. perniciosus can provide a valuable tool for testing canine 






1.3.5. Immune response to Leishmania infantum in dogs 
 
After the bite of an infected sand fly, L. infantum metacyclic promastigotes are inoculated 
under the host’s skin. After first contact with the skin immune system, parasites are 
phagocytized by macrophages, neutrophils and dendritic cells and transported to regional 
lymph nodes (Hosein et al., 2017). From this point, the infection outcome will vary depending 
on vector, parasite and host factors (Saridomichelakis, 2009). 
Parasite virulence is determined by its species and strain, as well as the number of 
promastigote forms inoculated (Saridomichelakis, 2009). Sand fly saliva injected during the 
bite also stimulates the host’s immune system (Abdeladhim et al., 2014), although its role in 
the establishment of infection or protection is still under debate (Collin et al., 2009; Rohoušová 
et al., 2011). The host’s immune response is crucial to infection progression, although the 
precise immune mechanisms responsible for resistance or susceptibility are still unknown 
(Hosein et al., 2017). The wide spectrum of possible outcomes varies from an immediate local 
elimination of the parasite by the host’s macrophages to a multisystemic overt disease 
(Solano-Gallego et al., 2009). 
 
1.3.5.1. Host genetics 
 
It is currently accepted that a host’s genetics play an important role in susceptibility or 
resistance to CanL (Baneth et al., 2008). Epidemiological studies in canine populations from 
CanL endemic areas have shown that mongrels and autochthonous breeds tend to show a 
higher resistance to infection than exotic breeds (Cortes et al., 2012; Fisa et al., 1999; Sanchez-
Robert et al., 2005; Solano-Gallego et al., 2000). 
Genetic studies have identified genotypes that may be involved in susceptibility to L. infantum 
infection, for example the DLA-DRB1*01502 allele of the major histocompatibility complex 
class II (MHC II) (Quinnell et al., 2003b), the Slc11α1 gene (Altet et al., 2002), or the canine β-
defensin-1 (CBD1) gene (da Silva et al., 2017). TAG-8-141 haplotype of Slc11α1 gene was found 
to be significantly associated with susceptibility to the disease in boxers (Sanchez-Robert et al., 
2005), as well as in other breeds (Sanchez-Robert et al., 2008), while other authors found no 




al., 2009; Turchetti et al., 2015). Genome-wide studies have also found evidence of high 
heritability and of genetic determinants for disease progression (Quilez et al., 2012; 
Utsunomiya et al., 2015). 
Other individual non-genetic factors, such as nutritional status, physiologic state (e.g. 
pregnancy) and concomitant infections and parasitism, have a recognized role in the 
susceptibility to CanL (Baneth et al., 2008). A recent study found a significant association 
between low levels of serum vitamin D and symptomatic L. infantum infection in dogs, 
although it has not yet been determined whether the avitaminosis is a cause or a consequence 
of CanL (Rodríguez-Cortés et al., 2017). 
 
1.3.5.2. Innate immune response 
 
The immediate inflammatory reaction produced at the skin level after parasite inoculation by 
sand flies is a non-specific immune response mediated by macrophages, dendritic cells and 
neutrophils (Hosein et al., 2017). These cells are able to phagocytise and destroy Leishmania 
parasites at the site of inoculation and, together with other molecular components of the 
innate immune system, are capable of innitiating the development of a long lasting specific 
adaptive immune response (Hosein et al., 2017; Kumar et al., 2009; Reis et al., 2010). 
The role of neutrophils or polymorphonuclear cells (PMN) is still under debate; while it is 
known that these cells are able to phagocytise and kill Leishmania promastigotes, the inability 
of PMN to completely clear the parasite may favour the infection (Pereira et al., 2017). 
Macrophages are the parasite’s main host cell and transporter, through which the parasite can 
multiply and invade other organic systems. Simultaneously, macrophages are also the most 
effective cells in parasite killing, whenever their effector mechanisms are activated 
(Saridomichelakis, 2009). 
Toll-like receptors (TLRs) are membrane receptors usually expressed on sentinel cells such as 
macrophages and dendritic cells that recognize pathogen-associated molecular patterns 
(PAMPs) from infectious agents, including parasites like Leishmania (Hosein et al., 2015). The 
role of TLRs is not completely understood, but they seem to up-regulate pro-inflammatory 
responses in infected macrophages resulting in parasite killing, while shaping adaptive 




1.3.5.3. Acquired immune response 
 
a) Cellular immune response 
 
L. infantum amastigotes are phagocytized and transported inside macrophages from the skin 
inoculation point to regional lymph nodes. There, macrophages present parasite antigens to T 
lymphocytes, via their MHC molecules (Saridomichelakis, 2009). An effective immune response 
after L. infantum infection is assumed to be mediated by cytokines released by activated T 
lymphocytes, namely gamma-interferon (IFN-γ), interleukin-2 (IL-2) and tumour necrosis 
factor-α (TNF-α) (Carrillo and Moreno, 2009; Chamizo et al., 2005; Pinelli et al., 1995, 1994). 
These cytokines will then upregulate macrophage ability to kill intracellular Leishmania 
parasites through the activation of inducible nitric oxide synthase (iNOS) and consequent 
production of nitric oxide (NO), responsible for amastigote apoptosis (Panaro et al., 2008). In 
susceptible dogs, this mechanism is not elicited and parasite multiplication inside macrophages 
goes unrestricted, resulting in the lysis of infected cells and the release of amastigotes, which 
are then able to infect other macrophages (Saridomichelakis, 2009). 
L. infantum-specific CMI is characterized by a mixed lymphocyte T helper type 1 (Th1) and type 
2 (Th2) responses, in which a predominance of one type or the other will define host 
susceptibility or resistance to infection (Hosein et al., 2017; Koutinas and Koutinas, 2014; 
Panaro et al., 2009; Saridomichelakis, 2009). Resistant animals usually show a predominant 
Th1 profile, with the corresponding production of protective cytokines (IFN-γ, TNF-α and IL-2), 
while susceptible dogs seem to display a mixed Th1-Th2 response, together with a decrease of 
CD4+ T-cells and reduced cytokine release (Saridomichelakis, 2009). CD8+ cytotoxic T-cells are 
also considered important for host immunity, as they are able to lyse infected macrophages in 
resistant dogs (Pinelli et al., 1995). However, higher levels of CD8+ T cells have also been found 
in lymph nodes and peripheral blood of symptomatic dogs (Giunchetti et al., 2008; Moreno et 
al., 1999). The CD4+/CD8+ ratio, which reflects the relative changes in both T-cell subset 
population numbers, is usually diminished in diseased animals and is considered by some 
authors as a good indicator of susceptibility (Papadogiannakis et al., 2010); nonetheless, other 
studies have found no relationship between this ratio and disease progression (Miranda et al., 




While the majority of studies tried to characterize Leishmania-specific CMI in peripheral blood, 
some authors demonstrated that immune response to the parasite is organ-specific 
(Alexandre-Pires et al., 2010; Barbosa et al., 2011; Foglia Manzillo et al., 2006b; Lage et al., 
2007; Quinnell et al., 2001; Reis et al., 2009; Rodríguez-Cortés et al., 2016; Sanchez et al., 
2004; Strauss-Ayali et al., 2007). Results revealed that different organs may simultaneously 
present Th1, Th2 or mixed Th1-Th2 profiles, and that these may change throughout the course 
of the infection (reviewed in Maia and Campino, 2012). These studies highlight the complexity 
of the CMI developed by the canine host to L. infantum infection and provide a possible 
explanation to the discrepancies observed across different studies which only focused on 
circulating cytokines. 
 
b) Humoral immune response 
 
Production of specific antibodies against L. infantum is not protective and is frequently marked 
in susceptible dogs, as opposed to resistant infected dogs, which usually present normal or 
only a moderate increase in antibody levels (Paltrinieri et al., 2010). Amongst Ig isotypes, IgG 
predominate, whereas IgM, IgE and IgA usually show lower concentrations (Saridomichelakis, 
2009) or present contradictory results across studies (Reis et al., 2006; Rodríguez-Cortés et al., 
2007b). In addition to the direct correlation between humoral immune response and the host 
clinical status, specific anti-Leishmania Ig levels are also directly related with tissue parasite 
density (Reis et al., 2006). In addition to the absence of protective effect, a strong humoral 
response is one of the main causes of CanL pathogenesis, due to type II (antibody-mediated) 
and III (immune complex-mediated) hypersensitivity reactions (Brandonisio et al., 1990; Lopez 
et al., 1996). Immune complex deposition frequently induces renal, muscular, articular, ocular, 
dermal and vascular damage, while the production of autoantibodies can cause anaemia, 







1.3.6. Commercially approved vaccines against canine leishmaniosis 
 
Given the limited efficacy of chemotherapy in CanL treatment, there is a pressing need for the 
development of effective prophylactic measures. Mathematical models have identified canine 
vaccination as the most effective method for reducing both CanL and HL in L. infantum 
endemic areas (Dye, 1996). 
The “ideal” CanL vaccine should induce a strong and long-lasting Th1-dominated immunity to 
control infection progression, as well as a significant reduction in dogs’ infectiousness to sand 
flies (Gradoni, 2015). Additionally, it should be able to protect equally against infection and 
disease (Alvar et al., 2013). Although there are currently three licensed vaccines for CanL 
(Leish-Tec® in Brazil and CaniLeish® and LetiFend® in Europe), these criteria are not fully met 
or, in some cases, additional studies are needed to confirm them. Furthermore, the diversity of 
study designs used to evaluate these vaccines, for which no standardization exists concerning 
study population characteristics, intervention methods or techniques used to assess infection, 
restrict any comparison of vaccine performance (Wylie et al., 2014). Assuming a high enough 
efficacy of current vaccines, an important challenge to Leishmania control through vaccination 
is uptake. To be most effective, vaccination coverage would need to be sufficient to induce 
herd immunity, whereby a significant reduction in infection at the reservoir and vector levels 
would induce protection of non-vaccinated individuals and humans (Fox et al., 1971). Finally, 
CanL vaccination introduces a potential added challenge to the screening and diagnosis of a 
complex disease (Solano-Gallego et al., 2017a). It is known that the strong seroconversion 
induced by some CanL vaccines can be detected by current serological diagnostic tests 
(Marcondes et al., 2013; Martin et al., 2014). The implications of this are the incorrect 
classification of false-positive individuals (vaccinated but not infected) or, as no vaccine is 
100% effective, the difficulty in correctly identifying vaccinated and infected dogs (Solano-
Gallego et al., 2017a). In this section, currently available information on each of the marketed 










Leishmune® (Fort Dodge Wyeth, later Zoetis, Brazil) was the first licensed vaccine for CanL, 
having been registered in Brazil in 2004. It is a second-generation vaccine, composed of the 
GP36 glycoprotein fraction of L. donovani, which bears a fucose-mannose ligand (FML), and 
the QuilA adjuvant (a plant-derived saponin isolated from the bark of Quillaja saponaria) 
(Borja-Cabrera et al., 2002). Vaccination protocol consists of 3 vaccine doses administered 
subcutaneously every 21 days to dogs 4 months old or older, followed by annual boosters 
(Zoetis, n.d.).  
Leishmune® vaccine proved to be well-tolerated in a large safety trial which included 600 dogs 
and where no severe adverse reactions were observed; likewise, mild adverse reactions 
registered after the first vaccine dose were transient and dissipated before the following 
vaccine administration (Parra et al., 2007). 
Several clinical trials have been conducted, showing vaccine-specific seroconversion and an 
effective cellular response, either evaluated through LST (Borja-Cabrera et al., 2008, 2002; da 
Silva et al., 2000) or by in vitro characterization of lymphocyte populations and cytokine 
production in vaccinated dogs (Araújo et al., 2011; Costa-Pereira et al., 2015; de Lima et al., 
2010; Moreira et al., 2016). Phase III field studies were performed in CanL endemic areas and 
included 117 (da Silva et al., 2000) and 85 dogs (Borja-Cabrera et al., 2002), although FML 
antigen alone and not the complete Leishmune® formulation with the QuilA adjuvant was used 
in the first study. Vaccine performance was evaluated through an FML-ELISA assay, LST and 
CanL-induced morbidity and mortality rates. Vaccine efficacy (VE) and protection against 
infection, severe disease and death due to CanL (Borja-Cabrera et al., 2008) were 76% and 
92%, respectively, for the first study (da Silva et al., 2000) while 80% VE and 95% vaccine 
protection were achieved in the second study (Borja-Cabrera et al., 2002). 
When formulated with a higher adjuvant concentration, Leishmune® also proved to be 
effective on the immunotherapy of experimental CanL (Borja-Cabrera et al., 2010, 2004; 
Santos et al., 2007). Leishmune® was considered a transmission-blocking vaccine based on the 
assumption that, as no CanL clinical signs or Leishmania DNA could be detected in vaccinated 
dogs, these could not be infectious to sand flies (Nogueira et al., 2005). For the same purpose, 
Saraiva et al. (2006) demonstrated that FML-induced antibodies present in dog sera were 




longipalpis midguts. In a comparative study of Leishmune® and Leish-Tec® vaccines, 5.1% 
(2/39) of Leishmune®-vaccinated dogs were infectious to sand flies by xenodiagnosis, against a 
36.6% (11/30) infectiousness in the control group (Fernandes et al., 2014). 
Vaccination of dogs with Leishmune® was claimed to reduce CanL and HL incidence in Brazilian 
endemic areas (Palatnik-de-Sousa et al., 2009), which in the case of an increased vaccine 
coverage, could make it more effective in controlling Leishmania infection than dog culling, the 
method currently adopted by the Brazilian Ministry of Health (Ministério da Saúde Brasileiro, 
2014). Conversely, a possible cross-reaction of Leishmune®-vaccinated dogs with the official 
Brazilian serological tests for CanL screening (Marcondes et al., 2013, 2011) would impede the 
use of this vaccine in areas where seropositive dog culling is regularly performed; however, a 
sero-cross-reactivity was not confirmed by all studies (Ribeiro et al., 2015). 
In 2014, the Brazilian Ministry of Agriculture decided to withdraw Leishmune® vaccine’s 





Leish-Tec® (Hertape Calier Saúde Animal, Brazil) is formulated with a recombinant protein A2 
from L. donovani amastigotes and saponin as vaccine adjuvant. It was licensed in Brazil in 2007 
and is currently the only authorized CanL vaccine in that country. It should be administered to 
dogs of 4 months or older and the primary vaccination course consists of 3 doses, 
administered subcutaneously at 21-day intervals, followed by annual boosters (Hertape, 2015). 
Although Leish-Tec® was shown to induce protective immunity in beagle dogs against a high 
dose intravenous infection with L. chagasi, the parasite was isolated in culture from bone 
marrow samples of 4 out of 7 vaccinated dogs. The appearance of clinical signs was delayed in 
the vaccine group (1 year post-infection) when compared with the control group (3-6 months) 
(Fernandes et al., 2008). A comparative study between Leishmune® and Leish-Tec® found no 
significant differences between vaccines in elicited humoral response or infection and 
transmission rates; the only difference detected was a higher rate of adverse reactions in the 




Side effects after Leish-Tec® administration were not found to be severe in a safety analysis, 
which registered a 3.09% rate of mild, site-specific, adverse reactions in vaccinated dogs, 
against a 0.68% rate in placebo animals (Toepp et al., 2017). Leish-Tec® did not induce 
unspecific seroconversion in the large majority of vaccinated animals (69/70), showing no 
cross-reactions with anti-Leishmania promastigote antigen (LPA) or the Dual Path Platform test 
(DPP), based on the recombinant antigens K39 and K26 (de Souza Testasicca et al., 2014). 
Vaccination also significantly reduced the infectiousness of dogs to sand flies, as demonstrated 
by xenodiagnosis (Fernandes et al., 2014; Regina-Silva et al., 2016). 
The first Leish-Tec® field trial included more than 500 dogs, equally allocated to vaccine and 
control groups. Animals were followed up by clinical, serological and parasitological exams 
over 18 months and a significant reduction in the number of CanL cases was observed in the 
vaccine group. Different VE were estimated according to results in different diagnostic tests 
and varied from 58.1% to 80.8% (Regina-Silva et al., 2016). A more recent efficacy trial, apart 
from presenting several methodological inaccuracies, showed very few advantages in the use 
of Leish-Tec® vaccine. Although reporting a significant difference in incidence of infection 
between vaccine (27%; 40/151) and control (42%; 33/78) groups, described a two-fold higher 
proportion of diseased dogs amongst the immunized animals (44%; 18/40) when compared to 




CaniLeish® vaccine (Virbac, France) was released in Europe in 2011 (EMA, 2011). It is a second 
generation vaccine and is composed of purified excreted-secreted proteins of L. infantum 
(LiESP) and a saponin adjuvant (QA-21) from a purified fraction of Quillaja saponaria (Moreno 
et al., 2012). Vaccination protocol consists of one vaccine dose administered subcutaneously 
to animals older than 6 months every 21 days for a total of 3 doses, followed by single dose 
annual boosters (EMA, 2011). According to the pharmacovigilance data reported by Virbac in 
October 2015, more than 1.8 million doses of CaniLeish® have been sold during the first 3.5 
years of marketing in the European Economic Area, Switzerland and Tunisia (Breton et al., 
2015). 
Several studies focusing on the LiESP antigen associated with another adjuvant (muramyl-




Holzmuller et al., 2005; Lemesre et al., 2007, 2005), demonstrating a good protective effect in 
vaccinated dogs. The first study performed on CaniLeish® measured the impact of a primary 
vaccination course in beagle dogs on selected humoral and cellular markers of immunity 
(Moreno et al., 2012). Results showed that only vaccinated dogs produced antibodies to both 
LiESP and parasite surface antigen (PSA), with a bias towards an IgG2 profile in the presence of 
PSA. Vaccination also induced a proper CMI, with in vitro isolated PBMC from vaccinated 
animals showing a specific T cell response and IFN-γ production when exposed to soluble 
Leishmania antigens (SLA). Monocyte-derived macrophages from the vaccinated group 
presented, when infected with L. infantum promastigotes and exposed to autologous 
lymphocytes, an increased parasite killing capacity, inducible nitric oxide synthase (iNOS) 
expression and NO2 production. The same immunity markers were evaluated at different time 
points during the first year after vaccination (Moreno et al., 2014), showing that a similar 
immune profile persisted during this period of time. 
One year after completing the vaccine primary course and before the annual booster, an 
infectious intravenous challenge was performed and animals were monitored for a year 
(Martin et al., 2014). As in the previous studies, the same humoral and cellular patterns were 
observed, showing that vaccinated dogs maintained a protective CMI throughout the study 
and consistently presented seroconversion after exposure to total L. infantum antigens, while 
in the control group this humoral recognition was only observed in infected animals. 
The pre-licensing randomised efficacy field trial of CaniLeish® included 90 beagle dogs 
introduced in two CanL endemic areas in Italy and Spain (Oliva et al., 2014). From these, 46 
animals were randomly assigned to the vaccine group and 44 were kept as controls. The 
vaccination phase was held in controlled conditions, during which vaccine safety was assessed 
by regular clinical examinations and serological responses to vaccination were quantified. 
Observed vaccine side effects were local oedema and crusting followed by local alopecia, all 
resolving spontaneously. Animals were then transferred to the study sites and naturally 
exposed to L. infantum vectors for 2 years. The results of this study demonstrated significant 
differences between groups in the number of dogs showing active infection (33.3% in the 
control group vs. 12.2% in the vaccine group) and the number of symptomatic cases (23.1% in 
the control group vs. 7.3% in the vaccine group). However, no significant difference was 
observed in the proportion of dogs presenting a positive PCR result on at least one occasion 
throughout the trial, confirming that the vaccine does not prevent parasite invasion of “deep” 
tissues (Martin et al., 2014). From the positive PCR dogs, some reverted to a Leishmania-free 




group than in placebo dogs. Based on these results, CaniLeish® VE in preventing clinical signs 
was 68.4% and the vaccine protection level, defined as the percentage of non-symptomatic 
vaccinated animals, was 92.7%. An odds ratio of 3.8 expressed the difference in the prevention 
of clinical disease between the groups. An important additional conclusion of this study is that 
IFAT alone cannot be used to test vaccinated dogs for Leishmania infection, as animals from 
this group consistently presented positive titres due to vaccine-induced antibodies. 
A more recent study, which evaluated the efficacy of two insecticide dog collars and 
CaniLeish® vaccine in the prevention of CanL in highly endemic areas, found no statistically 
significant differences in the frequency of active L. infantum infections between vaccinated 
(n=54) and control (n=55) groups (Brianti et al., 2016). This trial enrolled mixed breed dogs that 
were kept in 4 dog kennels in CanL endemic regions of Italy for one year. L. infantum infection 
was assessed through PCR in bone marrow and skin samples. Positive detections were 
followed by positive IFAT titres and asymptomatic cases were also registered. Similarly, no 
differences were observed in the frequency of symptomatic infection between vaccine and 
control individuals. 
The infectiousness potential of infected CaniLeish®-vaccinated dogs was assessed through 
xenodiagnosis (Bongiorno et al., 2013). Ten beagle dogs at different stages of L. infantum 
infection were enrolled in the study (6 vaccinated animals and 4 controls). The results showed 
no difference in the rate of sand fly infection in symptomatic dogs between groups, but 
infectiousness levels were considered lower in the vaccinated cohort. 
Starita et al. (2016) evaluated the impact of CaniLeish® vaccination in several haematological, 
biochemical and serological parameters of healthy canine blood donors. Slight 
hyperproteinaemia and a rise in some globulin fractions were the only observed changes 
detected in vaccinated dogs. Serologic diagnosis of L. infantum infection with IFAT proved 
unreliable, as it was not able to differentiate between vaccine and infection-induced 











LetiFend® (Laboratorios LETI, Spain) was licensed in Europe in February 2016 (EMA, 2016). It is 
a recombinant vaccine containing a chimerical protein (protein Q) formed by five antigenic 
fragments from four different L. infantum proteins (ribosomal proteins LiP2a, LiP2b and LiP0 
and the histone H2A), to which no adjuvant has been added (Carcelén et al., 2009). 
Vaccination protocol consists of one vaccine dose, followed by annual boosters, and should 
only be used in dogs aged 6 months or older (EMA, 2016).  
During phase II clinical trials, immunization results with protein Q were not consistent. Its use 
with live bacillus Calmette-Guérin (BCG) adjuvant provided an estimated 90% protection 
against infection and CanL-induced morbidity (Molano et al., 2003). However, BCG is not 
considered a safe adjuvant in dogs, as it frequently induces local pain, skin irritation, abscesses, 
ulcers and, occasionally, hypersensitivity reactions (Poot et al., 2009; Reguera et al., 2016). 
Protein Q was then combined with 6 different adjuvants, and the results showed that 
protection was not induced by any of the candidate vaccines, suggesting that live BCG could be 
responsible for the protective effect against L. infantum infection in dogs (Poot et al., 2009). 
Finally, the use of protein Q with no adjuvants (which corresponds to LetiFend® formulation) 
was able to demonstrate a protective effect in vaccinated dogs in a third clinical trial (Carcelén 
et al., 2009). 
The LetiFend® phase III trial included 549 dogs (275 vaccinated and 274 controls) exposed to 
natural infection in two CanL endemic areas in France and Spain during a two-year period. 
Humoral response to protein Q antigen and SLA, prevalence of infection defined by presence 
of the parasite in lymphoid organs and clinical assessment of all animals were performed at 
pre-determined time-points. According to the results of this field study, LetiFend® showed a 
72% VE in the prevention of CanL clinical signs and reduced the likelihood of confirmed CanL 
cases or development of clinical signs in vaccinated dogs vs. placebo dogs in 5 and 9.8 times, 
respectively (Fernández Cotrina et al., 2018). Additionally, no general or local adverse effects 
were observed after LetiFend® administration during laboratory or field studies (Carcelén et 
al., 2009; Fernández Cotrina et al., 2018) and vaccination does not seem to elicit false-positive 








































































The main objective of this thesis is to obtain independent results on the efficacy of canine 
leishmaniosis vaccine CaniLeish® under field conditions in a population of native dogs from an 
endemic region. 
El objetivo general del presente trabajo es obtener datos independientes acerca de la eficacia de la 
vacuna CaniLeish® frente a la leishmaniosis canina, dirigidos a supervisar el control de la 
enfermedad, a través de un estudio independiente y en condiciones de campo en una población de 
perros natural de zona endémica. 
 
The specific objectives are: 
Los objetivos específicos son: 
 
1. To characterize the distribution of Leishmania infantum infection in the canine population of 
Girona province (Catalonia, north-eastern Spain). 
Estudiar la distribución de la leishmaniosis canina por Leishmania infantum en la provincia de 
Girona (Cataluña, noreste de España). 
 
2. To determine possible risk factors associated with canine leishmaniosis infection in dogs in 
the study area 
Determinar los posibles factores de riesgo asociados a la distribución de la leishmaniosis canina 





3. To investigate the exposure of dogs to Leishmania infantum vectors through the detection 
of anti-sand fly saliva antibodies in the canine host. 
Analizar la exposición de los perros a los flebotomos vectores de Leishmania infantum a través 
de la detección de anticuerpos frente a su saliva. 
 
4. To assess the possible impact of vaccination with CaniLeish® in Leishmania infantum 
serological surveillance of canine populations from endemic areas. 
Determinar el posible impacto de la vacunación con CaniLeish® en estudios serológicos y en la 
vigilancia de la leishmaniosis canina, causada por Leishmania infantum, en áreas endémicas. 
 
5. To evaluate the performance of a vaccine against CanL (CaniLeish®) in preventing active 
Leishmania infantum infection in dogs from endemic areas under field conditions. 
Evaluar la eficacia de la vacuna CaniLeish® en la prevención de la leishmaniosis canina de una 
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3. MATERIALS AND METHODS 
 
3.1. STUDY REGION  
 
The present study took place in Girona province (42°10′0″N, 2°40′0″E; area of 5,910 km2), the 
most north-eastern province of Catalonia region (Spain). It is delimited by the Mediterranean 
Sea (to the east), France (to the north), and by Barcelona and Lleida Catalan provinces (to the 
south and west, respectively) (Figure 4). The province occupies a surface of 5,910 km² and it is 
divided into nine counties with altitudes ranging from zero meters above sea level (m a.s.l.) to 
2,910 m a.s.l. (Table 5). 
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Habitats and climates vary from Mediterranean on the coast to Alpine in the Pyrenees. Annual 
mean temperatures range from 16°C in the southern counties to 5°C in the north of the 
province, though maximum and minimum temperatures can reach 39°C and -16°C, 
respectively. Mean relative humidity varies from 61% to 81% and average annual rainfall 
ranges from 550 mm to 1350 mm (Servei Meteorològic de Catalunya, 2016) (Table 6).
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Table 5. Girona counties. Geographical position (2015) and demography (2017). 
Counties Altitude Longitude (E) Latitude (N) Surface Population Population 
density 
(inhab/km2) 









Girona counties 0-2,909 3°19'59,94" 1°57'27,27" 42°29'0,09" 41°39'4,42" 5,910.00 755,716 127.87 
Alt Empordà 0-1,451 3°19'59,94" 2°32'37,13" 42°29'0,09" 42°5'57,10" 1,357.54 139,705 102.91 
Baix Empordà 0-533 3°14'7,08" 2°53'13,71" 42°8'24,18" 41°45'14,81" 701.69 132,906 189.41 
Cerdanya* 1,088-2,914 2°0'59,08" 1°34'57,72" 42°30'20,01" 42°16'51,03" 546.69 17,623 32.24 
Garrotxa 146-1,557 2°46'53,44" 2°20'1,90" 42°20'7,35" 42°0'50,86" 734,62 56,184 76.48 
Gironès 34-988 2°59'18,89" 2°37'55,45" 42°7'6,23" 41°45'32,00" 575.6 188,083 326.76 
Pla de l'Estany 96-880 2°54'19,72" 2°38'17,22" 42°12'48,52" 42°1'59,10" 262.78 31,738 120.78 
Ripollès 690-2,909 2°33'35,26" 1°57'27,27" 42°26'24,29" 42°6'30,27" 956.62 24,999 26.13 
Selva 0-1,705 2°58'18,95" 2°24'28,49" 42°3'36,44" 41°39'4,42" 995.04 167,837 168.67 
Osona** 400-1,697 2°30'29,01" 1°59'12,40” 42°10'38,55" 41°43'39,39” 1,245.20 156,572 125.7 
Source: Institut d'Estadística de Catalunya (http://www.idescat.cat/pub/aec/200; https://www.idescat.cat/pub/?id=aec&n=208) and Diputació de Girona 
(https://www.enciclopedia.cat) 
*Cerdanya county is part of Girona (eleven municipalities in the oriental region) and Lleida (six municipalities) provinces. 
**Osona county belongs principally to Barcelona province, but there are three municipalities in the oriental region that are within the boundary of Girona 
province.
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Alt Empordà Roses 24 16.6 21.6 11.8 35.5 -0.9 545.9 65 3 N 
Baix Empordà la Bisbal d'Empordà 29 15.4 22.1 9.1 36.6 -3.4 603.8 73 1.9 S 
Cerdanya Das 1.097 8.7 17.8 0.8 34.3 -12.7 553.5 69 2.5 E 
Garrotxa Olot* 433 : : : 38.2 : : : : : 
Gironès Girona 72 14.8 22.6 7.8 36.3 -7 701.2 77 1.3 S 
Pla de l'Estany Banyoles 176 15.4 21.6 10.1 37.6 -2.6 658.3 71 2 NW 
Ripollès Sant Pau de Segúries 852 10.4 17.6 4.4 33.8 -7.5 936.2 80 1.2 SW 
Selva Anglès 150 14.8 22.3 8.1 39.3 -5.8 653.1 74 1.3 W 
Source: Departament de Territori i Sostenibilitat, Servei Meteorològic de Catalunya, Institut d'Estadística de Catalunya 
(http://www.idescat.cat/pub/?id=aec&n=214&t=2016) 
*Olot - Pla de Baix (DC), inactive since the 21st of July 2016 
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3.2. STUDY LOCATIONS AND STUDY POPULATION 
 
For this work, a total of 593 dogs living in 36 kennels and 26 localities in the province of Girona 
were sampled from 2012 to 2016. These dogs were all included in the L. infantum 
seroprevalence study, described in section 3.3. The study of humoral immune response to 
vector saliva and CaniLeish® vaccine trials only included animals sampled between 2015 and 
2016, totalling 406 dogs distributed across 21 kennels and 16 localities. Sampling and 
recruitment of dogs for these studies is described in sections 3.2.1 and 3.2.2. The work 
reported in these sections does not include field work performed before 2015. 
 
3.2.1. Preliminary assessment of Leishmania infantum infection in the study locations 
 
Field work for the project started in July 2015 by a serological survey in 16 dog kennels 
distributed over 11 localities. 
A total of 300 dogs were sampled and tested for the detection of anti-L. infantum antibodies. 
This cross-sectional study was intended to evaluate the level of infection at the different dog 
kennels and to estimate point L. infantum infection prevalence (Annex 1). 
During September 2015, sand fly surveys were performed in order to confirm the presence of 
L. infantum vectors in the study locations. One to two CDC light traps were placed for one 
night in each dog kennel. Collected sand flies were identified and the different phlebotomine 
species abundance and frequency were registered. Sand fly species captured at each dog 
kennel are described in Annex 2. 
The following serological survey took place in February 2016 and included 293 dogs. From 
these, 106 were dogs sampled for the first time, the majority of them belonging to five 
additional dog kennels in four different localities. The remaining 187 corresponded to dogs 
sampled for the second time. By comparison with the first survey, annual point L. infantum 
infection incidences were estimated (Annex 1). Apart from the locations selection, the 2016 
survey also allowed for a pre-selection of individuals to be enrolled in the vaccine field trial. 
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3.2.2. Location and individual selection for the study of humoral immune response to vector 
saliva and CaniLeish® vaccine trial 
 
In February 2016, dogs from 18 dog kennels and 12 localities were enrolled in the vaccine field 
trial. The selection of dog kennels was based on the detection of canine L. infantum infection 
cases and the presence of phlebotomine vectors. Thus, one dog kennel sampled in July 2015 
(Annex 1; kennel 15) and one dog kennel sampled in February 2016 (kennel 21) were not 
included in the study due to the absence of cases of L. infantum infection. A third kennel was 
also excluded when the dog owner refused to participate in the vaccine trial (kennel 17). 
Individuals were selected according to their serological result to L. infantum (only seronegative 


















Figure 5. Flow chart of pre-vaccination screening and criteria followed for selection of 
individuals for the vaccine field trial. 
 
 
Due to the reduced number of dogs in some dog kennels, their geographical proximity and the 
similar infection prevalence and/or incidence estimated for kennels in the same localities, a 
decision was made to group dogs by locality instead of dog kennels. This way, trial dogs were 
divided by “locations” in the following studies, as shown in Figure 6. Dog density per study 
location varied between 4 and 23. 
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Figure 6. Map of Girona province. Field trial locations are marked in black circles; the number 
of study dogs per location (n) is presented. 
 
The vaccine study population was initially composed of 177 dogs (90 in the vaccine group and 
87 in the control group), from which 168 (85 vaccine and 83 control) completed the first 
vaccination phase and were included in the field trial. The majority of the dog population was 
composed of hunting dogs (87.1% of the vaccine group and 83.9% of the control group), but 
breeding (8.9% of the total dog population), racing (6.5%) or pet dogs (0.6%) were also 
represented; no statistically significant differences in dog purpose between groups were 
observed (χ2=3.66, p=0.3). Crossbred dogs represented 55.3% of the vaccine group and 45.8% 
of the control group (χ2=1.52, p=0.218), while 55.3% and 65.1% of the vaccine and control 
group, respectively, were males (χ2=1.67, p=0.196). In total, 60.1% of the dog population were 
males and this high male/female ratio can be explained by the exclusion of gestating or 
lactating females, either at the beginning of the study or expected to be so during the duration 
of the trial. Mean dog age in the vaccine group was 3.3 years (SD=2.9) and in the control group 
was 3.4 years (SD=3.0), ranging from 6 months to 11 years (χ2=6.58, p=0.832). 
All animals were kept in open-air facilities, mostly in rural and periurban areas. Furthermore, 
no specific anti-sand fly insecticide treatments were applied in any location, providing the ideal 
conditions for dog exposure to L. infantum vectors. 
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3.3. SEROPREVALENCE OF CANINE Leishmania infantum INFECTION IN GIRONA 
PROVINCE AND IDENTIFICATION OF RISK FACTORS FOR THE INFECTION 
 
The L. infantum seroprevalence study performed in Girona province included data from canine 
serological surveys performed throughout the province between 2012 and 2016. From these, 
406 individuals were sampled in the context of this study, in July 2015 and February 2016, as 
described in section 3.2.1.  
 
3.3.1. Study design 
 
Study individuals were recruited through local veterinarians registered in the regional 
veterinary association (Col.legi Oficial de Veterinaris de Girona – COVGi). After an informative 
talk about CanL, a number of professionals were willing to participate by being the link 
between their clients and the project researchers. Dog owners consisted mostly of wild boar 
hunters, who usually keep large packs of dogs, allowing the sampling of several animals in the 
same location. Four cross-sectional surveys were conducted between April 2012 and March 
2016 in different locations of north-eastern and Pyrenean areas of Spain, in Girona province, 
including 36 sampling stations in 26 localities (Figure 7). Blood samples were collected from all 
animals by cephalic or jugular venepuncture to 5 mL EDTA tubes and preserved at -40°C until 
further processing. 
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3.3.2. Serological detection of Leishmania infantum infection 
 
Plasma was obtained and preserved at -40°C. Samples were analysed by an in-house enzyme-
linked immunosorbent assay (ELISA) for the presence of anti-L. infantum antibodies, using a 
technique previously described (Ballart et al., 2013a; Fisa et al., 2001; Iniesta et al., 2002; Riera 
et al., 1999). Briefly, dog plasma samples diluted at 1:400 were incubated in titration plates 
(Costar®) previously coated with sonicated whole promastigotes at a protein concentration of 
20 µg/mL in 0.05 M carbonate buffer at pH 9.6. Protein A peroxidase ((1:30,000, Sigma®) was 
used as conjugate and reactions were stopped with H2SO4 3M when a pre-determined positive 
control serum reached an optical density of 450 read at 450 nm. Sample optical densities were 
then read at 492 nm. All samples were run in duplicate and calibrator, positive and negative 
serums were included in all plates. Results were expressed in standard units (U) compared to a 
calibrator control sample set arbitrarily at 100U. The cut-off was established at 24U. 
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3.3.3. Data collection 
 
In addition to sample collection, information was gathered from each sampling location 
(geographical coordinates, altitude, county, nearest locality, type of habitat, and presence of 
other domestic and farm animals) and each animal’s individual characteristics (sex, age, breed, 
given use, type of night shelter, and presence of visible CanL clinical signs). Clinical exams were 
performed by veterinarians and the criteria for classifying dogs as “symptomatic” were the 
detection of the following clinical signs: weight loss, lymphadenomegaly, periocular or diffuse 
alopecia, onychogryphosis, ocular lesions, and/or pale mucous membranes. Dog owners were 
asked about their previous knowledge of CanL, as well as control measures regularly taken to 
prevent the disease. This data was then used to determine possible risk factors associated with 
CanL seroprevalence in the population studied. Data collected from each sampled dog and the 
questionnaire completed by the dog owners is presented in Annex 3. 
 
3.3.4. Statistical analysis 
 
True seroprevalence was calculated following the method described in Cortes et al. (2012). The 
formula used was: true prevalence (TP) = [apparent prevalence (AP) – 1 + test specificity (Sp)] / 
[test sensitivity (Se) – 1 + Sp]. Confidence intervals for true prevalence were also calculated 
with the following formula: TP 95%CI = 1.96 x √ [AP x (1-AP) / sample size (n) x (Se+Sp-1)]. The 
L. infantum in-house ELISA has a specificity of 90% and a sensitivity of 85%, when the chosen 
cut-off is used. These values were calculated based on a population of 77 dogs (Fisa et al., 
2001; Iniesta et al., 2002). Reference positivity status for L. infantum infection was determined 
by parasite detection (culture and/or direct exam and/or PCR). ELISA sensitivity and specificity 
analysis is provided in Annexes 4 to 6. 
The relationship between CanL seropositivity and a series of individual and location variables 
was assessed through a mixed logistic regression model. The choice of variables to analyse, as 
well as the categories defined, were based on those used in previous publications (Ballart et 
al., 2013a; Gálvez et al., 2010b; Martín-Sánchez et al., 2009) and adapted to the characteristics 
of the present study. In summary, the covariates considered in the analysis were: altitude 
(<800/>800 m.a.s.l.), type of habitat (rural or between villages/periurban or at the edge of 
villages/urban or inside villages), presence of other animal species (yes/no), sex (male/female), 
Materials and Methods 
54 
 
age (<1 to 13 years, introduced as a continuous variable), breed (purebred/crossbred), use 
given (hunting/breeding/others, with “others” including racing and pet dogs), night shelter 
(indoors/outdoors), dog owner knowledge of preventive methods against CanL (yes/no), dog 
owner use of preventive methods against CanL (yes/no) and dog owner use of prophylactic 
methods against other arthropods (yes/no). 
A bivariate logistic regression analysis was performed, in which the relationship between the 
outcome variable (“dog seropositivity”) and each explanatory variable listed above was 
assessed individually. Statistical significance was set at p<0.05. This was followed by a 
multivariable mixed logistic regression analysis, in which non-significant covariates (p>0.05) 
were sequentially deleted through a backward stepwise selection method until a final model 
was obtained. In this model, “Locality” was introduced as a random-effects variable to account 
for geographic clustering of the data (Alonso et al., 2010; Ballart et al., 2013a) and the year of 
the survey was included as a fixed-effects variable. 
The association between CanL seroprevalence calculated per dog shelter and owner’s 
perception of risk of infection (graded in percentage categories from 0 to 90-100%) was 
assessed through a Spearman’s coefficient correlation. 
All statistical analyses were performed using Stata 15 software (StataCorp LP, College Station, 
TX, USA). 
 
3.4. EVALUATION OF DOG EXPOSURE TO Phlebotomus perniciosus THROUGH THE 
DETECTION OF ANTI-SAND FLY SALIVA ANTIBODIES IN THE CANINE HOST 
 
3.4.1. Study design 
 
The study included a population of 176 dogs distributed across 12 locations, as described in 
section 3.2.2. Individuals were sampled before, during and after the L. infantum transmission 
season, at 5 pre-determined time points: February, August and October 2016, and January and 
April 2017. 
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3.4.2. Sand flies and salivary proteins 
 
A colony of P. perniciosus was reared under standard conditions as described previously (Volf 
and Volfova, 2011). Salivary glands were dissected from 4–6 day-old females, pooled at a 
concentration of 1 salivary gland per 1 µl of 20 mM Tris buffer with 150 mM NaCl and stored at 
-80 °C. The P. perniciosus 43 kDa yellow-related recombinant protein (rSP03B, Genbank accn. 
DQ150622) was obtained from Apronex s.r.o. (Prague, Czech Republic) and quantified by the 
Lowry method (Bio-Rad Laboratories, Inc.) following the manufacturer’s protocol. 
 
3.4.3. Serological detection of dog exposure to sand flies 
 
Anti-P. perniciosus IgG was measured by an in-house enzyme-linked immunosorbent assay 
(ELISA) as described previously (Kostalova et al., 2015). All samples from a single dog were 
processed in the same plate. Briefly, microtiter plates were coated either with salivary gland 
homogenate (SGH) (40 ng per well, equivalent to 0.2 salivary gland) or with rSP03B (5 μg/ml) in 
20 mM carbonate-bicarbonate buffer (pH 9.5) and incubated overnight at 4 °C. Plates were 
then blocked with 6% (w/v) low fat dry milk in PBS with 0.05% Tween 20 (PBS-Tw). Canine 
plasma were diluted 1:200 for SGH and 1:100 for rSP03B in 2% (w/v) low fat dry milk/PBS-Tw. 
Secondary antibodies (anti-dog IgG, Bethyl laboratories) were diluted 1:9000 in PBS-Tw. The 
reaction was stopped with 10% H2SO4 and absorbance was measured at 492 nm using a Tecan 
Infinite M200 microplate reader (Tecan®). Each sample was tested in duplicate and positive 
and negative controls were included in each plate. To account for the variability between 
plates, sample OD readings were normalized by dividing them by the mean OD of positive 
controls run in the same plate (Sanchez et al., 2002). The normalized OD values were 
multiplied by 100. Positivity cut-offs were calculated as the mean plus 3 standard deviations 





Materials and Methods 
56 
 
3.4.4. Serological detection of Leishmania infantum infection 
 
The serological technique used to assess L. infantum infection was an in-house ELISA described 
in section 3.3.2. 
 
3.4.5. Statistical analysis 
 
Statistical analyses were performed using R software (http://cran.r-project.org/) and Stata 15 
software (StataCorp LP, College Station, TX, U.S.A.). 
Correlations between IgG responses to P. perniciosus SGH and rSP03B and between each one 
of the salivary antigens and anti-L. infantum IgG levels were tested by the Spearman rank 
correlation test. Median OD values between time points were compared using the Wilcoxon 
signed rank sum test. 
The relationship between anti-SGH and anti-rSP03B antibodies and sampling month, L. 
infantum infection status and location was tested by fitting multilevel linear regression models, 
taking into account the correlation between repeated measures of the same dogs over time. In 
the models, log-transformed anti-saliva or rSP03B normalized OD values were considered as 
continuous dependent variables and sampling month, L. infantum infection and location as 
categorical predictor variables. In order to assess variations in OD between the first sampling 
month and those following, “February 2016” was set as reference level for this variable. 
Likewise, the locality with the lowest median OD (“Aiguaviva”) was considered to be the 
reference for the variable location. Finally, “seronegative” was set as the reference level for 
the variable L. infantum infection. The random component included dog and time to allow for 
variation at the intercept (between dogs) and the slope (over time). The inclusion of “dog” as a 
random effects variable significantly improved both models, with a between dog variance of 
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3.5. CANILEISH® VACCINE FIELD TRIAL: IMPACT OF VACCINATION IN 
SEROPREVALENCE STUDIES AND VACCINE EVALUATION IN NATIVE DOG 
POPULATIONS 
 
3.5.1. Study design 
 
At the beginning of the trial, in March 2016, 168 dogs were selected from a population of 406 
dogs, as described in section 3.2. Dog owners were previously informed of all details of the 
study and signed an informed consent before the start of the trial. 
Inclusion criteria for the vaccine study were those recommended by CaniLeish® manufacturer: 
seronegativity to L. infantum, normal clinical exam, minimum age of 6 months, and non-
gestating or lactating females (either at the beginning of the study or expected to be so during 
the trial). Furthermore, any dogs that had ever received a vaccine for CanL were also excluded 
(Figure 5). 
Sample size was calculated assuming a 1:1 ratio between the two experimental groups, an 
expected 17.6% incidence of L. infantum infection in the control group, 3.6 times fewer cases 
of active infection in the vaccine group, 10% estimated losses during 1 year trial, a power of 
0.8 and a significance level of 0.05 in a two-sided test. Final sample size was constrained by the 
number of individuals available and the limitations of the research team to follow a larger 
group of dogs during the one year trial. 
Selected animals were distributed over 12 locations, with the number of individuals per 
location ranging from 4 to 23 (Figure 6). Dogs were randomly assigned to either vaccine (n=85) 
or control (n=83) groups. As different locations had shown distinct infection levels, individual 
allocation to study groups was first stratified per dog kennel and then randomized. This way, 
an even proportion of dogs were assigned to each study group in each location, avoiding 
possible result bias introduced by distinct infection pressures. After vaccination, dogs were 
kept with their owners, under their usual housing and husbandry conditions, and naturally 
exposed to an L. infantum transmission season. 
As recommended by CaniLeish® vaccine manufacturer, all dogs from both groups were 
dewormed with a mixture of febantel, pyrantel pamoate and praziquantel prior to vaccination. 
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Individuals from the vaccine group received a three dose vaccine course, 21 days apart. Dogs in 
the control group did not receive any vaccine dose. 
The vaccine field study took place between March 2016 and May 2017. During this period, 
dogs were sampled at pre-determined time points, at which different samples were obtained. 
Blood was collected from the cephalic or jugular veins to EDTA tubes (for serology and clinical 
blood analysis) or heparin tubes (for peripheral blood mononuclear cells (PBMC) isolation and 
cellular-mediated immunity tests). Lymph node samples were collected by fine needle 
aspiration and placed in 100 µL of sterile 0.9% sodium chloride solution. Blood and lymph node 
samples were frozen at -40°C and PBMC were preserved in liquid nitrogen until processing. 
Follow-up samples from the same individual were analysed in parallel. The field study 
chronogram, which describes sampling months, number of dogs sampled at each time point, 
type of sample collected and laboratory tests performed, is presented in Figure 8




Figure 8. Vaccine field trial chronogram. Sampling months, number of dogs sampled, samples collected and tests performed at each time point are 
presented. 
Vac1: first vaccine dose (also T0); Vac2: second vaccine dose; Vac3: third vaccine dose; 1M: 1 month after the third vaccine dose; 4M, 6M, 9M and 12M: as 
in 1M; WB: whole blood; PBMC: peripheral blood mononuclear cells; CBC: complete blood count; BQ: biochemical plasma profile; PTG: protein 
electrophoretogram; LN aspirate: aspirate of popliteal lymph node; LN qPCR: real-time PCR on lymph node aspirate. 
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3.5.2. Vaccine safety assessment 
 
After each vaccine dose, dog owners were asked to monitor their dogs and to report any 
adverse clinical signs observed to the researchers. Periodical revisions by the veterinarians of 
the team were also performed. 
 
3.5.3. Serological follow-up 
 
The serological technique used to assess L. infantum infection is described in section 3.3.2. 
Serological assessments were performed at eight time points throughout the study (Figure 8). 
An increase of 4-fold ELISA units when compared with the same individual’s basal values (ELISA 
units measured at T0) was considered evidence of seroconversion to L. infantum (Paltrinieri et 
al., 2016; Solano-Gallego et al., 2011, 2009). 
 
3.5.4. Molecular assessment 
 
L. infantum qPCR on lymph node samples was performed in suspected cases of CanL and in the 
last sampling time point for seropositive dogs. DNA was extracted from lymph node aspirates 
using the High Pure PCR Template Preparation Kit (Roche®), following the manufacturer’s 
instructions. Quantitative PCR was performed in all samples as described elsewhere (Martín-
Ezquerra et al., 2009; Mary et al., 2004) with minor modifications. Briefly, PCR mix reaction 
was prepared with 5 µL of DNA, 10 µL of master mix (FastStart Universal Probe Master (ROX), 
Roche®), 10 µM of Leishmania primers (direct 5′-CTTTTCTGGTCCTCCGGGTAGG-3′ and reverse 
5′-CCACCCGGCCCTATTTTACACCAA-3’, supplied by StabVida®) and 5 µM TaqMan® probe (FAM-
TTTTCGCAGAACGCCCCTACCCGC-TAMRA), designed to target a kinetoplast DNA (kDNA) 
sequence, and 1 µL of H2O. Eukariotic 18S rRNA was used as endogenous control (VIC
TM/MGB 
probe, primer limited, Thermo Fisher Scientific®). Amplifications and detection were 
performed in an ABI7900 device (Applied Biosystems) and the thermal cycling profile was 50°C 
for 2 min, 95°C for 10 min, 45 cycles at 95°C for 15 sec, and 60°C for 1 min. All samples were 
analysed in triplicate and positive (DNA from L. infantum MHOM/FR/95/LEM3141 strain) and 
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negative controls were included in all qPCR reactions. Parasite quantification was performed 
by comparison with a standard curve generated with L. infantum DNA extracted from 1 x 106 
parasites/mL by using serial dilutions from 105 to 1 parasites/mL.  
 
3.5.5. Clinical follow-up  
 
All dogs were clinically assessed before the beginning of the vaccine trial. This included a 
clinical exam, complete blood count (CBC), renal and hepatic function assessment, and serum 
protein electrophoretogram. In addition to allowing an assessment of each dog’s health status 
at T0, these results were kept as a baseline to compare with subsequent exams throughout the 
study. 
The clinical exam included inspection of general body condition, hydration status, skin, hair 
and nail condition, mucosae, external lymph nodes and ocular lesions. Owners were asked 
about any recent disease, visible weight loss, anorexia, exercise intolerance, 
polyuria/polydipsia, vomit or diarrhoea. Clinical assessments were repeated throughout the 
field trial whenever there was a suspicion of CanL, either detected by the researchers during 
follow-up visits or by the dog owners. At the end of the trial, a thorough clinical exam was 
performed to all dogs. Likewise, blood analyses were repeated whenever needed to confirm a 
CanL case and at the end of the study for all seropositive dogs. 
Due to the nonspecific clinical presentation of CanL, dogs were considered symptomatic only if 
two or more clinical signs compatible with the disease were observed (Fisa et al., 1999). The 
same criterion was followed for any detected laboratory changes. 
 
3.5.6. Evaluation of vaccine-induced cellular mediated immunity (CMI) 
 
PBMC were obtained from each individual at three time points: before the first vaccine dose 
(T0), 4 weeks after the 3rd vaccine dose (M1) and 9 months after vaccination completion (M9) 
(Figure 8). Only dogs with samples for the 3 time points studied were included in the CMI 
assessment, in a total of 152 individuals (75 in the vaccine group and 77 in the control group). 
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Samples of heparinized whole blood were processed within 4h of collection. PBMC were 
isolated by centrifugation with a density gradient medium (LymphoprepTM; Stemcell 
Technologies), frozen in foetal bovine serum (FBS) supplemented with 10% dimethyl sulfoxide 
(DMSO), and stored in liquid nitrogen until processing (Requena et al., 2015). 
For assessment of antigen-specific cytokine responses, samples from the same dog were 
processed together. PBMC were slowly thawed, washed and left for an overnight rest at 37°C 
in 5% CO2. On the following day, cells were counted on a TC20
TM Automated Cell Counter (Bio-
Rad Laboratories, Inc.) and incubated in 96-well culture plates at a density of 106 cells/mL as 
described elsewhere (Rodríguez-Cortés et al., 2017). Briefly, PBMC were incubated with 10 
µg/mL soluble L. infantum antigen (LSA), or 2.5 µg/mL concanavalin A (ConA) (Sigma Aldrich®), 
or culture media (unstimulated, negative control) for a period of 5 days at 37°C in 5% CO2. On 
the fifth day, plates were centrifuged and supernatants were collected and stored at -40°C. 
Interferon-γ (IFN-γ) concentration was determined on PBMC supernatants by a sandwich-
ELISA. The Canine IFN-γ DuoSet ELISA kit (R&D Systems) was used, following the 
manufacturer’s instructions. All samples were processed in duplicate and a standard curve was 
included in all plates, with a range of IFN-γ concentrations from 0 to 2000 pg/mL. Optical 
densities were determined at 450 nm, with wavelength correction set to 570 nm. IFN-γ 
concentrations were calculated using a four parameter logistic curve produced in GraphPad 
Prism® version 5.3. To obtain the specific IFN-γ concentration for each sample, readings from 
the unstimulated cell supernatant were subtracted from the LSA-stimulated cell supernatant. 
All plates presented a coefficient of determination (R2) above 0.99. 
 
3.5.7. Definition of canine leishmaniosis case 
 
Classification of trial dogs’ infection status was determined based on the results of serological 
tests, presence of clinical signs, and detection of CBC or plasma biochemical abnormalities 
compatible with CanL. Any suspicion of L. infantum infection detected by the researchers 
during sample collection or the dog owners throughout the trial period would be further 
evaluated. Apart from these reported cases, and because all analyses were performed in 
parallel at the end of the field study, identification of CanL cases was mainly performed in April 
2017. 
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A confirmed case of leishmaniosis was defined as: 
- Seroconversion to L. infantum, defined as a 4-fold increase in ELISA units when compared 
with basal values (ELISA units measured at T0) for the same individual and, 
- Detection of L. infantum DNA in lymph node samples and, 
- Presence of clinical signs or laboratory abnormalities compatible with CanL. 
In addition, animals without detectable clinical signs or laboratory findings, but showing 
evidence of seroconversion and presence of Leishmania DNA in lymph nodes at the last time 
point (12M) were also considered confirmed cases of active L. infantum infection. 
 
3.5.8. Study endpoint 
 
Cases of CanL confirmed during the field study were submitted to treatment and follow-up or 
euthanasia, according to the dog owner’s decision. 
 
3.5.9. Statistical analysis 
 
All statistical analyses were performed using Stata 15 software (StataCorp LP, College Station, 
TX, USA). Continuous variables included in this study did not present a normal distribution and 
normality could not be achieved by data transformation. Therefore, non-parametric statistical 
tests were used to compare between and within group results for continuous variables. 
Comparisons between groups at each time point were tested by Mann-Whitney U test. 
Longitudinal comparisons within groups were tested by Wilcoxon signed-rank test. Statistical 
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4. RESULTS AND DISCUSSION 
 
4.1. SEROPREVALENCE OF CANINE Leishmania infantum INFECTION IN GIRONA 
PROVINCE AND IDENTIFICATION OF RISK FACTORS FOR THE INFECTION 
 
This study has been accepted for publication in the journal Preventive Veterinary 




La Cuenca mediterránea es una región endémica de la leishmaniosis canina (LCan), donde 
representa un importante problema veterinario y plantea problemas de salud humana. 
Sin embargo, la distribución de la enfermedad es heterogénea y no todos los países y 
lugares han sido estudiados y caracterizados por igual. Este trabajo describe la situación 
de la LCan en la provincia de Girona (Cataluña, España), para la cual no existen datos 
reportados y publicados. Entre 2012 y 2016, se realizaron cuatro encuestas transversales 
de seroprevalencia en toda la provincia, incluyendo 36 estaciones de muestreo en 26 
localidades y un total de 593 perros. Para cada animal también se recolectaron variables 
individuales y de ubicación. Además, cada propietario respondió a un cuestionario sobre 
sus conocimientos previos de la LCan y los métodos preventivos utilizados. Las muestras 
de sangre se analizaron mediante un ELISA in house y se utilizó un modelo de regresión 
logística mixta para evaluar la relación entre las variables predeterminadas y  la 
seropositividad del perro. Se utilizó la correlación de Spearman para evaluar la asociación 
entre el riesgo de LCan percibido por los dueños y la seroprevalencia de L. infantum en un 
lugar determinado. La seroprevalencia global estimada para la provincia de Girona fue del 
32,8% (IC 95%: 28,2-37,5), de los cuales solo el 6,8% de los perros (10/146) se 
consideraron sintomáticos. La edad del perro [OR = 1.21 (IC 95%: 1.11-1.31); p <0.001] y 
la altitud [OR = 0.02 (IC 95%: 0.001-0.19); p = 0.001] fueron identificados como factores 
de riesgo para la infección. Se espera que los resultados obtenidos en este estudio 
ayuden a la implementación de programas de control dirigidos en áreas endémicas de 
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LCan en toda Europa, así como proporcionen datos adecuados para el diseño de mapas de 
evaluación de riesgo de la enfermedad más idóneos. 
 
4.1.2. Background  
 
Spain is an endemic country for CanL and, as observed in other endemic areas, the 
distribution of the infection is highly heterogeneous throughout the territory (Miró and 
Molina, 2006). For this reason, Mediterranean endemic regions would benefit greatly 
from CanL directed control efforts, targeted at areas with higher levels of infection. CanL 
seroprevalence in owned dogs in Spain ranges from 1.6% in the northwest (Miró and 
Molina, 2006) to 34.6% in the south (Morillas-Márquez et al., 1996), with a range of 
intermediate values reported  across the territory (Alcover et al., 2013; Ballart et al., 
2013a; Martín-Sánchez et al., 2009; Miró et al., 2017a; Solano-Gallego et al., 2001a). 
Nevertheless, as in other Mediterranean countries, the map of CanL distribution in Spain 
is far from complete, with many regions still lacking documented information.  
Catalonia, in the north-east of Spain, is considered one such endemic area for CanL. Here, 
like in other regions, identifying locations for the implementation of CanL directed control 
programmes is constrained by the heterogeneous distribution of the infection and the 
lack of published data on CanL prevalence. Historically, the south of Catalonia was known 
for the presence of well-established and important foci of CanL (Fisa et al., 1999; Portús, 
2007) but recent studies in northern areas such as the Lleida region (Ballart et al., 2013a) 
showed that the infection is more widespread than previously thought. Furthermore, 
results of a recently published questionnaire-based study suggest that Girona province, in 
the north-east of Catalonia, may be an endemic area of CanL (Lladró et al., 2017). In a 
survey of local veterinarians, the general opinion was that CanL is well established 
throughout the province and the number of autochthonous cases has risen in the last 
years. Additionally, Girona province shares a range of physical and climatic characteristics 
with other Mediterranean locations and is therefore an appropriate example for CanL 
epidemiological studies. 
The objectives of this study were to provide the first data on CanL seroprevalence for 
Girona province, which could also confirm the hypothesis of CanL endemicity in this 
region suggested by Lladró et al. (2017), and to identify possible individual and location 
Results and Discussion 
69 
 
risk factors associated with the infection in the study area which can be applied in the 




Descriptive analysis of the study population 
A total of 593 blood samples were obtained from dogs distributed throughout the north-east 
and Pyrenean areas of Spain, in Girona province, with sampling points ranging from 1 to 10 per 
county (Table 7). 
Sampling sites were mainly rural (corresponding to 50.1% of the dog sample) and periurban 
(41.8% of sampled dogs), with dog density per site ranging from 3 to 34. Altitudes ranged from 
50 to 1300 m a.s.l., with the majority of dogs living below 800 m a.s.l. (83%). Most dogs were 
hunting animals (78.9%), but breeding (16%), shelter (2.5%), racing (2.2%) and pet dogs (0.3%) 
were also represented. A large number of sampled dogs were born in Girona province (60.4%) 
and were not reported to have left the region. All animals included in the study were kept with 
other dogs in open kennels during the day time, and the majority were also kept outdoors at 
night (87.9%). There were other animal species kept in close proximity to 49.6% of the 
sampled dogs. These included cats, horses, cows, goats and pigs. Observed age average was 
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Table 7. True seroprevalence for canine Leishmania infantum infection observed in each 
locality and overall true seroprelavence calculated per county and for Girona province. 











% (95% CI) 
Alt Empordà Cadaqués 2 29 (12) 41.4 41.8 
 Darnius 2 18 (6) 33.3 31.1 
 Ordis  1 31 (9) 29.0 25.4 
 Total 5 78 (27) 34.6 32.8 (20.6-45.0) 
Baix 
Cerdanya Urtx 1 30 (1) 3.3 0 
Baix 
Empordà Sant Feliu de Guíxols 1 19 (10) 52.6 56.8 (30.9-82.8) 
Garrotxa Hostalnou de Bianya 2 21 (3) 14.3 5.7 
 Montagut 2 55 (16) 29.1 25.5 
 Olot 1 12 (5) 41.7 42.2 
 Sant Esteve de Llémena 1 21 (2) 9.5 0 
 Total 6 109 (26) 23.9 18.5 (9.2-27.7) 
Gironès Aiguaviva 1 30 (4) 13.3 4.4 
 Canet d'Adri 3 44 (35) 79.6 92.7 
 Madremanya 1 20 (3) 15.0 6.7 
 Sant Gregori 1 24 (13) 54.2 58.9 
 Total 6 118 (55) 46.6 48.8 (38.4-59.2) 
Plà de 
l’Estany Banyoles 1 15 (7) 46.7 48.9 (19.7 -78.0) 
Ripollés Bruguera 1 9 (0) 0 0 
 Camprodon 1 8 (0) 0 0 
 Ogassa 1 32 (0) 0 0 
 Serrat 1 6 (0) 0 0 
 Setcases 1 3 (0) 0 0 
 Ventola 1 13 (0) 0 0 
 Total 6 71 (0) 0 0 
Selva Brunyola 1 10 (0) 0 0 
 Maçanet de la Selva 1 17 (3) 17.7 10.2 
 Massanes 2 29 (3) 10.3 0.5 
 Riells i Viabrea 2 31 (7) 22.6 16.8 
 Sta Coloma de Farners 2 32 (0) 0 0 
 Vilobí d'Onyar 2 34 (7) 20.6 14.1 
 Total 10 153 (20) 13.1 4.1 (0-10.3)  
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Dog owners’ perception on CanL and use of preventive measures 
The majority of dog owners showed previous knowledge of CanL (93.9%) and approximately 
half of them knew preventive methods against CanL (57.6%), although only 27.3% had ever 
used them (Table 8). 
 
Table 8. Results of the questionnaire asked to dog owners regarding their knowledge of canine 
leishmaniosis and the methods used to prevent the infection (n=33). 
Question No. replies (%)  
Have you ever heard of CanL?  
 Yes 31 (93.9) 
 No 2 (6.1) 
In your opinion, how great is the risk of any of your dogs having 
CanL throughout their lives? 
 
 0% 4 (12.1) 
 5% 9 (27.3) 
 10% 5 (15.2) 
 20% 7 (21.2) 
 50% 1 (3.0) 
 50-90% 4 (12.1) 
 90-100% 3 (9.1) 
Do you know of any measures to protect your dogs against CanL?  
 Yes 19 (57.6) 
 No 14 (42.4) 
Do you use any measure to protect your dogs against CanL?  
 Yes 9 (27.3) 
 No 24 (72.7) 
If YES, which method do you use? (n=9)  
 Collar 4 (44.5)
2
 








If NO, why not? (n=24)  
 Unawareness 14 (58.3)
2
 
 Do not believe it works 3 (12.5)
2
 
 Too expensive 2 (8.3)
2
 
 Do not believe there is CanL 1 (4.2)
2
 
 Others/no answer 4 (16.7)
2
 
Do you use any measure to protect your dogs against other 
arthropods (e.g. ticks, fleas, etc.) 
 
 Yes 25 (75.8) 
 No 8 (24.2) 
If YES, which method do you use? (n=25)  
 Pour-on 12 (48.0)
2
 
 Sprays 2 (8.0)
2
 








1 Includes the use of others or multiple preventive measures. 
2 Percentage based on the total for the subgroup YES or NO of the previous answer. 
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Only a small number of dog owners believed that their dogs were not at risk of contracting 
CanL during their lifetime (12.1 %), with the majority of them believing that the risk of CanL 
ranged from 5 to 20% (63.7%). The result of the Spearman’s correlation showed a positive 
association between dog owners’ perceived risk of CanL infection and CanL seroprevalence 
(rs=0.5046; p=0.0027). 
Prophylactic methods against CanL, when used, included dog collars (44.5%), spot-on (33.3%) 
and combined insecticide treatments (22.2%). Vaccination against CanL or immunomodulatory 
prophylactic treatments had not been used by any of the dog owners. The main reasons given 
for not using any preventive method against CanL were unawareness (58.3%) and not believing 
that prophylaxis worked (12.5%).  
 
CanL study results 
From the 593 dogs analysed, 146 were considered seropositive by ELISA. Apparent 
seroprevalence at the sampling point level ranged from 0% to 79.6%, with a total apparent 
seroprevalence calculated for Girona province of 24.6% (95% CI: 21.2-28.3). Considering these 
values, the estimated true CanL seroprevalence for Girona province was 19.5% (95%CI: 15.5-
23.5). Estimated seroprevalence at the county level ranged from 0 to 56.8%. Results for all 
localities and counties are summarized in Table 7. 
Only 10 out of 146 seropositive dogs were considered symptomatic (6.8%). Observed clinical 
signs included onychogryphosis (n=9), weight loss (3), skin wounds (3), diffuse alopecia (2), 
popliteal lymphadenomegaly (2), periocular alopecia (2), and ocular lesions (2). 
 
Bivariate statistical analysis 
One of the dog kennels included in the seroprevalence study (Banyoles, Plà de l’Estany) was 
excluded from the statistical analysis, following the criteria used in similar studies (Ballart et 
al., 2013a). This is a shelter kennel that collects stray dogs, which means that some of the 
individual data, as well as owners’ perception of CanL, could not be collected. Therefore, the 
statistical analysis included 578 individuals and 25 localities. Results of the bivariate analysis 
are summarized in Table 9. Dogs’ age and location altitude (p<0.001) showed a very strong 
relationship with dog seropositivity. In our population, a bimodal CanL seroprevalence 
distribution according to age was observed, with a first peak at 3-4 years and a second at 7-8 
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years old, with the risk of infection rising by each year of life [OR=1.18 (95%CI: 1.09-1.27)] and 
decreasing at altitudes above 800 m a.s.l. [OR=0.012 (95%CI: 0.002-0.07)]. Also, according to 
the results, being a crossbred dog raises the risk of infection [OR=2.19 (95%CI: 1.18-4.06); 
p=0.013] and the use of unspecific insecticides against arthropods has a protective effect 
[OR=2.94 (95%CI: 1.58-5.45); p=0.001]. All the other variables (sex of the dog, type of habitat, 
dog purpose, type of nocturnal refuge, presence of other animal species, owner’s knowledge 
of prophylactic measures against CanL and the regular application of these methods) showed 
no statistically significant relationship with dog seropositivity. 
 
Multivariable mixed model 
The final multivariable mixed logistic regression model identified age of the dog and altitude of 
the location as the explanatory variables that affect dog seropositivity. According to this 
model, the odds of being infected rise in 1.21 per each year of life [(95%CI: 1.11-1.31); 
p<0.001] and decrease at locations above 800 m a.s.l. [OR=0.02 (95%CI: 0.001-0.19); p=0.001]. 
The final model explains 53.7% of the total variance of the outcome variable, of which 42% is 
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Table 9. Number of dogs analysed and Leishmania infantum seropositivity observed for each 
category of the explanatory variables, followed by the results of the bivariate analysis 
expressed in odds ratios (OR). Statistically significant variables (p<0.05) are marked with (*). 




No. seropositive dogs 
(% seropositive dogs) 
Bivariate analysis 
OR (95% CI) p-value 
Altitude (m a.s.l.)     
< 800 492 144 (29) Ref  
>800 109 6 (6) 0.012 (0.002-0.07) <0.001* 
Type of habitat     
Rural 297 70 (24) Ref  
Periurban 228 51 (22) 1.64 (0.93-2.88) 0.082 
Urban 53 19 (36) 0.97 (0.42-2.22) 0.934 
Presence of other animals 
(other than dogs) 
    
Yes 302 73 (24) Ref  
No 299 78 (26) 1.10 (0.58-2.08) 0.763 
Sex     
Male 338 87 (26) Ref  
Female 240 53 (22) 0.88 (0.56-1.38) 0.581 
Age (years)   1.18 (1.09-1.27) <0.001* 
<1 53 6 (11)   
1 83 12 (14)   
2 91 13 (14)   
3 79 20 (25)   
4 51 16 (31)   
5 42 10 (24)   
6 42 12 (29)   
7 33 15 (45)   
8 33 14 (42)   
9 15 3 (20)   
10 18 5 (28)   
11 10 4 (40)   
12 3 0 (0)   
13 1 1 (100)   
Breed     
Purebred 258 51 (20) Ref  
Crossbred 320 89 (28) 2.19 (1.18-4.06) 0.013* 
Use given     
Hunting 468 118 (25) Ref  
Breeding 95 21 (22) 2.28 (0.78-6.63) 0.130 
Others
1
 15 1 (7) 0.20 (0.02-1.73) 0.145 
Night shelter     
Outdoors 506 126(25) Ref  
Indoors 72 14 (19) 0.50 (0.20-1.23) 0.131 
Owner knows preventive measures against CanL 
Yes 362 103 (28) Ref  
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No 216 37 (17) 0.58 (0.29-1.19) 0.138 
Owner has used preventive measures against CanL 
Yes 140 46 (33) Ref  
No 438 112 (26) 1.24 (0.63-2.43) 0.539 
Owner has used prevention methods against other arthropods 
Yes 472 112 (24) Ref  
No 106 28 (26) 2.94 (1.58-5.45) 0.001* 





Until now, data on CanL in north-eastern and Pyrenean areas of Spain is scarce and 
fragmented. The only published study regarding CanL in Girona province is a questionnaire-
based survey of veterinary practitioners working in the region (Lladró et al., 2017). This work 
provided the first data from a previously recognized, but non-documented CanL endemic area 
in north-east Spain and highlights gaps in the epidemiological picture in Mediterranean regions 
considered to be endemic for CanL (Ready, 2017). The veterinary survey showed that new 
cases of CanL in autochthonous animals were diagnosed annually, including some 
asymptomatic cases detected by CanL pre-vaccination screening (Lladró et al., 2017). The 
present study confirms the suspected endemicity of CanL in the region, providing results for 
canine seroprevalence, as well as an overview of the infection distribution throughout Girona 
province. Preliminary exploratory surveys showed the presence of phlebotomine vectors in the 
surroundings of many of the sampling points (Annex 2), confirming that all conditions are 
present for a complete L. infantum biologic cycle to be maintained in this region. In addition, 
the characterisation of all individuals and locations included in the study allowed for the 
identification of risk factors associated with CanL distribution.  
As previously mentioned, there was an active search for individuals to be enrolled in the study, 
assisted by local veterinarians. There was therefore a constraint in the distribution and type of 
animals recruited, depending on the availability of veterinary practitioners’ clients willing to 
participate. As a result, the dog population was mainly composed of hunting dogs. These 
animals have inherent characteristics, such as the fact that they are usually kept with other 
dogs in open kennels, in rural or periurban settings, and generally do not have the same type 
of veterinarian monitoring as pet dogs. Therefore, this type of population is usually considered 
Results and Discussion 
76 
 
a good sentinel for CanL (Ballart et al., 2013a; Cabezón et al., 2010). As similar hunting 
activities take place throughout Mediterranean areas in Europe, it can be expected that 
comparable dog populations are widespread. An overestimation of the overall infection 
prevalence can however occur due to an expected lower incidence in urban centres, mostly 
explained by a decreased probability of contact between dogs and sand fly vectors (Ballart et 
al., 2013a). Additionally, there was an increased difficulty in recruiting dogs from higher 
altitude regions, mainly because these areas are more inhospitable and less populated. 
Consequently, dogs living at locations above 800 m a.s.l. are less represented. 
Some degree of spatial clustering may have been introduced by sampling several dogs in the 
same kennel or locality. This could also have had a clustering effect on the positive results, as 
higher dog densities tend to favour the transmission of the parasite, especially if some of the 
dogs are already infected (Alonso et al., 2010). Nevertheless, in the present study we have 
used similar dog populations in the different sampling points, allowing comparison between 
them. Additionally, this methodology has also been used in similar studies describing other 
regions of Spain (Alcover et al., 2013; Ballart et al., 2013a). In the statistical analysis, the 
potential clustering effect was dealt with by introducing “Locality” as a random-effects term in 
the final multivariable mixed logistic regression model.   
The serological technique used to measure antibody levels to L. infantum was an in-house 
ELISA. ELISA is one of the methods recommended by the World Organization for Animal Health  
for performing CanL surveillance studies and to determine prevalence of infection (OIE, 2014), 
the other one being the indirect immunofluorescent antibody test (IFAT). Unlike IFAT, ELISA is 
easy to perform and interpret, being particularly useful in field study settings, where a large 
number of samples must be analysed (Maia and Campino, 2008). In addition, this ELISA has 
been widely used for CanL diagnosis, as well as in other CanL epidemiological studies (Alcover 
et al., 2013; Ballart et al., 2013a; Fernández-Bellon et al., 2008; Fisa et al., 2001; Iniesta et al., 
2002; Riera et al., 1999; Rodríguez-Cortés et al., 2010; Solano-Gallego et al., 2005). 
The overall estimated seroprevalence for Girona province was 19.5%, ranging from 0 to 56.8% 
across the different counties. These results are in accordance with previous reports for other 
regions of Spain, as well as the Mediterranean basin (Ballart et al., 2013a; Cortes et al., 2012; 
Maroli et al., 2008; Ntais et al., 2013). A series of CanL seroprevalence surveys undertaken in 
France, Italy, Spain and Portugal between 1971 and 2006 showed an overall seroprevalence of 
23.2%, with point prevalences of 0% and higher than 80% in some locations (Franco et al., 
2011). These values are comparable to the ones obtained in the present study and correspond 
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to the previous claims of the heterogeneous distribution of the disease. However, as pointed 
out by Franco et al. (2011), caution must be taken when comparing studies with different 
experimental designs and different criteria used in the selection of the target dog population, 
as this can introduce significant variations in seroprevalence results. A common European 
strategy for leishmaniosis surveillance and control would aid the implementation of 
standardized methodology. However, although leishmaniosis is currently listed as a notifiable 
disease by the World Organization for Animal Health (OIE, 2018), this is not clearly reflected in 
the European or Spanish legislation (BOE, 2014; Official Journal of the European Union, 2012). 
From the 146 seropositive dogs, only 10 (6.8%) showed clinical signs compatible with CanL and 
more than 50% presented low standard ELISA units (inferior to 50U). This can be explained by 
the cryptic nature of the infection and the wide clinical spectrum it can present, ranging from 
asymptomatic or mild symptomatic cases to very severe clinical stages (Solano-Gallego et al., 
2009). There is also the possibility that some of the dogs are in an early stage of infection (Fisa 
et al., 2001; Miró et al., 2012) or are immunologically resistant and only transiently 
seropositive, eventually showing spontaneous clearance of the parasite (Fisa et al., 1999). In 
such populations, serological techniques could have a lower sensitivity (Otranto et al., 2009). It 
is also known that, in endemic areas, only a small proportion of dogs display symptoms of 
CanL, while the majority of infected dogs do not show any clinical evidence of the disease 
(Baneth et al., 2008). It is believed that the high prevalence of asymptomatic infected dogs, 
comparable to that observed in Lleida province (other north-eastern and Pyrenean region 
studied in Spain), is strong evidence for a well-established CanL focus in Girona province 
(Ballart et al., 2013a). In the present study, clinical signs compatible with CanL were also 
identified in 10 out of 447 seronegative dogs (2%), illustrating the lack of specificity of the 
disease’s clinical presentation and the added difficulty in detecting affected dogs. As 
mentioned before, the ability of serological tests to detect infected animals is limited, 
especially in endemic settings, and a small number of seronegative asymptomatic infected 
dogs should be expected, as previously reported in other studies (Iniesta et al., 2002; Otranto 
et al., 2009; Solano-Gallego et al., 2011). These animals can harbour parasites in the skin, 
detectable by PCR (Otranto et al., 2009), and could also be infectious to sand flies, as has been 
demonstrated for asymptomatic seropositive dogs (Molina et al., 1994; Quinnell and 
Courtenay, 2009). Considering this, any control programme for CanL should be based on 
multiple diagnostic methods, as serology alone can prove to be insufficient in detecting all 
infected and infectious dogs. 
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In the present study, the risk of infection increased with dogs’ age. This is an individual factor 
commonly reported as being positively related with L. infantum infection (Alonso et al., 2010; 
Ballart et al., 2013a; Cortes et al., 2012; Gálvez et al., 2010b; Maresca et al., 2009; Martín-
Sánchez et al., 2009; Miró et al., 2012), and which can be explained by an incremental risk of 
exposure to infected sand flies. The bimodal CanL seroprevalence distribution observed has 
been previously described by other authors (Gálvez et al., 2010b; Miró et al., 2012). This 
pattern suggests that L. infantum may be able to infect immunologically vulnerable animals at 
an earlier age, followed by a later infection of resistant animals either by cumulative exposure 
or due to concomitant diseases that weaken the dogs’ immune system (Miranda et al., 2008). 
According to the results, altitude shows a negative correlation with L. infantum infection. This 
is mainly related to the bioclimatic needs of the phlebotomine vector species present in Spain, 
Phlebotomus perniciosus and P. ariasi (Rioux et al., 1986). Altitude is known to be closely 
linked to temperature, precipitation and land cover (Barón et al., 2011; Rivas-Martínez, 1983). 
In temperate regions, as atmospheric temperature rises, a higher biting rate is expected 
(Hartemink et al., 2011), therefore increasing the risk of sand fly bites to vertebrate hosts. 
Simultaneously, a shorter extrinsic incubation period (Hartemink et al., 2011) and a more 
effective development of the parasite inside the vector (Rioux et al., 1985) are observed, 
raising the risk of L. infantum infection. Also, an increased altitude may provide a more hostile 
environment for sand fly survival (Gálvez et al., 2010a), not only because of the more extreme 
bioclimatic conditions, but also due to a possible scarcity of vertebrate hosts. However, a 
relationship between altitude and risk of CanL infection was not observed in the neighbouring 
province of Lleida (Ballart et al., 2014, 2013a) or in France (Chamaillé et al., 2010), where both 
vector species are present and show different altitudinal preferences. In these areas, P. 
perniciosus is known to occupy ecological niches commonly below 800 m a.s.l., while P. ariasi 
shows a higher abundance above this altitude. Therefore, it would be of particular interest to 
perform entomological studies and risk factor analysis associated with the vector populations 
present in the study area. This could also help to improve the ability of the present model to 
predict the outcome variable. One of the possible reasons for the moderate performance of 
the final statistical model presented (which explains only 53.7% of variance of the outcome 
variable) is the absence of data on the abiotic factors mentioned above, which are known to 
have an important impact on sand fly populations, and indirectly on L. infantum infections 
(Dantas-Torres et al., 2014; Gálvez et al., 2010a). 
The present study failed to detect an effect of type of habitat (rural/urban) or access to night 
shelter, which several other authors identified as significantly related to L. infantum infection 
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(Ballart et al., 2013a; Cortes et al., 2012; de Almeida et al., 2012; Gálvez et al., 2010b; Martín-
Sánchez et al., 2009; Oliveira et al., 2016). According to these studies, dogs that live in rural 
habitats and are left outdoors at night show an increased risk of infection. In this study, the 
high percentage of dogs living in rural/periurban areas and kept permanently outdoors may 
not have allowed detection of such an effect. Also, periurban areas are increasingly described 
as the most suitable ecosystems for sand flies, due to the ideal microclimate offered by house 
gardens associated with the abundance of vertebrate hosts (Alvar et al., 2004; Ballart et al., 
2013a). 
Results from the bivariate statistical analysis identified dog breed and the use of general 
insecticide treatment against arthropods as variables associated with dog seropositivity. In the 
first case, crossbred dogs would be at higher risk of infection [OR=2.19 (95%CI: 1.18-4.06); 
p=0.013]. However, previous studies have shown that this should not be the case, as 
crossbred, autochthonous dogs tend to be more resilient to L. infantum infection (Alvar et al., 
2004; Solano-Gallego et al., 2000). This is even more noticeable when the purebred dogs 
belong to exotic breeds like boxers and beagles (both represented in this study), known for 
their higher sensitivity to CanL (Solano-Gallego et al., 2009). The effect of dog breed was 
absent in the mixed model, showing that the previous results were most probably induced by 
confounding factors related to the kennel locations (e.g. altitude) or dog owners’ attitudes 
(e.g. use of prophylactic measures against CanL). The non-use of generalist insecticide 
preventive methods against arthropods was also identified as a risk factor for L. infantum 
infection [OR=2.94 (95%CI: 1.58-5.45); p=0.001], while the use of specific prophylaxis against 
CanL failed to show a protective effect (p=0.539). Again, this may be related to confounding 
factors, such as a possible partial effect of some insecticides against phlebotomine vectors, 
even though they may not be licensed for sand fly prevention. Additionally, the improper use 
of specific sand fly prevention treatment, such as failure to apply it to all dogs or to maintain it 
during the whole transmission season, may impair the protective effect of these products 
(Courtenay et al., 2009). Once again, the effect of this variable lost significance in the 
multivariable analysis and was not included in the final statistical model. 
The majority of dog owners showed previous knowledge of CanL and to be aware of 
preventive methods for the infection. Although a positive correlation was observed between 
owners’ perceived risk of infection and CanL seropositivity at the dog kennel level, only 27.3% 
of dog owners stated that they regularly used CanL prophylactic measures. This result is in 
accordance with those reported by Lladró et al. (2017), in which all veterinary practitioners 
working in Girona province recommended at least one preventive measure against CanL, 
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though the majority did not believe that dog owners protected their dogs properly. When 
used, the most frequent prophylactic methods applied against CanL were dog collars and spot-
on insecticides, as recommended by veterinarians. However, most owners did not keep their 
dogs indoors at night and did not report the use of vaccination against CanL or 
immunomodulatory agents, as also suggested by veterinarians (Lladró et al., 2017). Our 
studyshows that the implementation of prophylactic measures by dog owners should be 
reinforced in order to reduce L. infantum transmission between dogs, as well as to reduce the 
public health risk (Miró and López-Vélez, 2018). 
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4.2. EVALUATION OF DOG EXPOSURE TO Phlebotomus perniciosus THROUGH THE 
DETECTION OF ANTI-SAND FLY SALIVA ANTIBODIES IN THE CANINE HOST 
 
This study has been published in the journal Parasites & Vectors and is available in article 




La transmisión de Leishmania infantum se hace a través de la picadura de vectores flebotomos. 
Por lo tanto, el monitoreo del contacto entre el hospedador y el vector representa una 
herramienta epidemiológica importante que podría usarse para evaluar la efectividad de los 
programas de control de vectores en áreas endémicas. Estudios previos han demostrado que 
los anticuerpos caninos contra la saliva de los flebotomos son marcadores específicos de la 
exposición a los vectores de Leishmania. Sin embargo, la validación de este método debe 
ampliarse a poblaciones heterogéneas de perros naturales de áreas endémicas de LCan. En 
este estudio, se siguieron durante 14 meses 176 perros que viven en 12 lugares diferentes de 
un área endémica para L. infantum en el noroeste de España (provincia de Girona). Las 
muestras de sangre a utilizar para evaluar la respuesta inmune humoral canina al 
homogeneizado de glándulas salivales (SGH) y a la proteína recombinante “yellow-related” de 
43 kDa (rSP03B) de Phlebotomus perniciosus, uno de los vectores confirmados de L. infantum 
presente de forma natural en esta región, fueron tomadas en 5 momentos de muestreo 
predeterminados (Febrero, Agosto y Octubre de 2016, Enero y Abril de 2017). 
Simultáneamente, se evaluó la infección por L. infantum en todos los perros por serología 
(ELISA in house). La relación entre los anticuerpos anti-SGH y anti-rSP03B con el mes de 
muestreo, la infección por L. infantum y la localidad se estudió mediante el ajuste de modelos 
de regresión lineal multinivel. La dinámica de las IgG caninas anti-saliva de SGH y rSP03B siguió 
las tendencias esperadas de actividad de P. perniciosus en la región. Se detectaron 
asociaciones estadísticamente significativas para ambos antígenos salivales entre la exposición 
al vector y el mes de muestreo o la seropositividad del perro a L. infantum. La correlación 
entre anticuerpos caninos contra SGH y rSP03B fue moderada. Los resultados confirman la 
presencia frecuente de vectores de LCan en el área de estudio así como la aplicabilidad de las 
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pruebas ELISA basadas en SGH y rSP03B para estudiar la exposición canina a P. perniciosus en 




The detection of anti-sand fly salivary antibodies in the blood of vertebrate hosts has proven to 
be highly specific (Rohoušová et al., 2005) and was successfully used as a marker of exposure 
to L. infantum vectors (Martín-Martín et al., 2014; Vlkova et al., 2011). In CanL endemic areas, 
monitoring the canine IgG response to sand fly saliva can be a useful epidemiological tool 
(Kostalova et al., 2015; Vlkova et al., 2011), complementing studies of vector population 
dynamics and host-vector interactions, as well as enabling the assessment of risk of 
Leishmania infection (Carvalho et al., 2015; Marzouki et al., 2011; Rohoušová et al., 2005). 
Furthermore, it can be used to measure the effectiveness of vector-control programmes and 
to assist in the design of better control strategies for the disease (Clements et al., 2010; 
Gidwani et al., 2011).  
Originally, sand fly whole salivary gland homogenates (SGH) were used to investigate the 
presence of anti-sand fly saliva antibodies in vertebrate hosts (Gidwani et al., 2011; Volf and 
Rohoušova, 2001). However, its use in large-scale studies is impaired by technical limitations 
(Lestinova et al., 2017). Additionally, the use of SGH in vector exposure tests may reduce the 
specificity of detection due to a possible cross-reactivity with saliva of sympatric and closely 
related sand fly species (Lestinova et al., 2015). 
An alternative to the use of SGH is the identification of species-specific salivary proteins that 
can be expressed in recombinant forms and produced in large quantities for use in large-scale 
epidemiological studies (Drahota et al., 2014; Kostalova et al., 2017). Recent studies identified 
P. perniciosus yellow-related protein rSP03B as the most promising candidate to replace SGH 
in the detection of host markers of exposure to this vector species (Kostalova et al., 2017, 
2015; Martín-Martín et al., 2014). This recombinant protein has been tested and validated in 
dogs and other animals in cross-sectional studies (Kostalova et al., 2017; Martín-Martín et al., 
2014), as well as in a canine longitudinal study (Kostalova et al., 2015), but no information 
exists on the seasonal dynamics of either SGH or rSP03B in natural heterogeneous dog 
populations from endemic areas. 
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Therefore, the objectives of this study were (i) to investigate the dynamics of P. perniciosus 
and their relative density in a previously uncharacterized CanL endemic area through the 
detection of anti-saliva IgG in dogs; and (ii) to evaluate the performance of both SGH and 




Seasonal dynamics of IgG response against salivary proteins from Phlebotomus perniciosus 
Median values of normalized ELISA OD values for SGH ranged from 9.04 (range: 3.94–66.23) in 
January 2017 to 18.51 (7.93–100.58) in August 2016 (Table 10). For rSP03B, median OD values 
varied between 12.21 (6.75–53.71) and 19.53 (10.64–124.01) in January 2017 and August 
2016, respectively. With both antigens, median OD readings raised from basal values in 
February 2016 (10.11 and 14.67 for SGH and rSP03B, respectively) to peak in August (18.51 
and 19.53 for SGH and rSP03B, respectively), sustained higher readings in October (11.15 and 
15.31 for SGH and rSP03B, respectively), and descended again to basal levels in January (9.04 
and 12.21 for SGH and rSP03B, respectively) and April 2017 (9.54 and 13.44 for SGH and 
rSP03B, respectively). Median normalized ELISA OD results obtained per month for both SGH 
and rSP03B are described in Table 10 and plotted in Figure 9. 
 
Table 10. Median values of normalized OD readings for SGH and rSP03B obtained per sampling 
month in all locations 
Variable N  SGH rSP03B 
 Median (Range) Median (Range) 
February 2016 174  10.11 (5.49–49.62) 14.67 (7.36–41.24) 
August 2016 33  18.51 (7.93–100.58) 19.53 (10.64–124.01) 
October 2016 164  11.15 (5.56–86.44) 15.31 (6.15–112.54) 
January 2017 154  9.04 (3.94–66.23) 12.21 (6.75–53.71) 
April 2017 148  9.54 (5.25–62.59) 13.44 (6.27–36.22) 
N: number of dogs sampled per sampling month 
 




Figure 9. Dynamics of anti-P. perniciosus salivary proteins IgG response in dogs from an 
endemic area during a sand fly activity season. Values presented refer to the normalized OD 
medians obtained at each sampling month for all dogs and locations. Statistically significant 




Cut-off values were set at 13 for SGH and 22 for rSP03B. When these were applied to the OD 
readings obtained in August 2016, 75.76% (25/33) of the dogs were positive to anti-SGH IgG, 
and 36.36% (12/33) to anti-rSP03B antibodies. In October, these values dropped to 35.98% 
(59/164) for SGH and 18.9% (31/164) for rSP03B. During the non-transmission season 
(considered to extend from November to May), the percentage of seropositive dogs ranged 
from 14.29% (25/175) in February 2016 to 17.57% (26/148) in April 2017 for SGH and 8.44% 
(13/154) in January 2017 to 12.16% (18/148) in April 2017 for rSP03B. 
Correlation results for IgG response between SGH and rSP03B were rS = 0.54 (95% CI: 0.48–
0.60, p<0.001) (Figure 10). 
 
 




Figure 10. Correlation between IgG recognizing SGH and rSP03B protein in dogs naturally 
exposed to P. perniciosus. Results from both SGH and rSP03B are presented in normalized OD 
(rS = 0.54; 95% CI: 0.48–0.60, p<0.001) 
 
 
Dogs’ exposure to Phlebotomus perniciosus in the study area 
Exposure of dogs to phlebotomine vectors showed some variation according to the location. 
Median OD readings varied from 9.11 (range: 5.25–20.57) to 14.14 (7.44–55.45) for SGH ELISA 
and from 12.71 (7.53–64.44) to 17.87 (8.39–112.54) for rSP03B. Minimum median values of 
response to both SGH and rSP03B corresponded to the same location (Aiguaviva), but 
maximum median values were registered in different sites for each antigen (Sant Feliu de 
Guíxols for SGH and Montagut for rSP03B) (Table 11). Figure 11 presents the dynamics of dogs’ 
IgG response to SGH (Figure 11a) and rSP03B (Figure 11b) in each locality. 
The percentage of anti-sand fly saliva seropositive dogs per location, defined as the number of 
dogs that showed a positive IgG titre at least once during the study period, ranged from 
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13.33% (1/8) in Ordis to 100% in Canet d’Adri (8/8) and Sant Feliu de Guíxols (4/4) for SGH, and 
from 8.16% (1/12) in Hostalnou de Bianya to 100% (4/4) in Sant Feliu de Guíxols for rSP03B. 
Total anti-sand fly saliva seropositivity calculated for the study area was 49.43% (87/176) for 
anti-SGH IgG and 28.98% (51/176) for anti-rSP03B antibodies. 
 
Dogs’ exposure to Phlebotomus perniciosus and Leishmania infantum infection 
Correlation results between antibody response to P. perniciosus saliva and L. infantum were 
low both for SGH (rS = 0.27, 95% CI: 0.19–0.35, p<0.001) and rSP03B protein (rS = 0.25, 95% CI: 
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Table 11. Median values of normalized OD readings for SGH and rSP03B obtained per sampling 
location at all time points 
Variable n (Range) Geographical 
coordinates 
SGH rSP03B 
 Median (Range) Median (Range) 
Ordis 8 (7–9) 42°13'37.7''N, 
2°54'24.1''E 
9.14 (6.45–45.95) 15.16 (8.35–54.50) 
Madremanya 14 (12–15) 41°58'47.0''N, 
2°58'7.2''E 
11.22 (6.79–49.84) 14.49 (8.95–43.99) 
Vidreres 8 (7–9) 41°47'27.4''N, 
2°45'0.4''E 
10.59 (7.80–16.86) 13.46 (8.58–40.23) 
Massanes 21 (20–23) 41°45'15.3''N, 
2°38'44.0''E 
9.31 (5.67–62.59) 16.35 (7.82–55.81) 
Hostalnou de 
Bianya 
12 (11–14) 42°13'26.0''N, 
2°26'9.7''E 
8.75 (5.35–33.16) 13.19 (6.27–46.82) 
Montagut 13 (7–15) 42°14'7.7''N, 
2°35'57.6''E 
12.01 (3.94–72.61) 17.87 (8.39–
112.54) 
St. Esteve de 
Llémena 
9 (9–10) 42°3'35.1''N, 
2°37'1.4''E 
9.49 (6.23–22.40) 14.18 (9.12–22.46) 






Aiguaviva 19 (16–22) 41°54'27.2''N, 
2°46'19.0''E 
9.11 (5.25–20.57) 12.71 (7.53–64.44) 
St. Feliu de Guíxols 4 41°47'2.3''N, 
2°59'58.7''E 
14.14 (7.44–55.45) 16.73 (8.57–65.97) 
Riells i Viabrea 20 (18–21) 41°43'59''N, 
2°33'39.3''E 
10.02 (6.07–66.23) 13.43 (8.59–35.31) 
Vilobí d'Onyar 23 (22–23) 41°53'3.2''N, 
2°43'38.6''E 
9.13 (5.17–16.49) 13.05 (6.15–38.07) 








Figure 11. Dynamics of dogs’ IgG recognizing SGH (a) and rSP03B protein (b) in the different 
sampling locations during a sand fly activity season. Values presented refer to the normalized 
OD medians obtained at each sampling month. 
 
 
Multilevel analysis of the relationship between anti-Phlebotomus perniciosus salivary proteins, 
month and location and Leishmania infantum seropositivity 
The multilevel model results confirmed the annual dynamics of anti-salivary proteins IgG 
responses. When compared to the first sampling month (February 2016), IgG responses to SGH 
significantly rose in August (t = 8.55, df = 491, p<0.001) and October (t = 6.49, df = 491, 
p<0.001) and dropped in January (t = -2.49, df = 491, p=0.013) and April 2017 (no significant 
difference when compared to February 2016). As expected, the highest log OD estimate was 
observed in August 2016 and the lowest in January 2017 (Table 12). The same trend was 
observed in the model run for the rSP03B protein, with comparable levels of significance 
(Table 13). There were no significant differences in IgG responses for both antigens between 
each sampling location and the one set as reference, except for Montagut, where significantly 
higher OD levels were observed for SGH (t = 2.28, df = 166, p=0.024) and rSP03B (t = 2.13, df = 
164, p=0.035). According to the multilevel model, seropositivity to L. infantum proved to be 
associated with a rise in anti-salivary proteins OD values for both SGH (t = 2.5, df = 491, 
p=0.013) and rSP03B (t = 2.15, df = 493, p=0.032). 
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Table 12. Estimates of the multilevel linear regression model of the relationship between log 
transformed normalized SGH OD values and sampling time, location and dog seropositivity to 
L. infantum. “Dog” was included as a random effects variable 
Variable Levels Estimate SE p-value
a
 
Intercept  2.40 0.06 < 0.001 
Sampling month February 2016 Ref – – 
August 2016 0.54 0.06 < 0.001 
October 2016 0.20 0.03 < 0.001 
January 2017 -0.06 0.03 0.013 
April 2017 -0.01 0.03 0.666 
Location Aiguaviva Ref – – 
Ordis 0.07 0.11 0.562 
Madremanya 0.08 0.10 0.427 
Vidreres 0.10 0.11 0.393 
Massanes 0.07 0.09 0.441 
Hostalnou de Bianya -0.08 0.10 0.404 
Montagut 0.22 0.10 0.024 
St. Esteve de Llémena -0.03 0.11 0.786 
Canet d'Adri -0.02 0.11 0.891 
St. Feliu de Guíxols 0.16 0.15 0.308 
Riells i Viabrea 0.03 0.09 0.703 
Vilobí d'Onyar -0.02 0.09 0.791 
L. infantum seropositivity Seronegative Ref – – 
Seropositive 0.10 0.04 0.013 
SE: standard error 
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Table 13. Estimates of the multilevel linear regression model of the relationship between log 
transformed normalized rSP03B OD values and sampling time, location and dog seropositivity 
to L. infantum. “Dog” was included as a random effects variable 
Variable Levels Estimate SE p-value
a
 
Intercept  2.79 0.06 < 0.001 
Sampling month February 2016 Ref – – 
August 2016 0.39 0.06 < 0.001 
October 2016 0.09 0.03 0.003 
January 2017 -0.13 0.03 < 0.001 
April 2017 -0.06 0.03 0.016 
Location Aiguaviva Ref – – 
Ordis 0.06 0.10 0.563 
Madremanya -0.04 0.09 0.652 
Vidreres -0.03 0.10 0.783 
Massanes 0.05 0.08 0.533 
Hostalnou de Bianya -0.16 0.09 0.074 
Montagut 0.18 0.09 0.035 
St. Esteve de Llémena -0.10 0.10 0.287 
Canet d'Adri -0.05 0.10 0.641 
St. Feliu de Guíxols -0.19 0.14 0.173 
Riells i Viabrea -0.08 0.08 0.302 
Vilobí d'Onyar -0.06 0.08 0.399 
L. infantum seropositivity Seronegative Ref – – 
Seropositive 0.07 0.03 0.032 
SE: standard error 
a












The quantification of anti-sand fly saliva antibodies in vertebrate hosts of L. infantum has been 
previously shown to be an effective way of measuring exposure to the parasite vectors 
(Martín-Martín et al., 2014). In the case of dogs, the most frequent host and reservoir of L. 
infantum, this has been proven for P. perniciosus (Kostalova et al., 2017; Vlkova et al., 2011), 
as well as for other sand fly species (Hostomska et al., 2008; Rohoušová et al., 2015; Sima et 
al., 2016). These markers of exposure can then be applied in host-vector epidemiological 
studies, in L. infantum infection risk assessment, and to assist in the design of control 
strategies for the disease. Therefore, it is important to validate these techniques in natural, 
heterogeneous populations from endemic areas, in which a higher individual variability is 
expected.  
Phlebotomus perniciosus activity period in Spain shows two main peaks, the first in June-July 
and the second in September-October. These peaks also correspond to the periods of highest 
L. infantum transmission (Gálvez et al., 2010a; González et al., 2017; Morillas-Márquez et al., 
1983). This trend was identified in our study and corresponds to the rise in anti-saliva antibody 
levels observed between August and October. Humoral immune response to P. perniciosus 
saliva elicited in experimentally bitten dogs showed that antibody levels significantly rose after 
2–4 weeks of continued exposure, peaking in week 5 (Vlkova et al., 2011). In our field study, 
the highest IgG levels were in August, which clearly corresponded to the June-July P. 
perniciosus expected activity peak. Similarly, the high IgG readings obtained in October are 
likely to correspond to P. perniciosus second peak of activity. The lower rise in antibody levels 
observed at this time point can be explained by an earlier sampling at the beginning of 
October, which may have hindered the display of a complete seroconversion. The high overall 
levels of seropositivity to anti-sand fly saliva antigens, especially for SGH (49.43%), strongly 
support the CanL endemicity status for the region (Lladró et al., 2017). These results also 
validate both SGH and rSP03B as suitable antigens to assess exposure to P. perniciosus in 
natural canine populations from endemic areas. 
An important remark when analysing the longitudinal dynamics of anti-sand fly saliva IgG in 
the study dog population is that there was a clear basal antibody level before the transmission 
season. After the expected rise in humoral response during summer months, IgG levels 
returned again to basal levels. These results show that, though exposed to repetitive bites 
during several months, dogs from endemic areas do not sustain high anti-saliva IgG levels 
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throughout the year, allowing the detection of recent exposure to sand flies in natural 
populations. Similar results were recently reported in a longitudinal field study in Brazil, where 
canine IgG against Lutzomyia longipalpis saliva were evaluated (Quinnell et al., 2018). Our 
study identified the same trends for both SGH and rSP03B, which reinforces the suitability of 
recombinant antigens in detecting recent exposure to phlebotomine vectors in endemic 
settings, particularly when considering the use of these tests in large-scale studies for vector 
control interventions (Marzouki et al., 2015; Souza et al., 2010).  
Antibodies recognizing both SGH and rSP03B followed similar dynamics throughout the field 
study. However, the correlation between the two antigens was only moderate (rS = 0.54; 95% 
CI: 0.48–0.60, p<0.001). Even so, available studies show that rSP03B is the most promising 
surrogate for SGH as a marker of exposure to P. perniciosus in the canine host. It has presented 
high levels of correlation with SGH in both experimentally (Drahota et al., 2014) and naturally 
bitten dogs (Kostalova et al., 2017, 2015; Martín-Martín et al., 2014). Two apyrase proteins 
(rSP01B and rSP01) have also shown a good correlation with SGH (Drahota et al., 2014). 
However, in a study where these three recombinant proteins presented similarly high 
correlations with SGH, rSP03B presented the lowest data dispersion and was considered a 
better option (Martín-Martín et al., 2014). These results were confirmed in a field trial, where 
single rSP03B demonstrated a higher correlation coefficient with SGH than the combination of 
rSP03B with rSP01 (Kostalova et al., 2015). 
A similar correlation between SGH and rSP03B to the one obtained in the present study has 
been observed before in Umbria region (central Italy) (rS=0.56; 95% CI: 0.38–0.71, p<0.001; 
n=96), in a screening study of dog exposure to P. perniciosus across European CanL endemic 
foci (Kostalova et al., 2017). A possible reason for these discordant results may be the 
presence of other closely related phlebotomine species which could induce cross-reactivity 
with the SGH (Volf and Rohoušova, 2001). In some parts of Catalonia, P. perniciosus is 
sympatric with P. ariasi, also a proven vector of L. infantum (E Guilvard et al., 1996). Due to the 
close relationship between P. perniciosus and P. ariasi, both belonging to the subgenus 
Larroussius, it is expected that they share similar salivary antigens (Anderson et al., 2006). 
When comparing the percentage of seropositive dogs detected by both methods during the 
study, results for SGH are higher (49.43%) than for rSP03B (28.98%). Also, median results per 
sampling location show differences between SGH and rSP03B: in some cases, the trend 
between antigens is very similar (e.g. sera from Sant Feliu de Guíxols); in other cases, there is a 
recognizable peak in anti-SGH IgG, while anti-rSP03B IgG shows no change (e.g. sera from 
Madremanya). These differences can also be observed over time in the same location, with 
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humoral responses to SGH and rSP03B peaking in different months along the transmission 
season (e.g. Canet d’Adri). We may hypothesize that SGH, because it contains more proteins 
than the single-antigen rSP03B, will more likely cross-react with antibodies against P. ariasi, 
inducing a stronger unspecific reaction to this vector species. It would also mean that the 
prevalence of sand fly species responsible for L. infantum transmission in the province varies 
according to the location, and possibly in the same location throughout the transmission 
season, for which it would be interesting to perform further entomological studies in the 
region.  
Correlation indexes between levels of antibodies against both salivary antigens and L. infantum 
infection were low [SGH: rS=0.27 (95% CI: 0.19–0.35, p<0.001); rSP03B: rS=0.25 (95% CI: 0.18–
0.32, p<0.001)]. Similar low correlations have been described before between sand fly bites 
and human visceral leishmaniasis (VL), while stronger correlations are reported between 
human cutaneous leishmaniasis (CL) and recent vector exposure (reviewed in Lestinova et al., 
2017). This can be explained by VL’s longer incubation period and/or the differences in host 
immune responses to cutaneous and visceral infection (Kedzierski and Evans, 2014). Results 
from some studies in human populations also suggest that the repeated contact with non-
infected sand flies could be correlated with markers of protection for VL (Andrade and 
Teixeira, 2012). Partial protection against L. major, an agent of CL, has also been achieved in 
immunized mice by the bites of uninfected sand flies (Kamhawi et al., 2000). However, another 
study with BALB/c mice demonstrated that this type of immunity is limited to short-term 
exposure and questioned the efficacy of sand fly saliva-induced protection against Leishmania 
infection in CL endemic areas (Rohoušová et al., 2011). CanL follows a pattern which is more 
similar to VL than to CL, therefore a low correlation between humoral responses to sand fly 
saliva and Leishmania would be expected (Vlkova et al., 2011). However, results of the 
multilevel linear regression model show a positive and statistically significant relationship 
between P. perniciosus bites and a seropositive status for L. infantum, both for SGH and 
rSP03B. Similar results have been described in other longitudinal field studies on both canine 
anti-P. perniciosus and anti-L. longipalpis IgG dynamics (Kostalova et al., 2015; Quinnell et al., 
2018). Unlike cross-sectional surveys, longitudinal studies are able to detect the relationship 
between a higher number of sand fly bites at a given time point and a subsequent L. infantum 
infection. Therefore, this type of study is likely to better explain the relationship between 
these two events, which can take place several months apart. 
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El desarrollo de vacunas efectivas contra las leishmaniosis humana y canina es un objetivo para 
la comunidad científica. Sin embargo, deben considerarse y evaluarse los posibles efectos 
secundarios de la vacunación, preferiblemente antes de la autorización y comercialización de 
la vacuna. Uno de estos posibles efectos es la reacción cruzada de los anticuerpos inducidos 
por la vacuna con las pruebas serológicas comunes utilizadas para la detección de la infección 
por Leishmania infantum. Se han realizado estudios longitudinales sobre el tipo de perfil 
humoral inducido por las vacunas para la leishmaniosis canina comercializadas en Brasil, pero 
poco se sabe sobre la situación en Europa. En este estudio, se realizó un seguimiento anual de 
85 perros vacunados con CaniLeish® y 83 perros control no vacunados. Se tomaron muestras 
de sangre de todos los animales en puntos de muestreo predeterminados: antes de iniciar la 
vacunación, inmediatamente antes de cada una de las dos dosis de vacuna siguientes (a 
intervalos de 21 días) y a los uno, cuatro, seis, nueve y 12 meses después de finalizar la 
primovacunación. Todas las muestras se analizaron mediante un ELISA in house para 
determinar la presencia de anticuerpos anti-L. infantum. La respuesta humoral detectable 
mediante el método de diagnóstico serológico utilizado fue significativamente mayor en el 
grupo de los perros vacunados en comparación con el grupo control (p <0,01) hasta un mes 
después de la vacunación. Los resultados muestran que los anticuerpos inducidos por la 
vacuna CaniLeish® reaccionan de forma cruzada con una prueba serológica de uso común para 
el diagnóstico de la infección natural por L. infantum. Se discuten las implicaciones de esta 
interferencia, con especial énfasis en un posible impacto negativo en los estudios de vigilancia 










Vaccination is considered one of the most effective methods of controlling CanL and, 
indirectly, human leishmaniosis (HL) (Palatnik-de-Sousa, 2012; Palatnik-de-Sousa et al., 2009). 
Mathematical models have shown that this method is more effective than treatment or culling 
of infected dogs (Dye, 1996). A vaccine for CanL should induce a strong, parasite-specific and 
long-lasting cellular mediated immunity to control infection progression, as well as to block 
Leishmania infantum transmission to sand fly vectors by significantly reducing parasite burden 
at the vertebrate host level (Courtenay et al., 2014; Gradoni, 2015). A possible side effect of 
most vaccines is the stimulation of humoral immunity and the consequent induction of 
antibody production (Solano-Gallego et al., 2017a). These can be vaccine-specific, which would 
not be detected by common serological tests for L. infantum infection diagnosis. However, 
vaccines can also elicit the production of non-specific antibodies that cross-react with standard 
diagnostic tests (Marcondes et al., 2013). In these cases, vaccinated individuals cannot be 
differentiated from naturally infected ones (Marcondes et al., 2011).  
CaniLeish® vaccine (Virbac) was licensed in Europe in 2011 (EMA, 2011). It is a second 
generation vaccine, composed of purified excreted-secreted proteins of L. infantum (LiESP) 
and a saponin adjuvant (QA-21) from a purified fraction of Quillaja saponaria (Moreno et al., 
2012). The pre-licensing CaniLeish® field trial (Oliva et al., 2014) showed that vaccine efficacy 
in the prevention of CanL clinical signs is 68.4% and the risk of developing active disease is 
reduced by 3.6 times in vaccinated dogs (EMA, 2011). This field trial also reported that vaccine-
induced antibodies were detected by a diagnostic IFAT, which was confirmed by two later 
vaccine follow-up reports (Montoya et al., 2017; Oliva et al., 2014; Sagols et al., 2013).  
Speed Leish KTM, a qualitative immunocromatographic test (ICT), is the pre-vaccination 
screening method recommended by the CaniLeish® vaccine manufacturer (Virbac, n.d.). 
Because in vaccine follow-up studies it showed no (Sagols et al., 2013) or low (Montoya et al., 
2017) cross-reactivity with vaccine-induced antibodies, its use as diagnostic tool able to 
discriminate between vaccinated and infected individuals has been proposed. However, 
reports of this ICT performance are not consistent (Ferroglio et al., 2013; Solano-Gallego et al., 
2014) and its sensitivity in L. infantum detection has been questioned (Solano-Gallego et al., 
2017a). 
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In the present study, a one year follow-up of CaniLeish® vaccinated dogs was performed and 
an in-house ELISA test was used to measure anti-L. infantum antibodies at pre-determined 
time points. The results reported are expected to provide information on the possible impact 
of CaniLeish® vaccination on L. infantum seroprevalence studies and to motivate a reflection 
on the need to rethink CanL research and control measures in endemic areas where 




Humoral response to whole L. infantum antigen in the trial groups is presented in Figure 12. 
During the immunization course, vaccinated dogs showed a progressive increase in anti-L. 
infantum antibody levels, which peaked at 1 month post-vaccination. Differences between 
groups at T2 [median (vaccine group) = 16.2; median (control group) = 14.0; z=-3.120; 
p=0.002], T3 [median (vaccine) = 24.1; median (control) = 14.1; z=-7.149; p<0.001] and T4 
[median (vaccine) = 32.3; median (control) = 16.6; z=-7.052; p<0.001] were considered 
statistically significant. At T2, 27.1% (23/85) of vaccinated dogs were considered seropositive 
[in comparison with 8.8% (7/80) in the control group], at T3 seropositivity was 50.6% (43/85) in 
vaccinated dogs [against 10.8% (9/83) in controls], and at T4 the proportion of seropositive 
vaccinated dogs was 74.1% (63/85) [20.7% (17/82) in controls]. Differences in the proportions 
of seropositive individuals between vaccine and control groups at these sampling points (T2 to 
T4) were considered statistically significant (p<0.01). 
After this, antibody levels between groups followed a similar trend, with no statistically 
significant differences detected between groups, except for T7 (in January 2017, 9 months 
post-vaccination) [median (vaccine) = 16.7; median (control) = 14.2; z=-2.010; p=0.044].  
 




Figure 12. Median and interquartile range ELISA units observed in control and vaccine groups 
at each sampling point. Statistically significant differences between groups assessed by a 
Mann-Whitney U test are marked with asterisks: *p <0.05; **p<0.01; ***p<0.001. The 
horizontal dashed line marks the ELISA cut-off, set at 24U. Outlier results are not represented 





The development of effective vaccines for CanL and HL should be the ultimate goal for disease 
control. (Dye, 1996; Palatnik-de-Sousa, 2012; Palatnik-de-Sousa et al., 2009). However, despite 
the obvious advantages of vaccination, possible drawbacks of its implementation should also 
be considered. Vaccines which are unable to block parasite transmission have the detrimental 
effect of “masking” vaccinated asymptomatic carriers (Miró et al., 2017b). These animals, 
although showing a lower susceptibility to developing active L. infantum infection or clinical 
disease, can still harbour the parasite and play a potential role in maintaining its life cycle in 
endemic areas (Solano-Gallego et al., 2001a). Furthermore, vaccines with low or only 
moderate efficacy do not prevent disease in all vaccinated dogs, and these are a potential 
diagnostic challenge (Solano-Gallego et al., 2017a).  
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“Differentiating between infected and vaccinated animals” (DIVA) is a well-known concept in 
veterinary vaccinology (Liu et al., 2013; Solano-Gallego et al., 2017a). According to the DIVA 
principle, veterinary vaccines should be produced in such a way that they allow serological 
differentiation between vaccinated and infected animals. This differentiation can be achieved 
by the non-interference with standard serological techniques or through the development of 
specific diagnostic tests, which should present high specificity and sensitivity (Schmitt, 2005). 
In any case, this aspect must be considered during the development of any new vaccine. 
The impossibility of distinguishing between vaccinated and naturally infected dogs can 
introduce considerable problems to disease or infection diagnosis and surveillance, especially 
in endemic areas (Solano-Gallego et al., 2017a). CanL serves as a good example of this 
situation. The diversity of possible infection outcomes and the high proportion of 
asymptomatic infected animals (Baneth et al., 2008), make CanL a diagnostic challenge that 
often requires the use of multiple diagnostic methods (Morales-Yuste et al., 2012; Otranto et 
al., 2009). After the introduction of Leishmune® in Brazil, the first licensed CanL vaccine, 
several studies pointed out the possibility of vaccine-induced antibodies cross-reacting with 
CanL official diagnostic tests (Marcondes et al., 2013, 2011). In a country where detection and 
culling of infected dogs is the control measure established by the Ministry of Health (Ministério 
da Saúde Brasileiro, 2014), this would pose a risk to healthy vaccinated dogs, which could be 
mistakenly identified as naturally infected individuals and removed (Marcondes et al., 2013). A 
more recent study demonstrated that Leishmune® vaccinated dogs did not test positive with 
the fast agglutination screening test (FAST) or the direct agglutination test (DAT) (Ribeiro et al., 
2015), which could then be used as confirmatory diagnostic methods for seropositive 
vaccinated dogs. Meanwhile, Leishmune® vaccine was withdrawn from the market by the 
Brazilian Ministry of Agriculture due to lack of effectiveness evidence in phase III trials (MAPA, 
2014) and no other cross-reactivity studies were performed. 
CaniLeish® vaccine was licensed in Europe in 2011. Results of preliminary studies on the 
vaccine’s safety and efficacy showed that vaccine-induced antibodies could cross-react with 
commonly used serological techniques like IFAT and ELISA (Martin et al., 2014; Oliva et al., 
2014). The use of IFAT to test for L. infantum infection in CaniLeish® vaccinated dogs was not 
recommended, as these animals consistently presented positive titres due to vaccine-induced 
antibodies (Oliva et al., 2014). This has also been confirmed by a long-term follow-up of owned 
CaniLeish® vaccinated dogs, in which 31.9-40.3% and 3.2% of individuals tested positive on 
IFAT one month and one year after vaccination, respectively (Montoya et al., 2017), while 
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another study reported 80% seropositivity with IFAT one month after the first annual vaccine 
booster (Sagols et al., 2013). 
Results from the longitudinal study presented here show that a similar situation occurs when 
ELISA is used. In this study, vaccine-induced antibodies were detected by a commonly used L. 
infantum diagnostic ELISA technique 3 weeks after the first vaccine dose and continued to rise 
until they peaked one month after vaccination completion. At this time point, 74.1% of 
vaccinated dogs would be classified as seropositive to L. infantum. Three months later (4 
months after the third vaccine dose), antibody levels in the vaccine and control groups did not 
show a statistically significant difference and the same non-significant results were observed at 
6 and 12 months post-vaccination. These results show that CaniLeish® vaccinated dogs have a 
high probability of testing positive by ELISA test until one month post-vaccination. 
Unfortunately, the absence of data between this time point and the following one (4 months 
post-vaccination), which showed a marked decrease in vaccine-induced humoral immunity (in 
comparison with the control group), did not allow detection of an antibody inflexion point. It 
should also be mentioned that the reduced number of animals tested 4 months after 
vaccination (n=33) could be a possible reason for the failure in detecting a significant 
difference between groups. Statistically significant differences in ELISA results between groups 
were again detected 9 months after vaccination. However, because this assessment was 
preceded by two sampling points where no significant differences between groups were 
observed and since it corresponds to a post-transmission season sampling, the observed 
difference cannot be clearly attributed to a vaccine effect. 
As mentioned before, follow-up studies of CaniLeish® vaccinated dogs receiving their annual 
vaccine boosters (up to the 4th annual booster in one of the studies) revealed that these 
individuals also cross-reacted with IFAT testing (Montoya et al., 2017; Sagols et al., 2013). 
Although it is expected that the same occurs with ELISA, it would be interesting to confirm it 
and to evaluate the duration and magnitude of interference with this diagnostic test.  
The impact of the interaction between vaccine and serological diagnostic tests at the individual 
dog level is well documented. Several reports describing CanL cases in CaniLeish® vaccinated 
dogs highlight the added complexity in the diagnosis of these animals (Ceccarelli et al., 2016; 
Gavazza et al., 2016; Solano-Gallego et al., 2017b). Unfortunately, no information exists on the 
impact of vaccination on L. infantum infection serological surveillance. Diagnostic techniques 
for CanL large-scale surveys should be simple to perform and interpret, low-cost and highly 
sensitive and specific. Due to the variable clinical presentation of L. infantum infection, 
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quantitative tests which can provide an assessment of infection stages across the community 
should be favoured over qualitative ones.  Finally, survey techniques must be applicable to the 
whole studied population so that results can be compared and conclusions can be drawn. 
Considering these points, quantitative serological methods remain the best tools for L. 
infantum infection mass-screening surveys (OIE, 2014) and are commonly used in 
epidemiological studies on CanL in Spain (Alcover et al., 2013; Amela et al., 1995; Ballart et al., 
2013a; Fisa et al., 1999; Gálvez et al., 2010b; Martín-Sánchez et al., 2009; Miró et al., 2012; 
Morales-Yuste et al., 2011; Morillas-Márquez et al., 1996). Rapid qualitative serological 
techniques, aside from only providing positive vs. negative results, can also show lower 
sensitivity in infection detection (Maia and Campino, 2018). In the case of Speed Leish KTM, the 
CaniLeish® recommended pre-vaccination screening and post-vaccination diagnostic test, 
reported performance results are not consistent. Although a preliminary comparative study of 
this ICT with IFAT and Western blot (WB) showed very high test sensitivity and specificity 
(Ferroglio et al., 2013), a later study did not confirm these results, considering Speed Leish KTM 
inferior to all the quantitative serological tests evaluated (Solano-Gallego et al., 2014). The use 
of a less sensitive screening test in epidemiological studies, even when it holds the advantage 
of not cross-reacting with vaccine-induced antibodies, compromises infection detection and 
yields false lower prevalence and incidence rates. Likewise, the use of these tests in pre-
vaccination screening produces apparent vaccine failure due to vaccination of previously 
infected dogs (Solano-Gallego et al., 2017a). 
Taking into consideration the results presented here and others previously obtained, a critical 
appraisal of the methods currently used for CanL epidemiological surveillance must be 
performed. The need to either change or complement the currently used diagnostic 
techniques and/or to develop new, more efficient, diagnostic methods capable of 
differentiating between vaccinated and naturally infected individuals is urgently needed. 
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4.4. EVALUATION OF CANINE LEISHMANIOSIS VACCINE CANILEISH® UNDER FIELD 




La vacunación es considerada como el mejor método para controlar la leishmaniosis, una 
importante enfermedad parasitaria y zoonótica transmitida por vectores. Los perros 
domésticos son el principal reservorio de Leishmania infantum, el agente etiológico de la 
infección. Por lo tanto, la inmunización de perros contra el parásito podría ser una forma 
efectiva de detener la transmisión del parásito y de reducir la incidencia de infección en la 
población canina, así como la transmisión a humanos. Con este objetivo,  en los últimos 14 
años fueron autorizadas cuatro vacunas para la leishmaniosis canina, dos en Brasil y dos en 
Europa. Sin embargo, el uso de vacunas solo parcialmente efectivas puede tener un efecto 
perjudicial "enmascarando" a los animales portadores asintomáticos vacunados, que pueden 
albergar al parásito y ser responsables de la transmisión de L. infantum a individuos 
susceptibles. Después de siete años en el mercado europeo, se han publicado muy pocos 
estudios sobre la seguridad y eficacia de la vacuna CaniLeish®. En el presente estudio, se 
realizó un ensayo de campo aleatorio de dicha vacuna ® durante un año en un área endémica 
de leishmaniosis canina. El estudio incluyó 168 individuos seleccionados de una población de 
perros nativa y heterogénea. Los criterios de inclusión en el estudio fueron los recomendados 
por el fabricante de la vacuna. El seguimiento serológico, molecular y clínico de los individuos 
permitió la detección de casos de infección activa por L. infantum en ambos grupos. 
Simultáneamente, se realizó la cuantificación de interferón-γ en tres puntos de muestreo para 
evaluar la inmunidad celular inducida por la vacuna contra L. infantum. No se observaron 
reacciones adversas graves en perros vacunados. Los resultados no mostraron diferencias en el 
número o gravedad de los casos de infección activa por L. infantum entre el grupo de perros 
vacunado y el grupo control. Un mes después de la vacunación, los niveles de interferón-γ 
inducidos por el parásito presentaban valores significativamente más altos en el grupo 
vacunado, en comparación con los niveles pre-vacunación (p <0,001) o con el grupo control en 
el mismo punto de muestreo (p = 0,001). Sin embargo, 9 meses después de la finalización de la 
vacunación, las diferencias en esta citoquina entre los dos grupos se consideraron 
estadísticamente no significativas (p = 0,078). Los resultados obtenidos sugieren el fallo de la 
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vacuna CaniLeish® en la prevención de la infección activa en perros de áreas endémicas y 
expuestos naturalmente al parásito. Esto podría explicarse por una reducción temprana en la 
inmunidad celular inducida por la vacuna, que no protegería a los perros vacunados durante 




Vaccination is seen as one of the optimal methods for controlling L. infantum infection (Dye, 
1996; Palatnik-de-Sousa, 2012; Palatnik-de-Sousa et al., 2009) and the development of 
effective vaccines against both CanL and human leishmaniosis (HL) has been a goal for the 
scientific community. A vaccine for CanL should induce a strong and long-lasting Th1-
dominated cellular immunity to control infection progression, while simultaneously reducing 
parasite burden in dogs in order to decrease their infectiousness to sand flies (Gradoni, 2015). 
Furthermore, it should be equally effective in protecting against infection or disease (Alvar et 
al., 2013). 
The first vaccines for CanL were licensed in Brazil, where leishmaniosis has a significant impact 
on human health. Leishmune® (Zoetis, Brazil) a second-generation vaccine composed of the 
fucose-mannose ligand (FML) glycoprotein complex of L. donovani and a saponin adjuvant 
(Borja-Cabrera et al., 2002) was licensed in 2004. Leish-Tec® (Hertape Calier, Brazil) is 
formulated with a recombinant protein A2 from L. donovani amastigotes associated to saponin 
and was released in 2007 (Fernandes et al., 2008). After 10 years of use, the Leishmune® 
production and marketing licence was withdrawn by the Brazilian Ministry of Agriculture due 
to lack of efficacy evidence in phase III trials (MAPA, 2014). 
The European Medicines Agency (EMA) granted a marketing licence to the first CanL vaccine in 
2011 (EMA, 2011). CaniLeish® (Virbac, France) is a second generation vaccine composed of 
purified excreted-secreted proteins (LiESP) of L. infantum and a saponin adjuvant (Moreno et 
al., 2012). In 2016, LetiFend® (Laboratorios LETI, Spain), a recombinant vaccine consisting of a 
chimerical protein (protein Q) with no added adjuvants (Carcelén et al., 2009), also received 
marketing permission for the European region (EMA, 2016). In both cases, licensing was 
granted based on the safety and efficacy results of a single field study (Fernández Cotrina et 
al., 2018; Oliva et al., 2014). 
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According to pharmacovigilance data reported by Virbac in October 2015, more than 1.8 
million doses of CaniLeish® had been sold during the first 3.5 years of marketing in the 
European Economic Area, Switzerland and Tunisia (Breton et al., 2015). However, few studies 
have been published since the preliminary phase II research (Martin et al., 2014; Moreno et 
al., 2014, 2012) and the only phase III trial performed before a licence was granted (Oliva et 
al., 2014). Very little is known about the vaccine’s effect in heterogeneous dog populations 
from endemic areas. In addition, after 7 years on the European market, CaniLeish® safety and 
efficacy have been questioned by veterinarians and the general public. Cases of CanL in 
vaccinated dogs have been reported (Ceccarelli et al., 2016; Gavazza et al., 2016), and the 
performance of the recommended pre-vaccination screening method has presented 
inconsistent results (Solano-Gallego et al., 2017b). 
The present study consists of a one-year randomized CaniLeish® vaccine field trial performed 
in a CanL endemic area with a heterogeneous and autochthonous canine population. Dogs of 
both sexes, different ages and various breeds have been included. Inclusion criteria were the 
same as recommended by the vaccine’s manufacturer for dog vaccination and were followed 
for both experimental groups. The objective of this study was to evaluate CaniLeish® vaccine 




From the 177 dogs initially enrolled in the vaccine study, 168 completed the vaccination phase 
(95%) [85 dogs in the vaccine group (94.4%) and 83 in the control group (95.4%)]. No 
statistically significant differences in dogs’ characteristics were detected between groups, as 
described in section 3.2.2 (pages 48-49).  
 
Vaccine safety 
No severe adverse reactions were observed in vaccinated dogs. One case of transient anorexia 
and apathy following first vaccine dose administration was reported, which was not observed 
again in the same animal following the second or third vaccination dose. No other adverse 
reactions were reported. 
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Humoral and molecular detection of L. infantum 
The dynamics in humoral response to whole L. infantum antigen during the one year vaccine 
trial in both groups was previously described in section 4.3.3. 
In April 2017 (one year post-vaccination), 35 individuals were seropositive for L. infantum and 
were further tested by qPCR on lymph node samples (21 in the vaccine group and 14 in the 
control group). From these, 19 (54.3%) presented a positive qPCR result [9 vaccine (42.9%) and 
10 control (71.4%)], with parasite loads ranging from less than one parasite/mL to 1.24x107 
parasites/mL. No statistically significant differences were detected in lymph node parasite load 
(z=1.31, p=0.1903) or in the incidence of positive results (χ2=2.76, p=0.096) between groups. 
 
Vaccine-induced CMI 
At the pre-vaccination sampling point, 28.1% of the trial dogs (43/153) presented L. infantum-
specific IFN-γ production (20 dogs in the vaccine group and 23 in the control group). 
Measurable IFN-γ concentrations at this time point ranged from 2.50 to 7317.25 pg/mL. 
Levels of IFN-γ in vaccine and control groups throughout the study are presented in Figure 13. 
Median IFN-γ levels for the control group were equal to zero (range: 0 to 7317.25 pg/mL) in 
the 3 sampling points tested and no differences were detected in this group between time 
points (p>0.05). Dogs in the vaccine group showed a marked increase in IFN-γ levels one 
month after vaccination completion (median=38.95 pg/mL; range: 0 to 5136.58 pg/mL), 
considered to be significantly higher when compared to pre-vaccination results (z=-6.624, 
p<0.001). At 9 months after vaccination, IFN-γ levels in the vaccine group had dropped 
considerably (median=12.74 pg/mL; range: 0 to 6235.92 pg/mL), but maintained significantly 
higher results than pre-vaccination levels (z=-2.931, p=0.003). Differences between vaccine 
and control groups were only considered significant at the 1M time point (z=-3.297, p=0.001). 
No statistically significant differences in IFN-γ levels were detected between groups at the pre-








Figure 13. Median and interquartile ranges of IFN-γ levels observed in the vaccine and control 
groups at 3 time points: before vaccination (T0), one month after vaccination completion (1M) 
and 9 months after vaccination completion (9M). (a) indicates a statistically significant 
difference in the vaccine group between T0 and each time point; (b) indicates a statistically 
significant difference between trial groups at the same time point. ** p<0.01; *** p<0.001. 
Outside results (above the 3rd quartile) are not presented in the figure. 
 
 
Clinical assessment of trial dogs 
At the end of the vaccine trial, 87.6% of dogs (127/145) were considered asymptomatic for 
CanL [62 dogs in the vaccine group (87.3%) and 65 in the control group (87.8%)]. The 
remaining 18 individuals (12.4%) showed two or more clinical signs compatible with CanL [9 in 
the vaccine group (12.7%) and 9 in the control group (12.2%)]. These were mainly 
characterized by localized or multifocal lymphadenomegaly (detected in 100% of symptomatic 
dogs) and pale mucous membranes (50% of symptomatic dogs). Other observed clinical signs 
were dermatological lesions (38.9%), poor body condition (27.8%) and ocular alterations 
(22.2%). 
Laboratory exams after T0 were only performed in dogs suspected of CanL and in seropositive 
dogs at the end of the trial. At 12M, 37.1% of the analysed dogs (13/35) were considered 
healthy (zero or one laboratory changes compatible with CanL) (11 in the vaccine group and 2 
in the control group), while 42.9% (7 dogs in the vaccine group and 8 dogs in the control 
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group) presented 2 or 3 analytical alterations, and 20.0% (3 vaccine and 4 control) showed 4 to 
6 laboratory abnormalities. 
Results of clinical exams and laboratory analysis were used as additional information for 
defining L. infantum active infection in trial dogs. Table 14 describes clinical and laboratory 
alterations found in confirmed cases of CanL. 
 
Confirmed cases of CanL in the vaccine and control groups 
During the vaccine field trial, two dogs were diagnosed with CanL (one in the vaccine group 
and one in the control group). The remaining individuals were evaluated one year after 
vaccination completion (April 2017) for seropositivity against L. infantum. From these, 33 dogs 
showed positive anti-L. infantum antibody levels (20 in the vaccine (28.2%) and 13 in the 
control (17.6%) groups) in one of the two post-transmission season serological assessments 
(January and April 2017). These 35 dogs were further assessed by L. infantum DNA detection in 
lymph node samples by qPCR and clinico-laboratory evaluation. Only dogs that met the 
parameters previously defined for L. infantum active infection were considered to be 
confirmed CanL cases. From these, 4 CanL cases were observed in vaccinated dogs (5.6%; 4/71) 
and 4 in control individuals (5.4%; 4/74). The results showed no difference in the development 
of active L. infantum infection between the two study groups (Table 14). 
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Table 14. Profile of dogs diagnosed as confirmed cases of canine leishmaniosis. 








Clinical findings Laboratory findings 
Control 5-009 109.81 Positive (3.05x10
3
) No clinical signs. - Anemia 
- Hypoalbuminemia 
 8-004 227.61 Positive (1.24x10
7
) - Poor body condition 
- Exfoliative dermatitis 




- Increased renal 
parameters (BUN and 
CREA) 
- Hypoalbuminemia 
- Decreased A/G ratio  
 12-003
c
 108.20 Positive (1.43x10
4
) - Poor body condition 










- Decreased A/G ratio 
Vaccine 2-013 159.67 Positive (4.76x10
2
) - Poor body condition - Hypoalbuminemia 
 8-025 158.94 Positive (2.00x10
4
) - Lymphadenomegaly - Hypoalbuminemia 
 18-003
d
 173.62 Positive (1.35x10
4
) - Lymphadenomegaly 
- Skin lesions 
No laboratory findings. 
 22-003 204.06 Positive (1.39x10
6




- Mild hypoalbuminemia 
a
ELISA units measured at 12M, except when specified otherwise; the ELISA cut-off considered was 24U. 
b
qPCR performed in lymph node samples at 12M, except when specified otherwise. 
c
CanL diagnosis in May 2017 
d
CanL diagnosis in October 2016 
BUN: blood urea nitrogen; CREA: creatinine; A/G ratio: albumin/globulin ratio





The present study, a multi-site randomized vaccine trial, had the objective of evaluating 
CaniLeish® vaccine in field conditions in a native heterogeneous population of dogs living in an L. 
infantum endemic region.  
Canine seropositivity to L. infantum at the end of the trial was detected in 75% (9/12) of the trial 
locations, demonstrating the presence of infection in most dog kennels. The study of dog 
exposure to sand fly saliva in the area showed a high incidence of reactivity to sand fly saliva 
antigens and a homogeneous vector presence in the trial locations (Velez et al., 2018a). 
Due to the duration of the present field trial, which included only one L. infantum transmission 
season, detection of CanL clinical cases was not expected. The mean period between infection 
and development of clinical disease was reported to be 7 months, ranging from 3 to 14 months 
(Oliva et al., 2006), but it can extend to years in resistant individuals (Baneth et al., 2008). For 
this reason, the studied outcome was active L. infantum infection and not clinical CanL. 
Additionally, previous longitudinal studies of natural L. infantum infection have shown that once 
an individual reaches a high specific antibody level, the evolution will be inevitably towards the 
development of clinical disease (Oliva et al., 2014, 2006). The expected effect of vaccination on 
the development of active infection is reported by the CaniLeish® vaccine manufacturer, which 
states that the risk of developing active disease is reduced by 3.6 times in vaccinated dogs (EMA, 
2011), and this was the parameter used to compare vaccine and control groups. 
CaniLeish® vaccine proved to be safe in the dog population studied. Apart from one single case 
of transient apathy and anorexia, no other adverse effects were reported by dog owners or 
observed by the researchers. It should be noticed, however, that the study population was 
mainly composed of robust crossbred or purebred hunting dogs weighing between 15 and 25 kg, 
which may be less likely to show discomfort. In a questionnaire-based survey of veterinary 
practitioners working in the Girona region, 82% of vaccine appliers reported adverse reactions, 
ranging from the most commonly observed local swelling and pain, to cases of anaphylactic 
shock. However, as also pointed out by the study’s authors, the attribution of these adverse 
effects to vaccine administration was based on veterinarians’ criteria and confirmation of the 
cause of clinical signs may not have been pursued on all occasions (Lladró et al., 2017). In the 
present study, severe adverse effects were not observed, which is in accordance with previous 
vaccine safety reports (Breton et al., 2015; Marino et al., 2017). 
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In the present study, a whole promastigote in-house ELISA was used as a diagnostic test for L. 
infantum infection (Ballart et al., 2013a; Riera et al., 1999; Velez et al., 2018b). By measuring the 
humoral immune response to L. infantum, quantitative serological tests are considered reliable 
indicators of active infection and good predictors of the onset of clinical signs (Oliva et al., 2006). 
In dogs, high levels of specific IgG antibodies against L. infantum have been related to the active 
phase of the disease and to the onset of pathophysiological disorders (Oliva et al., 2006; Pinelli 
et al., 1994). In a CanL longitudinal field study, it was observed that serology and parasite 
culture were the best predictors of progression to active L. infantum infection, with highly 
seropositive dogs showing no return to a parasite-free status (Oliva et al., 2006). Seroconversion 
is defined as a 4-fold increase in sequential samples from the same dog (Paltrinieri et al., 2010) 
or a 3-fold increase in the cut-off value of a well-standardized diagnostic test (Solano-Gallego et 
al., 2011, 2009). In endemic areas, the median time between the establishment of progressive 
infection and seroconversion was estimated to be 10.5 months (ranging from 4 to 22 months) 
(Oliva et al., 2006).  
Specific humoral response to vaccine antigens has not been evaluated in this trial for two 
reasons. First, because it has been characterized in all previous CaniLeish® studies (Martin et al., 
2014; Moreno et al., 2014; Moreno et al., 2012; Oliva et al., 2014), showing consistent results. 
Second, because no correlation was observed between CaniLeish®-induced IgG profile and 
protection in vaccinated dogs (Oliva et al., 2014). Considering these points, and because the 
main aim of this study was the characterization of L. infantum infection in the study population, 
a complete description of the humoral immune profile induced by the vaccine was not 
performed. 
Molecular detection of the parasite was performed in lymph node samples to confirm the 
diagnosis of active L. infantum infection in seropositive dogs at the end of the trial. Although the 
levels of seropositivity considered for infection diagnosis in the study were very conservative 
and clear indicators of progressive infection, the detection of the parasite in a target organ 
validated the serological results. On the other hand, the detection of parasite DNA in lymph 
nodes in the absence of seroconversion would not have been considered as a definitive 
confirmation of infection. Reversion from a PCR positive result in “deep” tissues to a 
Leishmania-free status has been documented before (Oliva et al., 2014, 2006; Paltrinieri et al., 
2010), showing that molecular detection alone, especially in the presence of low parasite loads, 
cannot be used to perform a definitive CanL diagnosis. 
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IFN-γ is considered to be a high-quality biomarker of immunogenicity and protection against 
Leishmania infection (Carrillo and Moreno, 2009; Reis et al., 2010). It is considered the key 
cytokine involved in the activation of macrophages and the killing of intracellular L. infantum 
amastigotes, in collaboration with other immune mechanisms (Carrillo and Moreno, 2009). High 
levels of IFN-γ are associated with host resistance to L. infantum infection (Chamizo et al., 2005; 
Reis et al., 2010; Solano-Gallego et al., 2016b) and it is used as a marker of response to CanL 
therapy (Manna et al., 2008a; Martínez-Orellana et al., 2017). It has also been quantified as a 
marker of protection in previous vaccine studies, both for CaniLeish® (Martin et al., 2014; 
Moreno et al., 2014; Moreno et al., 2012), and for other vaccines (Costa-Pereira et al., 2015; de 
Lima et al., 2010; Fernandes et al., 2008; Resende et al., 2013). Apart from providing an 
indication of vaccine-induced CMI, the quantification of IFN-γ in this study also allowed 
assessment of previous exposure to L. infantum in the trial population. According to the results 
obtained in the pre-vaccination evaluation, almost 30% of dogs demonstrated a positive IFN-γ 
response when exposed to SLA, which indicates recognition of L. infantum. It is also an indicator 
of resistance in the trial dogs, showing that some of the individuals enrolled in the vaccine trial 
were probably naturally immune to the parasite. This degree of resistance is expected in canine 
populations from endemic areas (Baneth et al., 2008), although its effect may be difficult to 
quantify and account for when setting a field trial. 
The diversity of methods described for IFN-γ quantification may induce variability in reported 
results (Cortese et al., 2013; Holzmuller et al., 2005; Moreno et al., 2012; Rodríguez-Cortés et 
al., 2016, 2007a). Previous CaniLeish® studies have measured this cytokine production through 
the ELISpot assay (R&D Systems), which quantifies the proportion of IFN-γ producing T cells after 
stimulation with SLA. The commercial ELISA kit used in this study provides a direct quantification 
of IFN-γ concentration in the supernatant of lymphocytes cultured with SLA and has been used 
in previous CanL studies (Martínez-Orellana et al., 2017; Solano-Gallego et al., 2016b). Although 
a direct comparison of results obtained with different methods is not possible, the detection of 
significant changes at different time points or between trial groups can still be performed. Levels 
of IFN-γ measured in the vaccine group one month after vaccination completion showed a 
marked increase when compared to the pre-vaccination time point or to parallel results in the 
control group. As mentioned before, this corresponds to the moment when vaccine-induced 
immunity should be established (EMA, 2011), and illustrates the stimulation of cellular immune 
response in vaccinated individuals. A similar significant difference was observed between 
vaccine and control groups 3 weeks after vaccination completion in a previous CaniLeish® study 
(Moreno et al., 2012). IFN-γ concentrations were measured again 9 months after vaccination, 
Results and Discussion 
111 
 
showing that the cytokine levels in the vaccine group were still significantly higher than in the 
pre-vaccination phase, but did not show a statistically significant difference when compared to 
the control group at the same time point. Results from previous CaniLeish® studies have shown 
a statistically significant difference in the proportion of IFN-γ producing cells between vaccine 
and control dogs at 6 months post-vaccination (Moreno et al., 2014) and no detectable 
difference one year post-vaccination (Martin et al., 2014; Moreno et al., 2014). In these studies, 
the 9 month post-vaccination time point was not assessed. If the results of this and the two 
CaniLeish® previous studies are gathered, it can be inferred that the levels of IFN-γ may drop to 
non-significant levels between 6 and 9 months post-vaccination. However, unlike the two 
studies mentioned, the present study was performed in field conditions and animals were 
naturally exposed to one L. infantum transmission season, which may also have interfered in 
IFN-γ levels. Nevertheless, 3 months after the end of the transmission season and of possible 
interactions with L. infantum parasites, vaccinated dogs did not show evidence of significant 
differences in IFN-γ production when compared to the control group. A short-lived vaccine-
induced CMI which fails to be protective during the whole period of expected vaccine coverage 
could explain the lack of difference in detected CanL cases between vaccine and control groups 
observed at the end of this study. However, care should be taken in the over-interpretation of a 
single parameter as it is known that IFN-γ is only part of a complex network of regulatory and 
counter-regulatory interactions involving multiple cells and cytokines (Hosein et al., 2017; Reis 
et al., 2010). Further studies on the immune response developed by trial individuals would be 
needed to fully characterize vaccine-induced CMI. 
Cases of L. infantum active infection were defined by the assessment of multiple parameters. 
Serological screening at the end of the vaccine trial allowed for the detection of potential cases. 
These were further analysed by molecular detection of L. infantum in lymph nodes and by 
characterization of general laboratory parameters (CBC, renal and hepatic biochemical profiles 
and serum protein electrophoretogram). The combined information provided by all these assays 
allowed for the identification of active L. infantum infection cases. Two individuals, one in each 
trial group, were identified as diseased during the study. The remaining six (3 in each group) 
were detected at the end of the trial. According to previous vaccine studies in natural 
conditions, where a continued parasite challenge is present, it is unlikely that these individuals 
reverted to a negative state (Oliva et al., 2014). The CaniLeish® vaccine manufacturer reports an 
efficacy of 68.4% in the prevention of clinical signs of CanL and a protection level, defined as the 
percentage of vaccinated animals which do not develop clinical signs, of 92.7%. These results 
were obtained during the vaccine pre-licensing field study in a homogeneous population of 
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naïve beagle dogs, 5 to 7.5 months old (Oliva et al., 2014). In the Oliva et al. study, four cases of 
active Leishmania infection were recorded at 12 months post-vaccination; one in the vaccine 
group (2.4%) and three in the control group (7.7%). All these dogs progressed to symptomatic 
active infection in the following months. In the present trial, no differences in the number or 
severity of active infection cases were observed between vaccine and control groups one year 
post-vaccination. Although the reduced number of CanL cases observed demands caution in the 
interpretation of the results of this trial, they are supported by the results of a recent field study, 
which compared the efficacy of the CaniLeish® vaccine and two insecticide dog collars in the 
prevention of CanL. After one year of study, although different protection efficacies could be 
determined for each insecticide collar, no difference was detected in the number of CanL cases 
between CaniLeish® vaccinated dogs and the control group (Brianti et al., 2016). Again, the total 
number of CanL cases detected in the trial presented by Brianti et al. was low, which may have 
impaired the detection of a difference between groups. However, considering the results 
obtained in both studies, if such a difference exists it is unlikely to be the one claimed by the 
vaccine’s manufacturer. 
The ultimate step to assess the efficacy of a vaccine against CanL is the phase III field trial, with 
native canine populations from endemic areas, where vaccinated and control dogs are exposed 
to natural infection by sand fly bites (Reis et al., 2010). However, in contrast to laboratory 
experimental challenge, natural infection depends on many variable factors related to the 
canine host, the vector and the parasite. According to Solano-Gallego et al. (2009), only an 
estimated 1/3 of dogs living in CanL endemic areas will be susceptible to infection during the 
course of their lives. This implies that, at the time of enrolment for a vaccine field trial, a high 
proportion of individuals testing negative for L. infantum are already resistant to the parasite 
and will be worthless in terms of vaccine effect assessment. Likewise, the proportion of 
individuals lost during a field trial cannot be accurately ascertained beforehand. In the present 
study, the expected loss to follow-up was 10%, based on preliminary assessments performed on 
the same dog population. However, at the end of the study, 18% of the initial dog sample had 
been lost. This was mainly due to deaths related to hunting activities and animal movement to 
other dog kennels. Another important factor of variability in field trials is vector-related. Sand fly 
populations are highly influenced by biotic and abiotic factors (Ballart et al., 2014; Gálvez et al., 
2010a; Hartemink et al., 2011), which change annually. Some of these factors, such as 
temperature, are also known to influence L. infantum development inside the vector (Rioux et 
al., 1985). Likewise, it is impossible to predict the success of natural parasite transmission in a 
given area and year. For these reasons, field trials with privately owned dogs are challenging and 
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their success difficult to predict. Nevertheless, they represent the closest situation to a “real 












































































5. GENERAL DISCUSSION 
 
The work presented in this thesis aimed to extend the current knowledge of canine L. infantum 
infection epidemiology and control. In a first phase, a survey of the dog population of Girona 
province allowed the first description of L. infantum infection in a previously uncharacterized 
region in the north-east of Spain, a CanL endemic country. An assessment of individual and 
environmental risk factors associated with canine L. infantum infection in the studied 
population provided additional information which can be applied to the design of directed 
control measures. The indirect detection of host-vector contact through markers of exposure 
to sand fly saliva completed the characterization of L. infantum infection in the province. 
The epidemiological study was followed by a field trial of CaniLeish®, the first CanL vaccine 
licensed in Europe in 2011. In addition to evaluating the possible role of CaniLeish® in CanL 
control, this work also looked at the potential impact of vaccination on the 
seroepidemiological vigilance of L. infantum infection. 
 
5.1. EPIDEMIOLOGICAL STUDIES OF CANINE Leishmania infantum INFECTION 
 
Epidemiological vigilance is essential for the study and monitoring of infectious diseases, as 
well as for the planning and implementation of directed control measures (WHO, 2014). This is 
certainly the case for L. infantum infection, the distribution of which in canine populations 
from endemic regions is highly heterogeneous (Gradoni, 2018; Pennisi, 2015). The expected 
existence of hyperendemic foci within an endemic region or country justifies the 
implementation of epidemiological surveys at a finer scale, in order to identify these 
“hotspots” of canine L. infantum infection (Ballart et al., 2013b; Capelli et al., 2004). This would 
also be fundamental for controlling HL, as these CanL hyperendemic foci correspond to higher 
reservoir concentration areas, thus increasing the risk of human infection (Sevá et al., 2016). 
Surveys of L. infantum infection and vector presence are needed to predict possible parasite 
geographic expansion (Ballart et al., 2013b; Maia and Cardoso, 2015; Maroli et al., 2008; Ntais 
et al., 2013) and to anticipate and minimize the impact of disease outbreaks (Arce et al., 2013). 
In addition to L. infantum infection incidence and prevalence, the characterization of 




disease (Franco et al., 2011; Hartemink et al., 2011; Pigott et al., 2014). The information 
gathered by these studies not only allows the selection of significant variables to introduce 
into the maps, but also provides suitable data for them. 
The study presented in section 4.1 of this thesis, an L. infantum infection prevalence study in 
Girona province (Catalonia, north-eastern Spain), is an example of this type of epidemiological 
survey. Although surrounded by proven CanL endemic areas (Ballart et al., 2013a; Pomares et 
al., 2016; Portús et al., 2007), very little was known about the status of the disease in Girona 
province. The only previously published study, by Lladró et al. (2017), presented results from a 
questionnaire-based survey of veterinary practitioners working in the region and reported the 
diagnosis of autochthonous cases of CanL in the province. Amongst the respondents, 75% 
confirmed between one and 20 cases of CanL annually, most of which had not been diagnosed 
before. Also, almost 50% of the veterinarians believed that the disease had been presenting a 
rising trend in the previous 10 years. The study presented in this thesis confirmed the 
endemicity of L. infantum infection in Girona and once again demonstrated the heterogeneity 
in CanL distribution throughout an endemic region. Characteristics of a stable CanL focus were 
identified, such as a significant infection prevalence detected in the canine population, 
associated to a high number of asymptomatic individuals, which is indicative of the adaptation 
of local dogs to the parasite (Baneth et al., 2008). Furthermore, contact between the canine 
host with phlebotomine vectors was demonstrated (section 4.2), proving that all conditions for 
the local maintenance of a complete L. infantum life cycle are gathered (Maroli et al., 2008). 
Canine infection distribution in Girona province seems to be influenced by landscape and/or 
climatic factors, as indicated by the close relationship found between altitude and infection. 
Simultaneously, at the individual level, dog’s age showed a positive association with L. 
infantum infection. The overall estimated seroprevalence for Girona province was 19.5%, 
which is in accordance to others reported recently in Spain (Alcover et al., 2013; Ballart et al., 
2013a; Gálvez et al., 2010b; Morales-Yuste et al., 2011), as well as in other countries of the 
Mediterranean basin (Cortes et al., 2012; Maroli et al., 2008; Ntais et al., 2013). Observed 
point seroprevalences of 0 to 80% are comparable to those reported in a study which compiled 
results from CanL seroprevalence surveys undertaken in France, Italy, Spain and Portugal 
between 1971 and 2006 (Franco et al., 2011), confirming the previous claims of the 
heterogeneous distribution of the disease.  
Individual and location factors partially explain the differences in reported CanL prevalence in 
endemic regions. Genetic factors can determine resistance or susceptibility to L. infantum 




et al., 2008, 2005; Solano-Gallego et al., 2000). Age of the host can also be considered a risk 
factor, as observed in Girona province and previously documented in several CanL studies 
(Alonso et al., 2010; Cortes et al., 2012; Fisa et al., 1999; Gálvez et al., 2010b; Miranda et al., 
2008; Miró et al., 2012), as well as for HL, in which children under 5 years old are considered to 
be at higher risk of L. infantum infection (Gradoni, 2018; WHO, 2010). Location risk factors are 
usually determined by the edaphoclimatic conditions needed by sand flies (Barón et al., 2011; 
Dantas-Torres et al., 2014; Gálvez et al., 2010a; Tarallo et al., 2010), as well as by vertebrate 
host densities (Sharma and Singh, 2008). The interaction between these variables will 
determine the presence and abundance of infected competent vectors, the main risk factor for 
L. infantum transmission (Maroli et al., 2013; Suarez Rodríguez et al., 2012). 
The design of epidemiological surveys can also introduce significant variations in L. infantum 
infection seroprevalence results (Franco et al., 2011). Different criteria in the selection of the 
target dog population or in its geographical distribution, as well as differences in the diagnostic 
techniques used, usually allow little or no comparison between studies in different areas or in 
the same region over a period of time (Morales-Yuste et al., 2012). Access to a representative 
sample of a region’s canine population can prove to be difficult in countries where dog 
registration is not mandatory and no population census exists. Alternative sources of study 
individuals can be veterinary practices (Goyena et al., 2016; Maia et al., 2015; Morales-Yuste et 
al., 2011), dog owners associations (hunters, breeders, etc.) or dog shelters (Cabezón et al., 
2010; Miró et al., 2012; Santi et al., 2014). Any of these options is not optimal and is expected 
to introduce bias in CanL prevalence results (Botet and Portús, 1993; Franco et al., 2011). Since 
the end of the compulsory anti-rabies vaccination in Catalonia (Escola d’Oficis Catalunya, 
2017), for which campaigns were organized that gathered a significant proportion of the dog 
population, it has become more difficult to perform large-scale surveys. For the work 
presented in this thesis, and in order to obtain a representative sample of the province’s 
canine population, dog recruitment was performed through local veterinarians. The target dog 
population were not dogs attending the veterinary practice, but mostly composed of hunting 
packs kept outdoors in rural or periurban settings, where CanL was expected to be present and 
prevalent as shown in other studies (Alcover et al., 2013; Ballart et al., 2013). Their inherent 
characteristics make them good sentinels for CanL (Ballart et al., 2013a; Cabezón et al., 2010) 
and the consistent use of the same type of canine population throughout this study, as well as 
in similar studies in Spain (Alcover et al., 2013; Ballart et al., 2013a), allowed for comparisons 




assumed in this work (discussed in detail in pages 75-76 of section 4.1) and should be 
accounted for in future surveys. 
As already mentioned, the choice of diagnostic methods also represents an important source 
of variability, which should be considered when comparing results obtained in different studies 
(Morales-Yuste et al., 2012). The most frequently used diagnostic methods in CanL 
epidemiological surveys are serological and molecular. While the former identify antibodies 
and are a reflection of the host’s humoral immune response to L. infantum, the latter detect 
parasite DNA in a host’s tissues, regardless of the level of host-parasite interaction (Solano-
Gallego et al., 2009). Both present advantages and drawbacks but, most importantly, the two 
methods provide different information that should be interpreted accordingly (Solano-Gallego 
et al., 2011). 
Serological methods are widely used and represent the most frequently reported screening 
method in CanL epidemiological studies (Alcover et al., 2013; Ballart et al., 2013a; Cortes et al., 
2012; Gálvez et al., 2010b; Miró et al., 2017a). However, their performance is greatly 
influenced by technical aspects and population-related parameters (de Mendonça et al., 
2017a; Dye et al., 1993; Greiner and Gardner, 2000; Morales-Yuste et al., 2012). By detecting 
anti-L. infantum antibodies and not the parasite, serological tests are unable to differentiate 
between infected, diseased, resistant and/or vaccinated individuals (Greiner and Gardner, 
2000). Thus, in endemic areas, where 50% to 80% of the canine population is expected to be 
infected or to have been exposed to the parasite (Noli and Saridomichelakis, 2014) and there is 
a likely predominance of asymptomatic dogs (Baneth et al., 2008), a method capable of 
discerning between the different levels of parasite exposure would certainly provide more 
useful results. The higher prevalence of L. infantum infection observed in endemic areas, 
together with the complexity of infection staging, can impact the sensitivity and specificity of 
serological tests (de Mendonça et al., 2017a; Greiner and Gardner, 2000). A test’s specificity 
will be reduced by the high number of false-positive results yielded by immune individuals (de 
Mendonça et al., 2017a), either naturally exposed or vaccinated (Marcondes et al., 2011), and 
possible cross-reactions with other common canine infectious agents, such as Ehrlichia canis, 
Babesia canis or Hepatozoon canis (Morales-Yuste et al., 2012). Likewise, infected dogs with 
prepatent infections, which have not yet seroconverted, will test negative (Dye et al., 1993; 
Oliva et al., 2006; Otranto et al., 2009). The duration of this seronegative prepatent period 
usually ranges between 1 and 22 months (Moreno and Alvar, 2002), but can be longer in dogs 
showing a subpatent condition, characterized by an apparent “parasite silencing” (Oliva et al., 




populations and subpopulations in an endemic area, as well as in the same population over 
time, according to changes in infection dynamics (Greiner and Gardner, 2000). In addition to 
these sources of variability, the accuracy of each serological method is distinct, and differences 
in detection are observed when using whole Leishmania antigen or recombinant antigens, 
either alone or combined (reviewed in Duthie et al., 2018). Finally, both quantitative and 
qualitative serological methods are available, and the choice between these should be based 
on the study purpose and resources. Quantitative methods provide a measurement of 
antibody levels, which can be correlated with infection severity and used to identify diseased 
individuals, as these tend to present significantly higher levels of anti-Leishmania antibodies 
(Oliva et al., 2006). When only a dichotomous result is required, qualitative methods may 
prove to be a better option, with the additional advantages of not requiring trained personnel 
or laboratory facilities and providing almost immediate results (Ribeiro et al., 2018). Claims of 
a possible lower diagnostic sensitivity provided by qualitative methods (Morales-Yuste et al., 
2012; Quinnell et al., 2013; Rodríguez-Cortés et al., 2013; Solano-Gallego et al., 2014) may not 
apply to more recently developed techniques (Duthie et al., 2018; Travi et al., 2018). 
Molecular techniques show high specificity which, unlike serological methods, is not affected 
by the prevalence of infection in the study area (de Mendonça et al., 2017a). However, their 
diagnostic sensitivity depends on the method and sample used (Solano-Gallego et al., 2016a) 
and on the target DNA sequence (Lachaud et al., 2001, 2002a, 2002b; Paltrinieri et al., 2016). 
Also, the use of PCR alone is not recommended for screening clinically healthy dogs in CanL 
endemic areas, where it should be used and interpreted together with serological and clinical 
findings for a correct diagnosis (Solano-Gallego et al., 2011). Kinetoplast DNA (kDNA) is the 
most used target for detection of Leishmania because of its multicopy nature and high 
sensitivity, but ribosomal DNA (rDNA) and protein-coding genes can also be used for diagnosis 
(Akhoundi et al., 2017). The use of qPCR instead of conventional PCR methods allows the 
reliable measurement of DNA products and provides higher detection sensitivity (Francino et 
al., 2006). Finally, PCR performance is dependent on the sample used, as parasite burdens will 
differ according to the organic tissue. Peripheral blood does not seem to provide enough 
sensitivity to be used as a sole method (Maia et al., 2009; Solano-Gallego et al., 2011), while a 
higher incidence of false-positives may be expected during the L. infantum transmission season 
due to natural contamination or transient infection (Maia and Campino, 2008). Tissues 
harbouring larger parasite burdens, for instance, bone marrow, lymph nodes or skin 
(Courtenay et al., 2014; Noli and Saridomichelakis, 2014; Solano-Gallego et al., 2011), may be 




non-invasive samples, such as conjunctival swabs (Di Muccio et al., 2012; Strauss‐Ayali et al., 
2004), would prove highly beneficial in large-scale epidemiological studies. Another significant 
step towards the application of molecular techniques to field studies is the development of 
methods capable of amplifying DNA at constant temperatures, avoiding the use of 
sophisticated equipment or the need for specialized personnel (Travi et al., 2018). Techniques 
such as loop-mediated isothermal amplification (LAMP) (Chaouch et al., 2013; Gao et al., 2015) 
or recombinase polymerase amplification (RPA) (Castellanos-Gonzalez et al., 2015) may prove 
to be effective ways of allowing access to molecular methods in the field and point-of-care. 
The choice of diagnostic methods for CanL epidemiological studies must be based on the 
proposed study objectives, cost, ease of sampling required and the characteristics of the target 
canine population (Duthie et al., 2018; Gomes et al., 2008; Greiner and Gardner, 2000). In 
general, the diagnostic tests needed for large-scale surveys of L. infantum infection in CanL 
endemic areas should be easy to use, low-cost, highly sensitive (Duthie et al., 2018), and 
showing high specificity in the differentiation between infected dogs (both symptomatic and 
asymptomatic) and healthy immune individuals (either naturally exposed to the parasite or 
vaccinated) (de Mendonça et al., 2017a). A “gold standard” diagnostic test for L. infantum 
surveillance in natural populations from endemic areas does not exist and, depending on the 
study goal, the possible use of more than one technique is advised (Maia and Campino, 2018, 
2008; Morales-Yuste et al., 2012). 
The L. infantum diagnostic method used in the prevalence study in Girona province (section 
4.1) was a whole promastigote antigen in-house ELISA, a quantitative serological method. 
There were several reasons for this choice. First, this method was developed by members of 
this research group and was standardized and consistently used for CanL diagnosis and survey 
of autochthonous canine populations (Alcover et al., 2013; Ballart et al., 2013a, 2012; 
Fernández-Bellon et al., 2008; Fisa et al., 2001; Iniesta et al., 2002; Riera et al., 1999; 
Rodríguez-Cortés et al., 2017, 2010, Solano-Gallego et al., 2016b, 2005, 2016a). Together with 
IFAT, ELISA is one of the methods recommended by the World Organization for Animal Health 
for performing CanL surveillance studies and to determine the prevalence of infection (OIE, 
2014). However, unlike IFAT, the ELISA is easy to perform and provides objective results, which 
are not conditioned by subjective operator interpretation (Solano-Gallego et al., 2014). Whole 
parasite antigen ELISA is considered suitable for the serological diagnosis of CanL in both 
symptomatic and asymptomatic dogs (Mettler et al., 2005); by contrast, IFAT shows very low 
diagnostic sensitivity in asymptomatic individuals (Adel et al., 2016; Mettler et al., 2005; 




field study settings and for processing large numbers of samples (Maia and Campino, 2008). 
Additionally, techniques based on whole crude Leishmania antigen are usually associated with 
a higher diagnostic sensitivity than monospecific tests, mainly due to a greater capacity in 
detecting the heterogeneous range of individual immune responses expected to be present in 
endemic settings (Morales-Yuste et al., 2012). However, this type of antigen is likely to exhibit 
less specificity due to cross-reactivity with other canine infectious agents, mainly tick-
transmitted diseases (Solano-Gallego et al., 2014); nonetheless, the frequent cross-reactions 
with other Leishmania or Trypanosomatidae species observed in other endemic regions 
(Ferreira et al., 2007; Paz et al., 2018) are not as great a concern in Europe. Finally, an ELISA 
was used to allow comparison with other CanL prevalence studies in the nearby regions of 
Catalonia and Andorra and in the Balearic Islands (Alcover et al., 2013; Ballart et al., 2013a). 
The use of molecular techniques is not yet sufficiently established in large-scale 
epidemiological studies and few results have been published to allow extensive comparison. 
Furthermore, as mentioned before, samples which provide higher sensitivity for PCR parasite 
detection are either too invasive or complex to collect in field settings. Blood samples do not 
provide enough diagnostic sensitivity for cross-sectional surveys (Maia et al., 2009; Solano-
Gallego et al., 2016a) and non-invasive samples, for example, hair or conjunctival swabs are 
still under validation (Corpas-López et al., 2016; Di Muccio et al., 2012; Strauss‐Ayali et al., 
2004). Being an endemic region, the inherent characteristics of L. infantum infection in the 
canine population of Girona province were anticipated to have an impact on ELISA 
performance, as discussed above. This negative impact was expected to be minimized in an 
assay standardized with very similar dog populations; nevertheless, as population 
characteristics are not stable (Greiner and Gardner, 2000), there would always be potential 
associated error. Likewise, assay-related characteristics would also influence the results. This 
error source was accounted for by calculating and reporting true seroprevalence results, which 
took into consideration the diagnostic test’s sensitivity and specificity (section 4.1). 
The study presented in section 4.2 evaluated the contact of dog populations in Girona province 
with P. perniciosus through the quantification of antibodies produced against sand fly saliva in 
dogs. Besides confirming the presence of phlebotomine vectors in the surveyed locations, this 
is the first longitudinal study performed with P. perniciosus saliva antigens in natural canine 
populations from CanL endemic areas, with significant results contributing to the validation of 
these techniques in field conditions. These methods are useful epidemiological tools and can 
be applied in endemic areas to complement studies of vector population dynamics, as markers 




effectiveness of vector-control programmes (reviewed in Lestinova et al., 2017). Two salivary 
antigens were used in parallel: total salivary gland homogenate (SGH) and the recombinant 
protein rSP03B, a yellow-related protein present in P. perniciosus saliva. Although SGH is 
considered the “gold standard”, its use in large-scale epidemiological surveys is impaired by 
technical limitations, such as the difficulty in maintaining a large enough sand fly colony and 
the laborious work of dissecting large numbers of salivary glands (Lestinova et al., 2017). 
Additionally, protein composition of SGH can vary depending on sand fly age and maintenance 
temperature (Volf and Tesar, 2000), as well as individually and between colonies from 
different geographic locations (Rohoušová et al., 2012). Finally, the use of SGH in diagnostic 
tests may reduce the specificity of detection due to a higher probability of cross-reactivity with 
saliva of sympatric sand fly species (Volf and Rohoušova, 2001). The recombinant rSP03B is 
considered to be the most promising candidate to replace SGH as a marker of exposure to P. 
perniciosus and studies have been conducted to validate this antigen in the field (Kostalova et 
al., 2017, 2015; Martín-Martín et al., 2014). Results obtained in the longitudinal study 
presented in this thesis (section 4.2) showed that canine humoral response (IgG) against SGH 
and rSP03B followed the expected trends for P. perniciosus activity in the region, confirming 
the applicability of both antigens as markers of exposure to L. infantum vectors in natural 
populations from endemic areas. Notably, it was observed that, despite the repeated exposure 
to sand flies during the vector activity season, dogs from endemic regions showed a marked 
decrease in IgG levels during the non-transmission season. This finding demonstrates the 
capability of salivary antigens in detecting recent host exposure, which can be particularly 
relevant to studies assessing the effectiveness of vector-control programmes (Clements et al., 
2010). 
The correlation observed between SGH and rSP03B was only moderate, which could be 
explained by the co-occurrence of P. ariasi, the other L. infantum vector species present in 
Spain. Due to its close relation to P. perniciosus (both belonging to the Larroussius subgenus), 
IgG produced against the bite of P. ariasi could potentially be detected by P. perniciosus SGH 
antigen. Unfortunately, due to the lack of colonies of sand fly species co-occurring with P. 
perniciosus (Lawyer et al., 2017), this possible cross-reaction has not yet been tested. 
Characterization of sand fly populations in the study area and comparison of SGH-rSP03B 
correlations between locations of single P. perniciosus occurrence and co-occurrence of both 
species could provide useful information to clarify this hypothesis. Nevertheless, because both 
species are proven vectors of L. infantum, possible cross-reactions between P. perniciosus and 




Finally, the results obtained in the study described in section 4.2 support the conclusions of 
section 4.1 regarding the endemicity status of Girona province for CanL. The detection of L. 
infantum vectors in an area where autochthonous CanL cases were confirmed and seropositive 
asymptomatic individuals were also found, fulfil the criteria for an indisputable leishmaniosis 
focus (Maroli et al., 2008). Despite some degree of variation observed across the different 
locations, the exposure of dogs to phlebotomine vectors was detected throughout the study 
area. Overall seropositivity to SGH and rSP03B during the trial was 49.4% and 29.0%, 
respectively. Differences between the two antigens could be explained by the previously 
suggested cross-reactivity with P. ariasi. Nevertheless, as also mentioned before, the observed 
seropositivity would still indicate contact with one of the two L. infantum vector species 
present in the region, which is equally significant for the proposed study objectives. The recent 
development of a rapid ICT containing rSP03B antigen, which demonstrated a good correlation 
with SGH ELISA, as well as a high diagnostic sensitivity and specificity in experimentally 
exposed dogs (Willen et al., 2018), shows that this is a promising line of research in the field of 
vector epidemiology. 
 
5.2. DOG VACCINATION AND THE CONTROL OF CANINE LEISHMANIOSIS 
 
Vaccination is considered to be one of the best methods for controlling leishmaniosis (Dye, 
1996), either alone or in combination with insecticide treatments (Sevá et al., 2016). A vaccine 
for CanL should be able to induce a strong and long-lasting Th1-dominated cellular immunity 
to control infection progression, while simultaneously reducing parasite burden in dogs and 
their infectiousness to sand flies (Courtenay et al., 2014; Gradoni, 2015). Additionally, it should 
be equally effective in protecting against infection or disease (Alvar et al., 2013). The success 
of vaccination at the population level is closely linked with vaccine efficacy and coverage, 
which when high enough, would be able to induce herd immunity and indirect protection of 
non-vaccinated individuals and humans (Fox et al., 1971). When effective, the advantages of 
vaccination are well recognized; however, failure to provide proper protection against 
infection can have the detrimental effect of “masking” vaccinated asymptomatic carriers, 
which can harbour the parasite and represent a source for transmission to naïve individuals; 
both other dogs and humans (Miró et al., 2017b). Another possible negative effect of 
vaccination is the cross-reaction of vaccine-induced antibodies with serological techniques 




with standard tests hinders the diagnosis of vaccinated and infected individuals (which 
assumes a greater relevance if vaccine efficacy is only moderate or low) and can have an 
important impact on L. infantum seroprevalence surveys. 
Unlike previous CaniLeish® vaccine studies, which were carried out under experimental 
laboratory conditions or with beagle dogs introduced into endemic areas, the studies 
described in sections 4.3 and 4.4 focused on an independent evaluation of CaniLeish® vaccine 
in field conditions and with native dogs in an endemic region. This vaccine has been licensed in 
Europe since 2011 (EMA, 2011) and very little has been published since the pre-licensing phase 
II and III trials. The studies presented in this thesis were performed with native canine 
populations from endemic areas, naturally exposed to phlebotomine vectors and to L. 
infantum infection. The recommended procedures for pre-vaccination screening and 
vaccination inclusion criteria provided by the vaccine’s manufacturer were followed. The 
vaccine trial was designed to mimic the conditions of field vaccination as closely as possible. 
The study of the possible impact of CaniLeish® vaccination in L. infantum infection 
seroprevalence studies is presented in section 4.3. Humoral immune response to the parasite 
was longitudinally assessed in the trial population over one year and antibody responses 
obtained in vaccinated and non-vaccinated dogs were compared. Results demonstrated a clear 
non-specific vaccine-induced seroconversion in the group treated with CaniLeish®, which 
cross-reacted with a standard diagnostic in-house ELISA. Vaccine-induced humoral immune 
response started increasing after the first vaccine dose, peaking one month after vaccination 
completion; it is possible that the duration of this false-seropositive state lasted until 4 months 
after vaccination. Similar results had been previously reported for IFAT and the use of this 
method in the diagnosis of L. infantum in CaniLeish® vaccinated dogs is not recommended 
(Martin et al., 2014; Montoya et al., 2017; Oliva et al., 2014 ; Sagols et al., 2013). A comparable 
situation was identified after the introduction of Leishmune® in Brazil, the first licensed CanL 
vaccine (Borja-Cabrera et al., 2002). Studies performed several years after its 
commercialization showed evidence of the cross-reaction of vaccine-induced antibodies with 
CanL official diagnostic tests (Marcondes et al., 2013, 2011). Detection and culling of infected 
dogs is the control measure adopted by the Ministry of Health in Brazil (Ministério da Saúde 
Brasileiro, 2014), meaning that, for a number of years, healthy Leishmune®-vaccinated dogs 
could have been mistakenly identified as naturally infected individuals and removed 
(Marcondes et al., 2013). This is not the case in Europe; however, there is now an added 
complexity in CanL diagnosis introduced by vaccination, which is extensive to CanL surveillance 




Vaccination with CaniLeish® is recommended for dogs living in CanL endemic areas. The fact 
that vaccination could be extensively implemented in areas where the most common 
diagnostic methods are unable to distinguish between vaccinated and infected individuals 
raises a number of pertinent questions. The use of traditional quantitative serological methods 
in epidemiological studies may need to be revised. Their use in association with other 
diagnostic methods (e.g. molecular techniques) has been previously recommended (Maia and 
Campino, 2018, 2008; Morales-Yuste et al., 2012), although this practice raises the cost and 
duration of surveillance programmes. Bourdoiseau et al. (2009) suggested the monitoring of 
LiESAP specific IgG2 to distinguish sera samples of LiESAP-MDP vaccinated dogs (a vaccine 
formulation with the same antigen as CaniLeish®, but with a different adjuvant) from infected 
individuals in large-scale studies in the field; however, the ability to diagnose vaccinated and 
infected dogs would not be improved by this approach. The replacement of quantitative 
serological methods by qualitative or molecular ones could also present some drawbacks, 
already discussed in this chapter. In the specific case of Speed Leish KTM, the pre-vaccination 
screening and post-vaccination diagnostic method recommended by CaniLeish®, reported 
performance results are not consistent across studies (Ferroglio et al., 2013; Solano-Gallego et 
al., 2014), raising doubts about its suitability for large-scale epidemiological surveys. 
An additional aspect to consider when performing surveys in CanL endemic areas where 
vaccination is implemented would be the need to collect extra information from vaccinated 
individuals. For immunized dogs, it would be important to know which vaccine had been used, 
if the initial vaccination protocol had been followed and when had the last vaccine booster 
been administered. This information would then support the interpretation of diagnostic tests. 
Finally, the development of new, highly sensitive serological diagnostic tests (or the 
improvement of existing ones), capable of detecting infection but not vaccine-induced 
humoral response, should be a priority. In such cases, the same detection method could be 
applied to the whole canine population and used alone or in conjunction with other diagnostic 
methods. However, the continuous development and possible licensing of new CanL vaccines 
makes the development of a “universal” diagnostic test difficult to achieve. Since 2016, 
another CanL vaccine, LetiFend® (Laboratorios LETI, Spain), was licensed in Europe (EMA, 
2016). According to results available until now, vaccination with LetiFend® does not seem to 
induce cross-reactions with the most common serological diagnostic tests (Iniesta et al., 2016).  
The evaluation study of CaniLeish® vaccine in field conditions is provided in section 4.4. The 
vaccine proved to be safe in the study population, in accordance with previous vaccine reports 




canine population was mainly composed of 15 to 20 kg robust hunting dogs, which may not be 
representative of the wide range of dog sizes and breeds presented for CanL vaccination in 
veterinary practices. Study of vaccine-induced CMI was performed through the quantification 
of L. infantum-specific IFN-γ production by canine PBMC. This cytokine is considered to be a 
high-quality biomarker of a Th1-predominant cellular immune response, and an indicator of 
immunogenicity and protection against Leishmania infection in dogs (Carrillo and Moreno, 
2009; Reis et al., 2010). Vaccination with CaniLeish® induced a marked production of specific 
IFN-γ, detectable one month after vaccination conclusion, with levels of this cytokine in the 
vaccine group being significantly higher when compared to control dogs or with both groups at 
T0. However, although higher levels of IFN-γ were still present in vaccinated dogs 9 months 
after immunization, these were not considered statistically different from the ones observed in 
the control group at the same time point. Similar results were reported in previous CaniLeish® 
studies, where differences in the number of IFN-γ producing cells between vaccine and control 
groups were detected 6 months post-vaccination, but not 12 months post-vaccination (Martin 
et al., 2014; Moreno et al., 2014). This could mean that CaniLeish® vaccine may not able to 
elicit a long enough protection against infection, but only a transiently effective CMI against L. 
infantum. A similar situation is described by de Luca and Macedo (2016) regarding some HL 
vaccine candidates, which although presenting satisfactory results in immunotherapeutic 
interventions, mainly characterized by Th1-type effector cells, could not generate memory T 
cells and an effective immunological memory. It could also be that IFN-γ quantification is 
insufficient for characterizing the immune response to L. infantum, known to be modulated by 
a complex network of regulatory and counter-regulatory interactions involving multiple cells 
and cytokines (Hosein et al., 2017; Reis et al., 2010). Further studies would be needed to fully 
assess the cellular immune response in vaccinated dogs and confirm its intensity and 
persistence.  
In the CaniLeish® vaccine study presented in section 4.4, no differences were found in number 
or intensity of active L. infantum infections between vaccine and control groups one year post-
vaccination. In the context of this study, “active infection” was defined as an established and 
progressive L. infantum infection, either symptomatic or asymptomatic, but that is expected to 
inevitably lead to clinical disease. This state was characterized by the concomitant evidence of 
specific-L. infantum seroconversion, defined as a 4-fold increase in ELISA units when compared 
with the same individual’s basal values (Paltrinieri et al., 2010), detection of parasite’s DNA in 
lymph node samples and, in the majority of cases, by the presence of clinical or laboratory 




of control dogs (4/74) were diagnosed with active L. infantum infection during one year follow-
up. These results confirm those presented in a previous field study, which compared the 
efficacy of CaniLeish® and two insecticide dog collars in the prevention of CanL. After one year, 
although different protection efficacies were determined for each insecticide collar, no 
difference was detected in the number of CanL cases between CaniLeish® and control groups 
(Brianti et al., 2016). As in the Brianti et al. (2016) study, the reduced sample size and trial 
duration of the present study may have impaired the detection of a vaccine effect.  
Another aspect deemed essential for an effective CanL vaccine is its capacity to reduce 
infectiousness at the vertebrate host level, blocking L. infantum transmission to the sand fly 
vector. The work presented in this thesis did not focus on this particular aspect of CaniLeish® 
vaccination; however, results on the number and severity of active L. infantum infection cases 
observed in the treated group strongly suggest that the vaccine does not stop or reduce 
parasite transmission to the vector. Vaccinated dogs presented the same incidence of infection 
as the control group, with similar levels of specific humoral response, parasite load in lymph 
nodes and presence of clinical or laboratory abnormalities. Nevertheless, infectiousness was 
not assessed in any group either by quantification of skin parasite loads (Courtenay et al., 
2014) or xenodiagnosis (Fernandes et al., 2014). The only previous xenodiagnosis study 
performed in CaniLeish® vaccinated dogs did not find any difference in the proportion of 
infectious vaccinated and non-vaccinated individuals progressing to active L. infantum 
infection, although a reduction in the infectiousness burden was observed in the vaccine group 
(Bongiorno et al., 2013). Nonetheless, the reduced number of dogs included in the mentioned 
study (6 vaccinated and 4 controls) did not allow for any conclusions to be drawn regarding a 
possible impact of vaccination on parasite transmission. 
The results of CaniLeish® field study described in section 4.4 of this thesis do not corroborate a 
significant role of this vaccine in the control of L. infantum infection in endemic areas. 
According to these results, CaniLeish® vaccine does not seem to meet the criteria proposed for 
an effective immunization against Leishmania parasites (Alvar et al., 2013; Gradoni, 2015). At 
the individual level, there is little evidence that vaccination enhances a long enough Th1-
dominated cellular immune response capable of protecting against infection progression 
during one year. This is suggested not only by the early decrease observed in IFN-γ levels in 
vaccinated dogs, but also by a failure in detecting difference in frequency or severity of active 
L. infantum infection cases between vaccinated and non-vaccinated animals. The apparent 
vaccine inefficacy in protecting against infection or disease (previously reported by Brianti et 




(Bongiorno et al., 2013), is also suggestive of an apparently negligible impact of CaniLeish® in 
blocking L. infantum transmission in canine populations from endemic areas, as well as to 
humans. Further studies are needed to corroborate these findings and to unequivocally 
determine whether recommendations for CaniLeish® vaccine use in canine L. infantum 
infection prophylaxis in endemic areas should be maintained. 
Field evidence of CanL vaccines effectiveness in reducing CanL and HL is essential to truly 
assess the usefulness of such control measures (Weinberg and Szilagyi, 2010). Studies of 
vaccine efficacy, designed to demonstrate the advantages of vaccination at the individual level, 
do not provide clear information on the impact of such interventions in Leishmania infection 
epidemiology. The only published example of population-level evaluation of vaccine impact 
was performed for Leishmune® in Brazil, showing that in areas where vaccination had been 
adopted, a decrease in the number of seropositive dogs and in the incidence of HL had been 
observed (Palatnik-de-Sousa et al., 2009). This study reported results on CanL and HL cases 
detected before and after vaccine introduction in regions subject to different vaccination 
coverage rates. Official reports from the Ministry of Health’s Centre for Zoonosis Control and 
data from the vaccine’s manufacturer and local veterinary practices were used. Surprisingly, 
ten years later, the production and marketing license for Leishmune® vaccine would be 
withdrawn by the Brazilian Ministry of Agriculture, under claims of lack of effectiveness 
evidence in phase III trials (MAPA, 2014). Epidemiological surveillance should be considered an 
essential procedure after any veterinary vaccine licensing to confirm safety and efficacy rates 
reported in phase II and III trials, thus avoiding long-term commercialization of suboptimal or 
ineffective medicines. Importantly, these results would also provide solid information to the 
general public, who could then make informed decisions on whether to use these products. So 
far, topical insecticides applied to the canine reservoir are the only prophylactic method 









5.3. STUDY LIMITATIONS 
 
As already mentioned, the main limitation of the canine L. infantum serological survey 
presented in section 4.1 was access to dogs. The selection of an unbiased and representative 
sample of dogs from a whole province can prove to be problematic, given the cessation of anti-
rabies vaccination campaigns and the lack of systematic canine registration. As also discussed 
before, alternative methods for recruitment of individuals will inevitably incur in some type of 
selection bias. Furthermore, the analysis of individual and environmental risk factors 
associated with the infection imposed the need for working with compliant dog owners. The 
recruitment method chosen involved the local veterinarians, who were the link between the 
research team and their clients. However, instead of sampling dogs attending the veterinary 
practices, the study focused on dog populations living in rural and periurban areas, which were 
considered to be a better sentinel for L. infantum infection. Sample selection and geographic 
bias introduced by the study design were assumed by the research team and discussed in 
section 4.1 (pages 75-76). 
The follow-up study of vaccinated dogs presented in section 4.3 was performed with 
individuals enrolled in the vaccine study presented in section 4.4. Likewise, the study was 
designed as a case-control trial, where both groups were exposed to natural L. infantum 
infection. Apart from a possible humoral response produced by vaccination, dogs could also 
have developed a humoral response to infection, which is not possible to differentiate from 
the vaccine-induced one. Interactions between vaccine-induced and parasite-induced humoral 
responses are not studied and represent an added hindrance when analysing the data. The 
study described in section 4.3 attempted to mimic possible cross-sectional seroprevalence 
studies, this way providing an insight into the impact of the presence of vaccinated dogs in any 
surveyed population. However, the only way of isolating a possible vaccine effect was by 
comparing vaccine and control groups, and this method is not able to provide conclusive 
results due to the confounding effect of natural infection. Furthermore, as observed in the 
study results, even humoral responses from the control group failed to show stability during 
the non-transmission season, when presence of the parasite is not expected, and may reflect 
previous host-parasite contacts. Alternative study designs are described to evaluate antibody 
levels in vaccinated dogs and their cross-reactivity with diagnostic methods (Marcondes et al., 
2013, 2011). In these studies, insecticide-impregnated collars were placed on trial dogs to 




on antibody titres at any given time point. Another possible way of performing such studies 
would be by vaccinating dogs in non-endemic areas, this way reducing the chances of infection 
and controlling for this confounding effect. 
The vaccine field study presented in section 4.4 also endured some limitations. Sample size 
was strongly conditioned by the number of available dogs, as well as by the research team’s 
capacity to perform the follow-up on a large number of dogs dispersed over 12 different 
localities in Girona province. Additionally, the one-year duration of the vaccine trial also 
hampered the detection of CanL cases. The outcome of L. infantum infection in dogs is known 
to be variable and to present long incubation periods, reported to range from 3 months to 7 
years (Miró et al., 2008; Oliva et al., 2006; Solano-Gallego et al., 2001a). In canine populations 
from endemic areas, which present some degree of immune adaptation to the parasite, 
infection progression can be even less predictable. These factors placed marked constraints on 
the study power to detect a possible vaccine effect. 
Additional limitations were mainly related to those inherent in long-term field studies and with 
the heterogeneity observed in autochthonous canine populations. Study samples selected 
from natural communities are more representative of the general population and the results 
obtained are more applicable to “real-life” conditions. However, they also represent an added 
difficulty in controlling for external factors and confounders that may interfere in the study 
results and are not directly related with the effect to be measured. Some of these limitations 
were discussed in section 4.4 (pages 112-113). Solutions for overcoming the impact of these 
interferences could be a considerable increase in sample size or by an exclusive recruitment of 
young dogs, not exposed to previous L. infantum transmission seasons. However, while the 
first option would make the study unfeasible, the second would diminish population 
representativeness, because vaccination for CanL is recommended for dogs of all ages, and not 
exclusively for 6-month-old puppies. 
 
5.4. FUTURE WORK 
 
Epidemiological characterization of canine L. infantum infection in Girona province should be 
maintained and extended in the future. Sampling of urban dog populations and of dogs in 
areas less represented in this survey could complement and improve the accuracy of reported 




currently characterized locations, in order to identify future changes in vector or infection 
distribution trends. Maintaining the same diagnostic method would be important to allow 
comparisons to be made, even if additional tests were added to the surveys. Comparing 
information from HL and CanL geographic incidence could be effectual in recognizing the 
importance of implementing L. infantum control measures at the reservoir level. 
The study of risk factors associated with L. infantum infection would also need further 
investigation. Although an altitudinal trend was identified, observations in the field strongly 
suggested that the infection is focally distributed, with the occurrence of clearly demarked 
CanL “hotspots”. The high infection incidence observed in these locations, although certainly 
influenced by altitudinal-related factors such as temperature, humidity and land cover, cannot 
be explained solely by these conditions. Therefore, the inclusion of other environmental 
variables, as well as information from entomological surveys and investigation of alternative 
reservoir species should be added to the analysis of risk factors for L. infantum infection. 
Extending the epidemiological surveillance to vector surveys would also assist in clarifying 
some questions raised during the study of dog exposure to sand fly vectors. The hypothesis of 
possible cross-reactions between P. perniciosus and P. ariasi in anti-vector saliva serological 
studies should be clarified. Due to the difficulties in maintaining P. ariasi colonies, a possible 
way of investigating this could be by the characterization of field sand fly populations in areas 
where these diagnostic tests have been previously used. This way, comparisons in serological 
results could be made between areas of single species occurrence and of co-occurrence of 
both Phlebotomus species. The estimation of L. infantum burdens in sand fly vectors would 
also provide meaningful information to assess the risk of dog and human infection and 
compare it with individual sand fly exposure. Finally, entomological studies would also provide 
data for building vector distribution and density maps in the region. 
Concerning CaniLeish® vaccine studies, further research is needed to confirm the results 
reported in this thesis. Amplifying the dog sample size and extending the duration of the 
vaccine field trial would provide more robust conclusions. It would also be interesting to use 
the PBMC samples collected during this field trial to better characterize a vaccine-induced 
cellular immune response to L. infantum infection. Quantification of additional cytokines or 
characterization of predominant lymphocyte populations at one and 9 months post-
vaccination would provide useful information and help to determine the duration of effective 
vaccine immunity. The extension of the vaccine field trial would also allow for a follow-up of 




information that is currently non-existent for ELISA and insufficient for IFAT. Nevertheless, as 
mentioned before, possible interactions with natural exposure to L. infantum could impede 
interpretation of results. An alternative study design could prove to be a better option for 



























































A. EPIDEMIOLOGICAL STUDIES OF CANINE Leishmania infantum INFECTION IN THE PROVINCE 
OF GIRONA / ESTUDIOS EPIDEMIOLÓGICOS DE LA INFECCIÓN CANINA POR Leishmania 
infantum EN LA PROVINCIA DE GERONA 
 
1. Girona province shows evidence of a stable and endemic focus of CanL, characterized by a 
high Leishmania infantum seroprevalence observed in dogs (19.5%), together with a large 
number of asymptomatic cases (93.2%). 
La provincia de Gerona muestra evidencias de ser un foco estable y endémico de 
leishmaniosis canina, caracterizado por una elevada seroprevalencia de Leishmania 
infantum observada en perros (19,5%) junto a una gran cantidad de casos asintomáticos 
(93,2%). 
 
2. The increase of dogs’ age and lower altitude of the kennel location were identified as risk 
factors for Leishmania infantum infection in the population studied. 
El incremento de la edad de los perros y la disminución de la altura en donde estaban 
ubicadas las perreras se han identificado como factores de riesgo para la infección por 
Leishmania infantum en la población estudiada. 
 
3. The correlation found between SGH and rSP03B salivary antigens was moderate, but both 
antigens proved to be suitable to assess exposure to Phlebotomus perniciosus in native and 
heterogeneous canine populations from leishmaniosis endemic areas. 
La correlación entre los antígenos salivales SGH y rSP03B ha sido moderada, pero ambos 
antígenos han demostrado ser adecuados para evaluar la exposición a Phlebotomus 






4. Despite exposure to repeated sand fly bites during their period of activity, anti-saliva 
immunoglobulin G levels in the study dogs show a marked decrease during the non-
transmission season, which allows detection of recent host exposure to vectors and their 
implementation in studies assessing the effectiveness of vector control programs. 
A pesar de la exposición a repetidas picaduras de los flebotomos durante su período de 
actividad, los niveles de inmunoglobulina G anti-saliva de los perros analizados en el área 
endémica presentan una marcada disminución durante la temporada de no transmisión, lo 
que permite la detección de la exposición reciente del hospedador a los vectores y su 
implementación en estudios que evalúen la efectividad de los programas de control de 
vectores. 
 
5. Levels of antibodies against both SGH and rSP03B salivary antigens detected in the dog 
population analyzed are associated with seropositivity to Leishmania infantum. 
Los niveles de anticuerpos frente a los antígenos salivares SGH y y rSP03B detectados en 
la población canina analizada están asociados a la seropositividad frente a Leishmania 
infantum. 
 
B. DOG VACCINATION AND THE CONTROL OF CANINE LEISHMANIOSIS / LA VACUNACIÓN DE 
PERROS Y EL CONTROL DE LA LEISHMANIOSIS CANINA 
 
1. Vaccination with CaniLeish® induces the production of non-specific antibodies after the first 
vaccine dose administration, peaking one month after vaccination completion. 
La vacunación con CaniLeish® induce la producción de anticuerpos inespecíficos después de la 
primera dosis de administración de la vacuna y alcanza un máximo un mes después de finalizada 
la vacunación. 
 
2. The cross-reactivity shown with an in-house ELISA, a test commonly used for the detection 
of Leishmania infantum infection, interferes with infection and disease diagnosis, as well as 




La reactividad cruzada mostrada al aplicar un ELISA convencional comúnmente utilizado para la 
detección de la infección por Leishmania infantum interfiere en el diagnóstico de la infección y 
enfermedad, así como en las encuestas seroepidemiológicas de la leishmaniosis canina. 
 
3. The widespread use of canine leishmaniosis vaccines in endemic regions may impose the 
need to change current surveillance methodologies. 
El uso generalizado de las vacunas frente a la leishmaniosis canina en regiones endémicas 
puede suponer la necesidad de cambiar las metodologías actuales de vigilancia. 
 
4. CaniLeish® vaccine induces a marked and specific cellular mediated immunity in vaccinated 
dogs, measured by the production of interferon gamma against soluble Leishmania 
antigens, detectable one month after vaccination but not at nine month post-vaccination, 
when no statistically significant differences between vaccinated and control groups were 
observed; this suggests that the cellular immunity induced by the vaccine may not be 
effective throughout the year of alleged vaccine coverage. 
La vacuna CaniLeish® produce una marcada y específica inmunidad mediada por células en los 
perros vacunados, medida por la producción de interferón gamma contra antígenos solubles de 
Leishmania, un mes después de la vacunación y sin mostrar diferencias estadísticamente 
significativas entre el grupo control y el vacunado a los nueves meses post-vacunación, lo que 
sugiere que la inmunidad celular inducida por la vacuna no sería efectiva durante todo el año de 
su supuesta cobertura. 
 
5. Vaccination with CaniLeish® did not protect dogs against Leishmania infantum infection or 
clinical disease during the first year post-vaccination and does not seem to meet the criteria 
needed for an effective canine leishmaniosis vaccine. 
La vacunación con CaniLeish® no protegió a los perros contra la infección por Leishmania 
infantum o la enfermedad clínica durante el primer año post-vacunación y no cumpliría con los 
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ANNEX 1. Results of serological Leishmania infantum infection surveys performed in the study population for the vaccination studies in July 2015 and 
February 2016. Estimated point seroprevalences and incidences obtained are reported. 





































Ordis 1 N 42° 13' 37.7'' 
E 2° 54' 24.1'' 
30 5 21 4 16.7 
(5.6-34.7) 
24 5  20.0 
(6.8-40.7) 
Madremanya 2 N 41° 58' 47.0'' 
E 2° 58' 7.2'' 




3 N 41° 47' 27.4'' 
E 2° 45' 0.4'' 
17 1 14 2 5.9 
(0.1-28.7) 
13 3  18.8 
(4.0-45.6) 
Massanes 4 N 41° 45' 15.3'' 
E 2° 38' 44.0'' 
11 1 10 0 9.1 
(0.2-41.3) 
12 0  0 
 5 N 41° 45' 53.8'' 
E 2° 39' 0.1'' 
14 1 12 1 7.1 
(0.2-33.9) 




6 N 42° 13' 26.0'' 
E 2° 26' 9.7'' 
5 0 4 1 0 7 2  40.0 
(5.3-85.3) 
 7 N 42° 12' 39.2'' 
E 2° 28'35.0'' 
13 1 11 1 7.7 
(0.2-36.0) 
10 0  0 
Montagut 8 N 42° 14' 7.7'' 
E 2° 35' 57.6'' 
30 7 20 3 23.3 
(9.9-42.3) 
21 3  13.0 
(2.8-33.6) 
 9 N 42° 13' 41.8'' 
E 2° 35' 58.1'' 
21 4 16 1 19.0 
(5.4-41.9) 




10 N 42° 3' 35.1'' 
E 2° 37' 1.4'' 
20 0 18 2 0 16 0  0 
Canet d’Adri 11 N 42° 1' 53.7'' 
E 2° 44' 15.3'' 
16 8 4 4 50.0 
(24.7-75.3) 
 





 12 N 42° 2' 43.9'' 
E 2° 44' 59,2'' 
11 5 2 4 45.5 
(16.7-76.6) 
5 2  33.3 
(4.3-77.7) 
 13 N 42° 1' 57.0'' 
E 2° 44' 8.6'' 
16 6 2 8 37.5 
(15.2-64.6) 
9 5  50.0 
(18.7-81.3) 
Aiguaviva 14 N 41° 54' 27.2'' 
E 2° 46' 19.0'' 
27 1 23 3 3.7 
(0.1-19.0) 




15 N 41° 50' 39.4'' 
E 2° 40' 48.4'' 
32 0 32 0 0 Excluded from the vaccine study 
St. Feliu de 
Guíxols 
16 N 41° 47' 2.3'' 
E 2° 59' 58.7'' 
19 7 9 3 36.8 
(16.3-61.6) 
9 5  41.7 
(15.2-72.3) 
Olot 17 N 42° 10' 19'' 
E 2° 30' 29'' 





18 N 41° 43' 59'' 
E 2° 33' 39.3'' 





19 N 41° 53' 3.2'' 
E 2° 43' 38.6'' 
No information    23 5 21.7 
(7.5-43.7) 
 
 20 N 41° 54' 15.4'' 
E 2° 42' 57.1'' 
No information    11 2 18.2 
(2.3-51.8) 
 
Brunyola 21 N 41° 54' 25.9'' 
E 2° 42' 9.9'' 
No information    10 0 0  
TOTAL 21  300 47 212 41 15.7 
(11.7-20.3) 




1Doubtful results correspond to individuals who tested positive to an in-house ELISA and negative to a commercial ELISA assay (Leiscan®); these individuals 
were retested in February 2016. 
2Point seroprevalences were not estimated for the second survey. 














No. of dogs No. CDC light traps 
recovered/night 
Sand fly species 
captured 
Ordis 1 N 42° 13' 37.7'' E 2° 54' 24.1'' 104 30 1 --- 




Maçanet de la 
Selva 
3 N 41° 47' 27.4'' E 2° 45' 0.4'' 73 17 1 S. minuta 
Massanes 4 N 41° 45' 15.3'' E 2° 38' 44.0'' 88 11 2 
P. perniciosus 
S. minuta 
 5 N 41° 45' 53.8'' E 2° 39' 0.1'' 117 14 2 --- 
Hostalnou de 
Bianya 
6 N 42° 13' 26.0'' E 2° 26' 9.7'' 396 5 2 --- 
 7 N 42° 12' 39.2'' E 2° 28'35.0'' 355 13 2 P. perniciosus 
Montagut 8 N 42° 14' 7.7'' E 2° 35' 57.6'' 254 30 2 P. ariasi 




Sant Esteve de 
Llémena 
10 N 42° 3' 35.1'' E 2° 37' 1.4'' 283 20 2 S. minuta 




 12 N 42° 2' 43.9'' E 2° 44' 59,2'' 248 16 1 
P. perniciosus 
S minuta 








Sta. Coloma de 
Farners 
15 N 41° 50' 39.4'' E 2° 40' 48.4'' 128 32 2 P. perniciosus 
Sant Feliu de 
Guíxols 
16 N 41° 47' 2.3'' E 2° 59' 58.7'' 84 19 2 P. perniciosus 















ANNEX 3. Data collected from each sampled dog and questionnaire performed to the dog owner during the Leishmania infantum seroprevalence study in 
Girona province. 
DATOS DEMOGRÁFICOS DEL PERRO DATOS DEL VETERINARIO CUESTIONARIO DEL PROPIETARIO DEL PERRO 
Nombre Apellidos y Nombre Apellidos y Nombre 
Longitud del pelo: 
Corto       Medio       Largo  
Dirección Dirección 
Color del pelo Ciudad Longitud                                            Latitud 
Sexo: M      H 
Si hembra, ¿está preñada? 
Provincia y comarca Ciudad 
Código postal Provincia y comarca 
Fecha de nacimiento         /      / Teléfono Código postal 
Edad (años) e-mail Teléfono 
Peso (kg) e-mail 
Raza SIGNOS CLÍNICOS 
COMPATIBLES CON LA 
LEISHMANIOSIS CANINA 
DATOS EXTRACCIÓN ¿Ha oído hablar de la leishmaniosis visceral?:  Sí         No  
País de origen Formulario No. ¿Qué posibilidad cree que tiene su perro de padecer leishmaniosis a lo 
largo de su vida? 
0%      5%     10%     20%     50%     50-90%     90-100%  
Región de origen  
Provincia de origen Ninguno  
Inflamación de ganglios 
linfáticos  





Palidez mucosas  
Lesiones ocularares  
Esplenomegalia  
Pérdida  de peso  
Otro  (especificar): 
Tipo de muestra 
Suero  
Muestra cutánea  
Sangre periférica  
Ganglio linfático  
Médula ósea  
Otra  
Si otra, especificar: 
RESIDENCIA HABITUAL DEL PERRO ¿Conoce algún método para proteger a su perro de las picadas de los 
flebotomos?  Sí         No  Dirección 
Localidad Si SÍ, ¿ha oído hablar de alguna medida para proteger a su perro contra la LV?  
Sí         No  Comarca                     Provincia 
Long                           Lat ¿Ha utilizado alguna medida para proteger a su perro contra la LV?   
Sí         No   
Si SÍ, ¿cuáles? 
Reside en: 
En vivienda   En exterior   En perrera  
Hábitat usual: 
Urbano        Periurbano        Rural  
Plano           Montaña  
Collar  
Scalibor  
Otro  (especificar): 
Otros  (especificar): 
TEST DIAGNÓSTICO 
Refugio nocturno/vivienda: 





¿Aplica a su perro algún otro 
insecticida para protegerlo de la picada 
de otros insectos o de garrapatas? 
Sí         No  
Spot-on  
Advantix     Expot    




Ocupación del perro: 
Mascota            Guardia            Ovejero            Cazador  
Perrera      Vagabundo       Otro  (especificar): 
Cultivo in vitro  
PCR  
Otro  (especificar) 
Spray  
Duowin  
Otro  (especificar): 
Si SÍ, proporcione detalles 
Vive con otros perros:  Sí         No        
Si SÍ, ¿cuántos? 
Resultado 





Si NO aplica profilaxis, ¿por qué? 
No lo puedo encontrar en la tienda  
Demasiado caro  
No creo que funcione  
La LV no es importante  
Otro (especificar)  
Vive con otros animales:  Sí         No        
Si SÍ, ¿cuáles? 
Jarabe LeisGuard® 
Desplazamientos/viajes:  Sí         No        
Si SÍ, detalle de los lugares 
Si SÍ, periodo 









ELISA result (U) Reference 
B1 Positive 337 Iniesta et al., 2002 
B2 Positive 31  
B3 Negative 40  
B4 Positive 177  
B5 Positive 58  
B6 Positive 174  
B7 Positive 247  
B8 Positive 17  
B9 Positive 13  
B10 Positive 252  
B11 Positive 209  
B12 Negative 33  
B13 Negative 8  
B14 Negative 11  
B15 Positive 30  
B16 Negative 27  
B17 Negative 2  
B18 Negative 12  
B19 Positive 118  
B20 Positive 16  
B21 Positive 24  
B22 Positive 69  
B23 Positive 42  
B24 Positive 20  
B25 Positive 40  
B26 Positive 75  
B27 Positive 29  
B28 Positive 90  
B29 Positive 24  
B30 Positive 69  
B31 Positive 12  
B32 Negative 13  
B33 Positive 258  
B34 Positive 348  
B35 Positive 11  
B36 Positive 12  
B37 Negative 18  
B38 Positive 375  
1 Positive 53 Fisa et al., 2001 
2 Positive 100  
3 Positive 38  
4 Positive 100  
5 Positive 107  
6 Positive 84  
7 Positive 147  
8 Positive 27  




10 Positive 86  
11 Positive 183  
12 Positive 153  
13 Positive 355  
14 Positive 197  
15 Positive 200  
16 Positive 298  
17 Positive 48  
18 Positive 102  
19 Positive 132  
NC1 Negative 17  
NC2 Negative 11  
NC3 Negative 12  
NC4 Negative 7  
NC5 Negative 6  
NC6 Negative 10  
NC7 Negative 9  
NC8 Negative 23  
NC9 Negative 6  
NC10 Negative 7  
NC11 Negative 9  
NC12 Negative 8.5  
NC13 Negative 9  
NC14 Negative 7  
NC15 Negative 14  
NC16 Negative 11  
NC17 Negative 7  
NC18 Negative 9  
NC19 Negative 7  
NC20 Negative 8.5  
*Dogs were classified as positive if parasite culture, direct examination and/or PCR (on lymph 













ANNEX 5. Leishmania infantum in-house ELISA sensitivity and specificity analysis (Stata 
output) 
            77     0.9508       0.0210        0.90958     0.99200
                                                                 
           Obs       Area     Std. Err.      [95% Conf. Interval]
                      ROC                     Asymptotic Normal  
                                                                              
( >  375 )          0.00%       100.00%       37.66%                    1.0000
( >= 375 )          2.08%       100.00%       38.96%                    0.9792
( >= 355 )          4.17%       100.00%       40.26%                    0.9583
( >= 348 )          6.25%       100.00%       41.56%                    0.9375
( >= 337 )          8.33%       100.00%       42.86%                    0.9167
( >= 298 )         10.42%       100.00%       44.16%                    0.8958
( >= 258 )         12.50%       100.00%       45.45%                    0.8750
( >= 252 )         14.58%       100.00%       46.75%                    0.8542
( >= 247 )         16.67%       100.00%       48.05%                    0.8333
( >= 209 )         18.75%       100.00%       49.35%                    0.8125
( >= 200 )         20.83%       100.00%       50.65%                    0.7917
( >= 197 )         22.92%       100.00%       51.95%                    0.7708
( >= 183 )         25.00%       100.00%       53.25%                    0.7500
( >= 177 )         27.08%       100.00%       54.55%                    0.7292
( >= 174 )         29.17%       100.00%       55.84%                    0.7083
( >= 153 )         31.25%       100.00%       57.14%                    0.6875
( >= 147 )         33.33%       100.00%       58.44%                    0.6667
( >= 132 )         35.42%       100.00%       59.74%                    0.6458
( >= 118 )         37.50%       100.00%       61.04%                    0.6250
( >= 107 )         39.58%       100.00%       62.34%                    0.6042
( >= 102 )         41.67%       100.00%       63.64%                    0.5833
( >= 100 )         45.83%       100.00%       66.23%                    0.5417
( >= 90 )          47.92%       100.00%       67.53%                    0.5208
( >= 86 )          52.08%       100.00%       70.13%                    0.4792
( >= 84 )          54.17%       100.00%       71.43%                    0.4583
( >= 75 )          56.25%       100.00%       72.73%                    0.4375
( >= 69 )          60.42%       100.00%       75.32%                    0.3958
( >= 58 )          62.50%       100.00%       76.62%                    0.3750
( >= 53 )          64.58%       100.00%       77.92%                    0.3542
( >= 48 )          66.67%       100.00%       79.22%                    0.3333
( >= 42 )          68.75%       100.00%       80.52%                    0.3125
( >= 40 )          70.83%        96.55%       80.52%      20.5416       0.3021
( >= 38 )          72.92%        96.55%       81.82%      21.1458       0.2805
( >= 33 )          72.92%        93.10%       80.52%      10.5729       0.2909
( >= 31 )          75.00%        93.10%       81.82%      10.8750       0.2685
( >= 30 )          77.08%        93.10%       83.12%      11.1771       0.2461
( >= 29 )          79.17%        93.10%       84.42%      11.4792       0.2238
( >= 27 )          81.25%        89.66%       84.42%       7.8542       0.2091
( >= 24 )          85.42%        89.66%       87.01%       8.2569       0.1627
( >= 23 )          85.42%        86.21%       85.71%       6.1927       0.1692
( >= 20 )          87.50%        86.21%       87.01%       6.3437       0.1450
( >= 18 )          87.50%        82.76%       85.71%       5.0750       0.1510
( >= 17 )          89.58%        79.31%       85.71%       4.3299       0.1313
( >= 16 )          91.67%        79.31%       87.01%       4.4306       0.1051
( >= 14 )          91.67%        75.86%       85.71%       3.7976       0.1098
( >= 13 )          93.75%        72.41%       85.71%       3.3984       0.0863
( >= 12 )          97.92%        65.52%       85.71%       2.8396       0.0318
( >= 11 )         100.00%        55.17%       83.12%       2.2308       0.0000
( >= 10 )         100.00%        51.72%       81.82%       2.0714       0.0000
( >= 9 )          100.00%        37.93%       76.62%       1.6111       0.0000
( >= 8.5 )        100.00%        31.03%       74.03%       1.4500       0.0000
( >= 8 )          100.00%        27.59%       72.73%       1.3810       0.0000
( >= 7 )          100.00%        10.34%       66.23%       1.1154       0.0000
( >= 6 )          100.00%         3.45%       63.64%       1.0357       0.0000
( >= 2 )          100.00%         0.00%       62.34%       1.0000     
                                                                              
Cutpoint      Sensitivity   Specificity   Classified          LR+          LR-
                                           Correctly
                                                                              





ANNEX 6. Area under the ROC curve (95%CI) for the Leishmania infantum in-house ELISA 
(Stata output) 
 
            77     0.9508       0.0210        0.90958     0.99200
                                                                 
           Obs       Area     Std. Err.      [95% Conf. Interval]























ANNEX 7. Article accepted for publication in the journal Preventive Veterinary Medicine (doi: 















































ANNEX 8. Article published in the journal Parasites & Vectors (doi: 10.1186/s13071-018-3123-
y). 
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